📘

Definitions

1

GeneReviews Molecular Diagnostic Criterion for FOXP1 Syndrome

Diagnosis requires supportive clinical findings (global developmental delay with speech and language impairment out of proportion to cognitive level, behavior abnormalities, and mild dysmorphism) together with a heterozygous pathogenic FOXP1 variant on molecular genetic testing. There are no consensus clinical-only criteria; the molecular finding is required.

DIAGNOSTIC_CRITERIA

Inclusion criteria

Heterozygous pathogenic FOXP1 variant A heterozygous pathogenic or likely pathogenic FOXP1 variant (sequence variant, or whole- or partial-gene deletion) identified by molecular genetic testing.
Supportive clinical findings Supportive clinical findings, including global developmental delay and speech and language impairment.

Show evidence (1 reference)

PMID:37733892 SUPPORT Human Clinical

"The diagnosis of FOXP1 syndrome is established in a proband with a heterozygous pathogenic variant in FOXP1 identified by molecular genetic testing and supportive clinical findings."

The GeneReviews diagnostic statement is the source of both inclusion criteria.

👪

Inheritance

1

Autosomal dominant inheritance HP:0000006

FOXP1 syndrome is autosomal dominant. Nearly all molecularly characterized probands carry a de novo pathogenic variant; rare parental somatic and germline mosaicism or a complex chromosome rearrangement involving FOXP1 has been reported. Sib recurrence risk is approximately 1% because of possible parental germline mosaicism.

Autosomal dominant inheritance Penetrance: COMPLETE Expressivity: VARIABLE

Show evidence (3 references)

PMID:37733892 SUPPORT Human Clinical

"FOXP1 syndrome is an autosomal dominant disorder typically caused by a de novo pathogenic variant."

GeneReviews states the mode of inheritance and the predominance of de novo origin.

PMID:37733892 SUPPORT Human Clinical

"Rarely, a parent of an individual with FOXP1 syndrome has somatic and germline mosaicism for the FOXP1 pathogenic variant or a complex chromosome arrangement involving FOXP1."

Documents the rare non-de-novo mechanisms that underlie the residual sib recurrence risk.

PMID:34109629 SUPPORT Human Clinical

"with pathogenic FOXP1 variants (14 truncating, three missense, three splice site, one in-frame deletion, eight cytogenic deletions; 28 out of 29 were de novo variants) were studied."

An independent 29-patient cohort quantifies de novo origin (28/29) and the allele spectrum.

?

Discussions and Knowledge Gaps

1

Postnatal FOXP1 reinstatement rescues electrophysiological, behavioral and cell-type-specific transcriptional phenotypes in mice. Does a comparable postnatal window of reversibility exist in humans, in whom the disorder is diagnosed after several years of atypical development and in whom cortical and striatal circuit maturation follows a much longer timescale?

HUMAN MODEL MISMATCH OPEN foxp1_postnatal_reinstatement_window

Attached to

pathophysiology#Altered Striatal Circuit Excitability

This is a translational-validity question rather than an absence of evidence. Strong in vivo mouse evidence exists that the striatal arm of the mechanism is postnatally reversible, which would reclassify FOXP1 syndrome from a fixed prenatal malformation disorder to a partially modifiable circuit disorder and would justify FOXP1-restoration strategies. But mouse reinstatement occurs early in a short developmental program, whereas human diagnosis typically follows years of atypical development; delivery to the relevant cell types, dosage and isoform control, off-target transcriptional effects, and the human timing window are all unresolved. The cortical arm of the mechanism (lamination, barrel formation, dendritic spines) has not been shown to be reversible at all.

Proposed experiments

Age-series mapping of the FOXP1 reinstatement window in mice

exp_foxp1_reinstatement_age_series

Reinstate FOXP1 at a graded series of postnatal ages in the same conditional model and measure D2 SPN glutamatergic input strength, synaptically driven excitability, and the corresponding behavioral readouts at each timepoint. The objective is the shape of the closing window, not a single permissive early timepoint, because only a rate of closure can be extrapolated to the much longer human developmental timescale.

Test whether the cortical arm is reversible under the same protocol

exp_foxp1_cortical_arm_reversibility

Apply the same postnatal reinstatement protocol to cortex-restricted Foxp1 loss and assay laminar positioning, somatosensory barrel organization, dendritic spine density, and tactile behavior. A negative result would confine the reversibility claim to the striatal arm and would materially change what a FOXP1-restoration therapy could be expected to achieve.

FOXP1 dose-response in patient-derived and isogenic human neurons

exp_foxp1_dose_response_ipsc

Use patient-derived iPSC neurons and isogenic corrected lines to establish the FOXP1 dose-response relationship, determining whether a normal transcriptional state is reachable without overexpression toxicity and which isoforms must be restored. FOXP1 is dosage sensitive in both directions, so a human dose window is a prerequisite for any restoration strategy.

Show evidence (2 references)

PMID:38701209 SUPPORT Model Organism

"Last, we demonstrate that postnatal FOXP1 reinstatement rescues electrophysiological deficits, cell type-specific gene expression changes, and behavioral phenotypes."

The mouse result that creates the translational question; it is model-organism evidence with no human counterpart.

PMID:40066139 SUPPORT Human Clinical

"Caregivers reported continued development in adaptive skills even into adulthood."

Continued human skill acquisition into adulthood is weakly consistent with retained plasticity, but it is not evidence that the underlying circuit deficit is reversible.

⚙

Pathophysiology

13

Heterozygous FOXP1 Loss-of-Function Variation

The initiating lesion is a heterozygous, usually de novo, pathogenic FOXP1 variant: whole- or partial-gene deletion, frameshift, nonsense, essential splice-site change, in-frame deletion, or missense substitution. Missense and in-frame alleles cluster in the C-terminal forkhead DNA-binding domain, where they either perturb residues required for DNA contact or interfere with the domain swap that mediates FOXP1 dimerization. FOXP1 also heterodimerizes with its paralog FOXP2, the classic speech-and-language gene, which is one route by which reduced FOXP1 dosage reaches speech circuitry.

FOXP1 hgnc:3823

DNA-binding transcription factor activity GO:0003700 ↓ DECREASED FOXP1 domain-swap dimerization GO:0042803 ⚠ ABNORMAL

Downstream

Loss of FOXP1 Transcriptional Repression

Show evidence (2 references)

PMID:29090079 SUPPORT Human Clinical

"The majority of pathogenic missense and in-frame mutations, including all four missense mutations in our cohort, lie in the DNA-binding domain. Through structural analyses, we show that the mutations perturb amino acids necessary for binding to the DNA or interfere with the domain swapping that..."

Establishes both the mutational clustering in the forkhead domain and the two structural mechanisms by which those alleles impair FOXP1 function.

PMID:29090079 SUPPORT Human Clinical

"We have identified nine de novo mutations, including three frameshift, one nonsense, one mutation in an essential splice site resulting in frameshift and insertion of a premature stop codon, three missense, and one in-frame deletion."

Documents the de novo origin and the truncating-predominant allele spectrum of the initiating lesion.

Loss of FOXP1 Transcriptional Repression

FOXP1 is a sequence-specific transcriptional repressor. Pathogenic alleles converge on loss of repression activity, most often accompanied by abnormal subcellular (cytoplasmic or aggregated nuclear) localization; the recurrent p.Arg525Gln allele loses repression while retaining normal nuclear localization, showing that the repression defect, not mislocalization per se, is the shared consequence. Repression is exerted in part through interaction with the NuRD chromatin-remodeling complex, an interaction that requires SUMOylation of FOXP1 during embryonic brain development.

negative regulation of transcription by RNA polymerase II GO:0000122 ↓ DECREASED FOXP1 SUMOylation required for NuRD interaction GO:0016925

Downstream

Dysregulated Neurodevelopmental Transcriptional Program

Extra-CNS Developmental Consequences of FOXP1 Dosage Reduction

Show evidence (3 references)

PMID:30385778 SUPPORT In Vitro

"Here we present three patients with the same FOXP1 mutation, c.1574G>A (p.R525Q), that results in the characteristic loss of transcription repression activity. This mutation, however, represents the first reported FOXP1 mutation that does not result in cytoplasmic or nuclear aggregation of the..."

Dissociates loss of repression from mislocalization, identifying loss of repression as the convergent molecular defect.

PMID:25853299 SUPPORT In Vitro

"Functional analyses using cellular models show that the variant disrupts multiple aspects of FOXP1 activity, including subcellular localization and transcriptional repression properties."

An independent patient-derived frameshift allele shows the same loss of repression in cellular assays.

PMID:29138280 SUPPORT Model Organism

"We also uncovered mechanistic insight into Foxp1 function by demonstrating that sumoylation of Foxp1 during embryonic brain development is necessary for mediating proper interactions between Foxp1 and the NuRD complex."

Identifies the chromatin-remodeling partner through which FOXP1 exerts repression in the developing brain.

Dysregulated Neurodevelopmental Transcriptional Program

Reduced FOXP1 dosage releases repression of its direct targets and reconfigures the downstream network. Two arms are best characterized: de-repression of Notch pathway genes, notably the ligand Jagged1, which sustains Notch signaling and holds progenitors in a proliferative, undifferentiated state; and dysregulation of autism-associated signaling pathways and neuronal-activity genes, including a striatal neuron-identity program that is conserved between mouse brain and human neural progenitors. In developing neocortex the Foxp1-regulated networks are specifically enriched for neurogenesis and neuronal-migration effectors.

regulation of transcription by RNA polymerase II GO:0006357 ↕ DYSREGULATED Notch signaling pathway GO:0007219 ↑ INCREASED

Downstream

Impaired Neural Progenitor Differentiation

Impaired Striatal Medium Spiny Neuron Development

Impaired Cortical Radial Migration and Neuronal Morphogenesis

Show evidence (3 references)

PMID:29141232 SUPPORT In Vitro

"FOXP1 was found to repress the expression of Notch pathway genes including the Notch-ligand Jagged1, resulting in inhibition of Notch signaling."

Identifies Jagged1/Notch de-repression as a specific, mechanistically resolved consequence of FOXP1 loss.

PMID:26494785 SUPPORT Model Organism

"We demonstrate a role for FoxP1 in the transcriptional regulation of autism-related pathways as well as genes involved in neuronal activity."

Defines the FOXP1-regulated program in patient-relevant heterozygous Foxp1 mouse brain and human neural cells.

PMID:29138280 SUPPORT Model Organism

"Using a genomics approach, we identified the transcriptional networks regulated by Foxp1 in the developing neocortex and found that such networks are enriched for downstream targets involved in neurogenesis and neuronal migration."

Shows the dysregulated program is specifically enriched for the neurogenesis and migration effectors that produce the downstream cortical phenotype.

Impaired Neural Progenitor Differentiation

FOXP1 is expressed in embryonic neural stem cells, and reducing it shifts the balance away from neuronal (and astrocytic) differentiation. In utero FOXP1 knockdown reduces neural stem cell differentiation and migration during corticogenesis, and transplanted FOXP1-knockdown neural stem cells fail to differentiate and function normally in vivo. The mechanism is established in murine and cellular models; direct confirmation in human FOXP1-syndrome brain tissue is lacking.

neural stem cell CL:0000047 radial glial cell CL:0000681

neuron differentiation GO:0030182 ↓ DECREASED neural precursor cell proliferation GO:0061351 ⚠ ABNORMAL

Downstream

Neocortical Cytoarchitectonic Alteration

Show evidence (1 reference)

PMID:29141232 SUPPORT Model Organism

"Using a murine model of cortical development, FOXP1-knockdown in utero was found to reduce NSC differentiation and migration during corticogenesis."

In vivo knockdown demonstrates the progenitor differentiation and migration defect that follows FOXP1 loss.

Impaired Cortical Radial Migration and Neuronal Morphogenesis

Foxp1 is required for radial migration of newly generated cortical neurons. Suppressing Foxp1 in mouse cerebral cortex produces a migration defect that is rescued by Foxp1 re-expression, with ectopic neurons persisting in deep cortical layers postnatally. Differentiation per se is preserved in that model, but the neurons show inhibited axonal growth, a weakened multipolar-to-bipolar transition, and altered late dendritic maturation.

cerebral cortex neuron CL:0010012 glutamatergic projection neuron CL:0000679

cerebral cortex radial glia-guided migration GO:0021801 ↓ DECREASED neuron migration GO:0001764 ↓ DECREASED

Downstream

Neocortical Cytoarchitectonic Alteration

Show evidence (2 references)

PMID:26010426 SUPPORT Model Organism

"Here, we report that suppression of Foxp1 expression in mouse cerebral cortex led to a neuronal migration defect, which was rescued by overexpression of Foxp1."

Knockdown-plus-rescue is the strongest available demonstration that the migration defect is Foxp1 dose dependent.

PMID:26010426 SUPPORT Model Organism

"However, morphological analysis showed that the neurons with Foxp1 deficiency had an inhibited axonal growth in vitro and a weakened transition from multipolar to bipolar in vivo."

Identifies the cell-biological substrate of the migration defect and an added axon-growth deficit.

Neocortical Cytoarchitectonic Alteration

Mispositioned cortical neurons yield altered neocortical cytoarchitecture and circuit assembly. In forebrain-specific Foxp1 conditional knockout mice this is accompanied by impaired neonatal vocalization, providing the closest model-system correlate of the human speech phenotype. In affected humans, imaging shows only non-specific structural brain abnormalities, so the correspondence between the murine cytoarchitectonic lesion and human cortical pathology is inferred rather than demonstrated.

cerebral cortex neuron CL:0010012

cerebral cortex development GO:0021987 ⚠ ABNORMAL

Downstream

Impaired Speech Motor and Vocal Communication Output

Autistic Features and Behavioral Dysregulation

Global Developmental Delay and Intellectual Disability

Show evidence (3 references)

PMID:29138280 SUPPORT Model Organism

"To elucidate the contribution of FOXP1-mediated signaling to brain development and, in particular, neocortical development, we generated forebrain-specific Foxp1 conditional knockout mice."

Establishes the model system in which the cytoarchitectonic alteration and the vocalization deficit are jointly demonstrated.

PMID:29090079 SUPPORT Human Clinical

"Medical features included non-specific structural brain abnormalities and dysmorphic features, endocrine and gastrointestinal problems, sleep disturbances, and sinopulmonary infections."

Human neuroimaging documents structural brain abnormality but is non-specific, so it only partially corroborates the model-derived cytoarchitectonic mechanism.

PMID:37691105 SUPPORT Model Organism

"Moreover, Foxp1 deficiency in cortical neurons altered the dendrite development, reduced the number of dendritic spines, and disrupted barrel formation in the somatosensory cortex, suggesting impaired somatosensory processing may underlie the aberrant tactile responses."

Extends the cytoarchitectonic phenotype beyond lamination to dendritic and columnar (barrel) organization, and links it to a sensory behavioral output.

Impaired Striatal Medium Spiny Neuron Development

FoxP1 is the most highly upregulated gene in the developing mouse whole ganglionic eminence, marks medium spiny projection neurons from precursor through maturity, and co-localizes with essentially all striatal DARPP-32 positive projection neurons without labelling interneurons. FoxP1 knockout ganglionic eminence fails to generate DARPP-32-positive medium spiny neurons in vitro, establishing FoxP1 as required for their differentiation. The same expression pattern is present in human fetal brain at equivalent gestational stages.

medium spiny neuron CL:1001474

striatum development GO:0021756 ⚠ ABNORMAL neuron differentiation GO:0030182 ↓ DECREASED

Downstream

Altered Striatal Circuit Excitability

Show evidence (4 references)

PMID:27154297 SUPPORT Model Organism

"Furthermore, DARPP-32 expression was absent from FoxP1 knock-out mouse WGE differentiated in vitro, suggesting that FoxP1 is important for the development of DARPP-32-positive MSNs."

Loss-of-function evidence that FoxP1 is required for medium spiny neuron differentiation.

PMID:27154297 SUPPORT Model Organism

"FoxP1 expression persisted through into adulthood in the mouse brain, where it co-localised with all striatal DARPP-32 positive projection neurons and a small population of DARPP-32 negative cells. There was no co-localisation of FoxP1 with any interneuron markers."

Establishes the cell-type specificity of FoxP1 within the striatum, identifying the medium spiny neuron as the vulnerable population.

PMID:32130906 SUPPORT Model Organism

"Using single-cell RNA sequencing (RNA-seq), we examine the cellular diversity of the early postnatal striatum and show that Foxp1, a transcription factor strongly linked to autism and intellectual disability, regulates the cellular composition, neurochemical architecture, and connectivity of the..."

Single-cell profiling of the early postnatal striatum shows the effect of Foxp1 loss is cell-type dependent rather than uniform, and extends it from neuron identity to neurochemical compartmentalization and connectivity.

+ 1 more reference

Altered Striatal Circuit Excitability

Beyond specifying medium spiny neuron identity, FoxP1 dose sets the intrinsic excitability of these neurons. In patient-relevant heterozygous Foxp1 mice, reduced Foxp1 alters medium spiny neuron excitability and correlates with defective ultrasonic vocalization; brain-specific Foxp1 knockout pups have strongly reduced ultrasonic vocalization and lose the normal sex-specific call rate. FoxP1 is co-expressed with the androgen receptor in striatal medium spiny neurons, and FOXP1 heterodimerizes with FOXP2, tying this node to the canonical speech-and-language pathway. The proximate mechanism is subtype specific: FOXP1 strengthens and matures the long-range cortical and thalamic glutamatergic inputs onto D2 (indirect-pathway) SPNs and thereby promotes their synaptically driven excitability. Critically, postnatal FOXP1 reinstatement in mice rescues the electrophysiological, cell-type-specific transcriptional, and behavioral abnormalities, so at least part of this node is not a fixed prenatal malformation.

medium spiny neuron CL:1001474

regulation of membrane potential GO:0042391 ⚠ ABNORMAL

Downstream

Impaired Speech Motor and Vocal Communication Output

Autistic Features and Behavioral Dysregulation

Show evidence (4 references)

PMID:28204507 SUPPORT Model Organism

"Foxp1 KO pups had strongly reduced USV and lacked the sex-specific call rate from WT pups, indicating that Foxp1 is essential for normal USV."

Independent knockout model confirms that Foxp1 loss impairs vocal output.

PMID:28204507 SUPPORT Model Organism

"Since Foxp1 and Foxp2 form heterodimers for transcriptional regulation, we investigated USV in neonatal brain-specific Foxp1 KO mice."

Documents the FOXP1-FOXP2 heterodimer that connects FOXP1 dosage to the established speech-and-language transcription factor.

PMID:38701209 SUPPORT Model Organism

"We find a neuron subtype-specific role of FOXP1 in strengthening and maturing glutamatergic inputs onto dopamine receptor 2-expressing SPNs (D2 SPNs). We also find that FOXP1 promotes synaptically driven excitability in these neurons."

Resolves the excitability effect to a specific mechanism (maturation of long-range cortical and thalamic glutamatergic input) and a specific neuron subtype (D2, indirect-pathway SPNs).

+ 1 more reference

Impaired Speech Motor and Vocal Communication Output

The clinical convergence point that distinguishes FOXP1 syndrome from other syndromic intellectual disabilities: speech and language impairment is present in essentially every affected individual regardless of cognitive level. The profile is complex rather than a pure verbal dyspraxia - all verbal patients show dysarthric and apraxic features with persistent phonological errors, and in individuals with truncating or splice-site variants and small deletions expressive ability is relatively preserved compared with comprehension. This differs from the primary oromotor verbal dyspraxia of FOXP2 deficiency.

Show evidence (3 references)

PMID:37733892 SUPPORT Human Clinical

"speech and language impairment in all individuals regardless of level of cognitive abilities"

GeneReviews establishes speech and language impairment as the invariant feature, independent of cognitive level.

PMID:34109629 SUPPORT Human Clinical

"All had atypical speech, with 21 being verbal and eight minimally verbal. All verbal patients had dysarthric and apraxic features, with phonological deficits in most (14 out of 16)."

Standardized speech assessment in 29 patients quantifies the profile and its universality.

PMID:20571508 SUPPORT Human Clinical

"The nature of the speech deficit is different from the primary oromotor verbal dyspraxia found in patients with FOXP2 deficiency."

Contrasts the FOXP1 speech phenotype with the FOXP2 phenotype, supporting it as a distinct mechanism-level endpoint.

Global Developmental Delay and Intellectual Disability

Impaired cortical and striatal development produces early motor and language milestone delay and mild-to-severe intellectual disability, present in essentially all affected individuals. Longitudinal caregiver report finds continued, if slow, acquisition of adaptive skills into adulthood, with no developmental regression, neuropsychiatric decompensation, or catatonia, distinguishing FOXP1 syndrome from regressive neurodevelopmental disorders.

Downstream

Dependence in Activities of Daily Living

Show evidence (2 references)

PMID:38123995 SUPPORT Human Clinical

"All patients had developmental problems, including cognitive, communication, social-emotional and motor delays."

An unbiased 40-person cohort establishes the universality of multi-domain developmental delay.

PMID:40066139 SUPPORT Human Clinical

"There were no reports of developmental regression, neuropsychiatric decompensation or catatonia."

Establishes the non-regressive natural history, an important negative finding for counseling and for the mechanistic model.

Autistic Features and Behavioral Dysregulation

A complex neurobehavioral profile rather than a single behavioral diagnosis. Restricted and repetitive behaviors are near-universal even in individuals who do not meet criteria for autism spectrum disorder; ADHD is the most common formal psychiatric diagnosis, followed by anxiety, with sensory symptoms (particularly sensory seeking) common. The behavioral phenotype persists into adolescence and adulthood as anxiety plus externalizing behavior. The mechanistic path from FOXP1-dependent striatal and cortical circuits to these behaviors is supported by model systems but not established in humans.

Show evidence (2 references)

PMID:34588003 SUPPORT Human Clinical

"In addition, 24% of the cohort met criteria for ASD. Seventy-five percent of individuals met DSM-5 criteria for attention-deficit/hyperactivity disorder and 38% for an anxiety disorder. Repetitive behaviors were almost universally present (95%) even without a diagnosis of ASD."

Quantifies each component of the behavioral phenotype in a prospectively assessed cohort.

PMID:29090079 SUPPORT Human Clinical

"Individuals with FOXP1 syndrome presented with delays in early motor and language milestones, language impairment (expressive language > receptive language), ASD symptoms, visual-motor integration deficits, and complex psychiatric presentations characterized by anxiety, obsessive-compulsive..."

The first prospective standardized characterization of the composite behavioral phenotype.

Extra-CNS Developmental Consequences of FOXP1 Dosage Reduction

FOXP1 is required outside the brain. In mice it has critical roles in spinal motor neuron, lymphocyte, cardiomyocyte, foregut and skeletal development, and reduced dosage in humans is associated with cardiac malformations, congenital anomalies of the kidney and urinary tract, cryptorchidism, ophthalmic anomalies, and recurrent sinopulmonary or airway infections. Which of these are obligate consequences of FOXP1 dosage versus variable stochastic developmental effects is unresolved; single-patient reports of lung and skeletal disease remain unreplicated.

Show evidence (3 references)

PMID:28884888 SUPPORT Human Clinical

"In humans FOXP1 mutations have been associated with language and speech defects, intellectual disability, autism spectrum disorder, facial dysmorphisms, and congenital anomalies of the kidney and urinary tract."

Sets out the established extra-CNS human associations that motivate the node. The murine requirement is cited separately, as MODEL_ORGANISM evidence, on the causal edge into this node.

PMID:28884888 SUPPORT Human Clinical

"Although attribution of these traits to mutation of FOXP1 requires ascertainment of additional patients, we hypothesize that the variable expression of these additional features might arise by means of stochastic developmental variation."

The authors themselves flag the unreplicated single-patient features as provisional, which is why this node carries PROVISIONAL confidence.

ORPHA:391372 SUPPORT Other

"Brain, cardiac, urogenital and ocular malformations may be associated."

Orphanet independently records the organ systems affected by congenital malformation in FOXP1 syndrome.

Dependence in Activities of Daily Living

The lifetime functional endpoint. Most individuals acquire some basic self-care tasks independently, but the majority rely heavily on caregivers, and many require continuous supervision into adulthood. Skills continue to accrue rather than decline, so the trajectory is one of slow gain against a persistent support requirement.

Show evidence (1 reference)

PMID:41175749 SUPPORT Human Clinical

"Although most individuals learn to perform some basic daily living tasks independently, the majority heavily rely on their parents, many needing 24-7 supervision to support many aspects of daily life up to adulthood."

Directly quantifies the level of ongoing support required, the practical endpoint families ask about.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

46

Cardiovascular 1

Congenital Cardiac Malformation FREQUENT Abnormal heart morphology HP:0001627

Show evidence (3 references)

PMID:37733892 SUPPORT Human Clinical

"abnormalities, renal abnormalities, cryptorchidism"

GeneReviews lists cardiac abnormalities among the common findings.

ORPHA:391372 SUPPORT Other

"Brain, cardiac, urogenital and ocular malformations may be associated."

Orphanet independently records cardiac malformation.

PMID:33892622 SUPPORT Human Clinical

"Congenital heart defect - 2/9 (iv) 9/19 (v) - - 1/3 (vi) - - - 17/56 (30%)"

The pooled review quantifies congenital heart defects at 30%, mapping to the FREQUENT band.

Digestive 2

Feeding Difficulties OCCASIONAL HP:0011968

Show evidence (2 references)

PMID:37733892 SUPPORT Human Clinical

"Other common findings are oromotor dysfunction (contributing to speech and feeding difficulties)"

GeneReviews explicitly attributes feeding difficulties to oromotor dysfunction.

PMID:33892622 SUPPORT Human Clinical

"(18/62; 29%) and feeding issues (13/62; 21%)"

The pooled review quantifies feeding issues at 21%, mapping to the OCCASIONAL band.

Dysphagia HP:0002015

Show evidence (1 reference)

ORPHA:391372 SUPPORT Other

"mild to severe intellectual disability, dysphagia, hypotonia"

Orphanet includes dysphagia in the clinical definition.

Ear 2

Hearing Impairment OCCASIONAL HP:0000365

Show evidence (2 references)

PMID:37733892 SUPPORT Human Clinical

"cryptorchidism, hypertonia, hearing loss, and epilepsy"

GeneReviews lists hearing loss among the common findings.

PMID:33892622 SUPPORT Human Clinical

"Hearing loss was also reported (8/48; 17%)."

The pooled review quantifies hearing loss at 17%, mapping to the OCCASIONAL band.

Recurrent Otitis Media OCCASIONAL HP:0000403

Show evidence (1 reference)

PMID:33892622 SUPPORT Human Clinical

"Recurrent ear infections were reported in some cases (7/60; 12%)."

The pooled review quantifies recurrent ear infections at 12%, mapping to the OCCASIONAL band.

Eye 5

Hypermetropia HP:0000540

Show evidence (1 reference)

PMID:38123995 SUPPORT Human Clinical

"The most prevalent medical signs and symptoms include delayed bladder control, sleeping problems, hypermetropia, strabismus, sacral dimple, undescended testes, abnormal muscle tone and airway infections."

Hypermetropia is explicitly named among the most prevalent findings.

Strabismus OCCASIONAL HP:0000486

Show evidence (3 references)

PMID:38123995 SUPPORT Human Clinical

"The most prevalent medical signs and symptoms include delayed bladder control, sleeping problems, hypermetropia, strabismus, sacral dimple, undescended testes, abnormal muscle tone and airway infections."

Strabismus is explicitly named among the most prevalent findings.

PMID:37733892 SUPPORT Human Clinical

"refractive errors, strabismus, cardiac"

GeneReviews includes strabismus among the common findings.

PMID:33892622 SUPPORT Human Clinical

"myopia (29/58; 50%), and strabismus (11/60; 18%) were reported in a significant number of cases."

The pooled review quantifies strabismus at 18%, mapping to the OCCASIONAL band.

Hypertelorism OCCASIONAL HP:0000316

Show evidence (2 references)

ORPHA:391372 SUPPORT Other

"Facial gestalt typically features a broad, prominent forehead, hypertelorism, downslanting palpebral fissures, ptosis, a short bulbous nose with broad tip"

The Orphanet facial-gestalt description names hypertelorism.

PMID:33892622 SUPPORT Human Clinical

"ocular hypertelorism (17/59; 29%), and frontal hair upsweep (16/59; 27%)"

The pooled review quantifies ocular hypertelorism at 29%, mapping to the OCCASIONAL band.

Ptosis FREQUENT HP:0000508

Show evidence (2 references)

ORPHA:391372 SUPPORT Other

"hypertelorism, downslanting palpebral fissures, ptosis, a short bulbous nose with broad tip"

The Orphanet facial-gestalt description names ptosis.

PMID:33892622 SUPPORT Human Clinical

"fissures (24/59; 41%), ptosis (22/59; 37%), thick"

The pooled review quantifies ptosis at 37%, mapping to the FREQUENT band.

Myopia FREQUENT HP:0000545

Show evidence (1 reference)

PMID:33892622 SUPPORT Human Clinical

"myopia (29/58; 50%), and strabismus (11/60; 18%) were reported in a significant number of cases."

The pooled review quantifies myopia at 50%, mapping to the FREQUENT band.

Genitourinary 3

Renal and Urinary Tract Anomaly Abnormality of the kidney HP:0000077

Show evidence (2 references)

PMID:28884888 SUPPORT Human Clinical

"In humans FOXP1 mutations have been associated with language and speech defects, intellectual disability, autism spectrum disorder, facial dysmorphisms, and congenital anomalies of the kidney and urinary tract."

Explicitly names congenital anomalies of the kidney and urinary tract as an established FOXP1 association.

PMID:37733892 SUPPORT Human Clinical

"renal abnormalities, cryptorchidism"

GeneReviews lists renal abnormalities among the common findings.

Cryptorchidism OCCASIONAL HP:0000028

Show evidence (3 references)

PMID:38123995 SUPPORT Human Clinical

"sacral dimple, undescended testes, abnormal muscle tone and airway infections"

Undescended testes named among the most prevalent findings.

PMID:37733892 SUPPORT Human Clinical

"renal abnormalities, cryptorchidism, hypertonia"

GeneReviews lists cryptorchidism among the common findings.

PMID:33892622 SUPPORT Human Clinical

"cryptorchidism (9/41 males; 22%), and micropenis"

The pooled review quantifies cryptorchidism at 22% of affected males, mapping to the OCCASIONAL band.

Micropenis OCCASIONAL HP:0000054

Show evidence (1 reference)

PMID:33892622 SUPPORT Human Clinical

"cryptorchidism (9/41 males; 22%), and micropenis"

The pooled review reports micropenis in 3/41 males (7%), mapping to the OCCASIONAL band.

Head and Neck 5

Broad and Prominent Forehead VERY_FREQUENT HP:0011220

Show evidence (3 references)

PMID:33892622 SUPPORT Human Clinical

"prominent forehead (48/59; 81%), short nose with a broad tip or base (41/59; 69%), down slanting"

The pooled review quantifies prominent forehead at 81%, the most frequent dysmorphic feature, mapping to the VERY_FREQUENT band.

PMID:24214399 SUPPORT Human Clinical

"Facial features include a broad forehead, downslanting palpebral fissures, a short nose with broad tip, relative or true macrocephaly, a frontal hair upsweep and prominent digit pads."

The delineating paper defines the recognizable facial phenotype and calls the same feature a broad forehead.

ORPHA:391372 SUPPORT Other

"Facial gestalt typically features a broad, prominent forehead"

Orphanet uses both descriptors for the same feature, supporting the choice of the Prominent forehead term with a combined preferred term.

Downslanted Palpebral Fissures FREQUENT HP:0000494

Show evidence (2 references)

PMID:24214399 SUPPORT Human Clinical

"Facial features include a broad forehead, downslanting palpebral fissures, a short nose with broad tip"

Named in the delineating facial-gestalt description.

PMID:33892622 SUPPORT Human Clinical

"fissures (24/59; 41%), ptosis (22/59; 37%), thick"

The pooled review quantifies down-slanting palpebral fissures at 41%, mapping to the FREQUENT band.

Short Nose with Broad Tip FREQUENT HP:0003196

Show evidence (2 references)

PMID:24214399 SUPPORT Human Clinical

"a short nose with broad tip, relative or true macrocephaly"

Named in the delineating facial-gestalt description.

PMID:33892622 SUPPORT Human Clinical

"short nose with a broad tip or base (41/59; 69%), down slanting"

The pooled review quantifies short nose with a broad tip or base at 69%, mapping to the FREQUENT band.

Relative or True Macrocephaly OCCASIONAL HP:0000256

Show evidence (3 references)

PMID:24214399 SUPPORT Human Clinical

"a short nose with broad tip, relative or true macrocephaly, a frontal hair upsweep and prominent digit pads."

Named in the delineating facial-gestalt description.

ORPHA:391372 SUPPORT Other

"dysphagia, hypotonia, relative to true macrocephaly"

Orphanet independently records relative-to-true macrocephaly.

PMID:33892622 SUPPORT Human Clinical

"macrocephaly (9/59; 15%), and broad nasal"

The pooled review scores frank macrocephaly in only 15% of dysmorphology examinations, so this feature is curated as OCCASIONAL despite its prominence in the classic gestalt description.

Thick Vermilion Border HP:0012471

Show evidence (1 reference)

ORPHA:391372 SUPPORT Other

"a short bulbous nose with broad tip, thick vermilion border, wide, and open mouth with downturned corners"

Orphanet's facial-gestalt description names a thick vermilion border.

Immune 1

Recurrent Respiratory Infections HP:0002205

Show evidence (2 references)

PMID:38123995 SUPPORT Human Clinical

"undescended testes, abnormal muscle tone and airway infections"

Airway infections named among the most prevalent findings.

PMID:29090079 SUPPORT Human Clinical

"endocrine and gastrointestinal problems, sleep disturbances, and sinopulmonary infections"

Independent prospective cohort confirms sinopulmonary infections.

Integument 1

Prominent Fingertip Pads HP:0001212

Show evidence (1 reference)

PMID:24214399 SUPPORT Human Clinical

"a frontal hair upsweep and prominent digit pads"

Named in the delineating description of the recognizable phenotype.

Musculoskeletal 3

Hypotonia OCCASIONAL HP:0001252

Show evidence (3 references)

ORPHA:391372 SUPPORT Other

"mild to severe global development delay, severe speech and language impairment, mild to severe intellectual disability, dysphagia, hypotonia"

Orphanet includes hypotonia in the core clinical description.

PMID:25853299 SUPPORT Human Clinical

"We report on a female child with a history of severe hypotonia, autism spectrum disorder and mild intellectual disability with severe speech/language impairment."

Case report with a functionally validated FOXP1 frameshift documents severe hypotonia.

PMID:33892622 SUPPORT Human Clinical

"(18/62; 29%) and feeding issues (13/62; 21%)"

The pooled review quantifies a history of hypotonia at 29%, mapping to the OCCASIONAL band (5-29%).

Hypertonia HP:0001276

Show evidence (2 references)

PMID:37733892 SUPPORT Human Clinical

"cryptorchidism, hypertonia, hearing loss, and epilepsy"

GeneReviews lists hypertonia among the common findings; the collective wording does not license a specific frequency band.

PMID:38123995 SUPPORT Human Clinical

"The most prevalent medical signs and symptoms include delayed bladder control, sleeping problems, hypermetropia, strabismus, sacral dimple, undescended testes, abnormal muscle tone and airway infections."

Supports abnormal muscle tone as highly prevalent without specifying the direction of the abnormality.

Contractures and Spasticity OCCASIONAL Flexion contracture HP:0001371

Show evidence (1 reference)

PMID:33892622 SUPPORT Human Clinical

"Spastic/contractures - - 10/19 - - - - 1/1 - 16/56 (29%)"

The pooled review quantifies spasticity/contractures at 29%, mapping to the OCCASIONAL band.

Nervous System 11

Global Developmental Delay VERY_FREQUENT HP:0001263

Show evidence (2 references)

PMID:38123995 SUPPORT Human Clinical

"All patients had developmental problems, including cognitive, communication, social-emotional and motor delays."

Forty of forty individuals in an unbiased cohort had multi-domain developmental delay, supporting the VERY_FREQUENT band.

PMID:33892622 SUPPORT Human Clinical

"Gross and fine motor delays were present in virtually all cases (59/61; 97%)."

The pooled 62-person literature review independently reports 97% for the motor domain, consistent with the VERY_FREQUENT band.

Intellectual Disability VERY_FREQUENT HP:0001249

Show evidence (3 references)

PMID:37733892 SUPPORT Human Clinical

"FOXP1 syndrome is characterized by delays in early motor and language milestones, mild-to-severe intellectual deficits, speech and language impairment in all individuals regardless of level of cognitive abilities, and behavior abnormalities"

GeneReviews lists mild-to-severe intellectual deficits as a defining characteristic of the syndrome.

PMID:34588003 SUPPORT Human Clinical

"Previous observations of intellectual disability, motor delays, and language deficits were confirmed."

Prospective replication of intellectual disability in a second cohort.

PMID:33892622 SUPPORT Human Clinical

"present in 90% (55/61) of cases evaluated"

The pooled review quantifies intellectual disability or global developmental delay at 90%, mapping to the VERY_FREQUENT band.

Speech and Language Impairment OBLIGATE Delayed speech and language development HP:0000750

Show evidence (3 references)

PMID:37733892 SUPPORT Human Clinical

"speech and language impairment in all individuals regardless of level of cognitive abilities"

GeneReviews states the impairment is present in all individuals, supporting the OBLIGATE band.

PMID:34109629 SUPPORT Human Clinical

"All had atypical speech, with 21 being verbal and eight minimally verbal."

Standardized speech assessment found atypical speech in 29 of 29 patients.

PMID:33892622 SUPPORT Human Clinical

"Speech and language delays were reported in all the cases (60/60; 100%)"

A third, independent aggregation reports 60/60 (100%), the quantitative basis for the OBLIGATE band.

Dysarthria FREQUENT HP:0001260

Show evidence (2 references)

PMID:34109629 SUPPORT Human Clinical

"All verbal patients had dysarthric and apraxic features, with phonological deficits in most (14 out of 16)."

All 21 verbal patients out of the 29-patient cohort (72%) had dysarthric features, supporting the FREQUENT band.

PMID:33892622 SUPPORT Human Clinical

"Articulation problems 3/3 9/9 9/11 - - 1/3 - 1/1 - 32/48 (67%)"

The pooled review reports articulation problems in 67%, independently supporting the FREQUENT band for the motor-speech deficit.

Speech Apraxia FREQUENT HP:0011098

Show evidence (2 references)

PMID:34109629 SUPPORT Human Clinical

"Features of speech apraxia occur alongside persistent phonological errors."

The authors' summary of the speech profile documents apraxic features in the cohort.

PMID:24214399 SUPPORT Human Clinical

"DVD appears not to be a distinct feature in this group."

Earlier literature review found developmental verbal dyspraxia not to be a distinguishing feature, so apraxic features are curated as present but not defining.

Motor Delay VERY_FREQUENT HP:0001270

Show evidence (2 references)

PMID:29090079 SUPPORT Human Clinical

"Individuals with FOXP1 syndrome presented with delays in early motor and language milestones, language impairment (expressive language > receptive language), ASD symptoms, visual-motor integration deficits"

Prospective standardized assessment documents motor milestone delay across the cohort.

PMID:38123995 SUPPORT Human Clinical

"All patients had developmental problems, including cognitive, communication, social-emotional and motor delays."

All 40 individuals had motor delay, supporting the VERY_FREQUENT band.

Seizures OCCASIONAL HP:0001250

Show evidence (3 references)

PMID:37733892 SUPPORT Human Clinical

"cryptorchidism, hypertonia, hearing loss, and epilepsy"

GeneReviews includes epilepsy among the common findings; no quantitative frequency is given, so frequency is omitted.

PMID:20571508 SUPPORT Human Clinical

"This patient presented with speech and motor developmental delays, a Chiari I malformation, and epileptiform discharges."

Documents epileptiform activity in a patient with an isolated FOXP1 deletion.

PMID:33892622 SUPPORT Human Clinical

"Seizures were reported in some cases (7/59; 12%)."

The pooled review quantifies seizures at 12%, mapping to OCCASIONAL and confirming that epilepsy is a minority rather than a defining feature.

Autism Spectrum Disorder OCCASIONAL HP:0000717

Show evidence (3 references)

PMID:34588003 SUPPORT Human Clinical

"In addition, 24% of the cohort met criteria for ASD."

A direct quantitative estimate of 24% maps to the OCCASIONAL band (5-29%).

PMID:34588003 SUPPORT Human Clinical

"Notably, standardized testing for ASD showed high sensitivity, but low specificity, when compared to expert consensus diagnosis."

Cautions that instrument-based ASD rates in this population overcall the diagnosis relative to expert consensus.

PMID:33892622 SUPPORT Human Clinical

"ASD features - 4/8 14/20 - - - 1/1 1/1 - 28/56 (50%)"

The pooled literature review reports ASD *features* in 50%, roughly double the 24% who met formal DSM-5 criteria on prospective expert-consensus assessment. The curated frequency follows the stricter prospective diagnosis; this item records the higher retrospective trait-level figure rather than silently averaging the two.

Attention Deficit Hyperactivity Disorder FREQUENT HP:0007018

Show evidence (1 reference)

PMID:34588003 SUPPORT Human Clinical

"Seventy-five percent of individuals met DSM-5 criteria for attention-deficit/hyperactivity disorder and 38% for an anxiety disorder."

Seventy-five percent maps to the FREQUENT band (30-79%).

Anxiety FREQUENT HP:0000739

Show evidence (3 references)

PMID:34588003 SUPPORT Human Clinical

"Seventy-five percent of individuals met DSM-5 criteria for attention-deficit/hyperactivity disorder and 38% for an anxiety disorder."

38% meeting criteria for an anxiety disorder maps to the FREQUENT band.

PMID:40066139 SUPPORT Human Clinical

"Anxiety and externalizing behaviors were common in this cohort and psychiatric features, such as psychosis or bipolar symptoms, were present in two participants."

Confirms persistence of anxiety into adolescence and adulthood.

PMID:33892622 SUPPORT Human Clinical

"Behavioral problems 2/2 9/9 12/19 - 1/1 2/3 - 1/1 - 32/56 (57%)"

The pooled review documents psychiatric comorbidity (ADHD, aggression, obsessive-compulsive traits, mood disorders and anxiety) in 57%.

Sleep Disturbance HP:0002360

Show evidence (2 references)

PMID:38123995 SUPPORT Human Clinical

"The most prevalent medical signs and symptoms include delayed bladder control, sleeping problems, hypermetropia, strabismus, sacral dimple, undescended testes, abnormal muscle tone and airway infections."

Sleeping problems rank among the most prevalent symptoms; no numeric rate is given, so frequency is omitted.

PMID:29090079 SUPPORT Human Clinical

"Medical features included non-specific structural brain abnormalities and dysmorphic features, endocrine and gastrointestinal problems, sleep disturbances, and sinopulmonary infections."

Independent prospective cohort confirms sleep disturbance.

Growth 2

Short Stature OCCASIONAL HP:0004322

Show evidence (1 reference)

PMID:33892622 SUPPORT Human Clinical

"Short stature (8/60; 13%) and obesity (3/60; 5%) were"

The pooled review quantifies short stature at 13%, mapping to the OCCASIONAL band.

Obesity OCCASIONAL HP:0001513

Show evidence (1 reference)

PMID:33892622 SUPPORT Human Clinical

"Short stature (8/60; 13%) and obesity (3/60; 5%) were"

The pooled review quantifies obesity at 5%, the lower edge of the OCCASIONAL band.

Other 10

Expressive Language Delay HP:0002474

Show evidence (2 references)

PMID:24214399 SUPPORT Human Clinical

"Review of our patient and others reported in the literature reveals an emerging phenotype of GDD/ID with moderate to severe speech delay where expressive speech is most severely affected."

The delineating literature review identifies expressive speech as the most severely affected domain.

PMID:34109629 SUPPORT Human Clinical

"In the 21 individuals who carried truncating or splice site variants and small deletions, expressive abilities were relatively preserved compared with comprehension."

Qualifies the classic expressive-predominant claim; formal testing shows a genotype-dependent expressive and receptive relationship.

Oromotor Dysfunction Oromotor apraxia HP:0007301

Show evidence (1 reference)

PMID:37733892 SUPPORT Human Clinical

"Other common findings are oromotor dysfunction (contributing to speech and feeding difficulties), refractive errors, strabismus, cardiac abnormalities, renal abnormalities, cryptorchidism, hypertonia, hearing loss, and epilepsy."

GeneReviews lists oromotor dysfunction among the common findings; the collective wording does not support a specific frequency band, so frequency is omitted.

Chiari Type I Malformation HP:0007099

Show evidence (1 reference)

PMID:20571508 SUPPORT Human Clinical

"In this study, we report the case of a patient with a single deletion of FOXP1. This patient presented with speech and motor developmental delays, a Chiari I malformation, and epileptiform discharges."

Single-patient report; recorded without a frequency because it is not established as a recurrent feature.

Restricted and Repetitive Behaviors VERY_FREQUENT Restricted or repetitive behaviors or interests HP:0031432

Show evidence (1 reference)

PMID:34588003 SUPPORT Human Clinical

"Repetitive behaviors were almost universally present (95%) even without a diagnosis of ASD."

95% maps to the VERY_FREQUENT band (80-100%).

Refractive Error Abnormality of refraction HP:0000539

Show evidence (1 reference)

PMID:37733892 SUPPORT Human Clinical

"Other common findings are oromotor dysfunction (contributing to speech and feeding difficulties), refractive errors, strabismus, cardiac abnormalities, renal abnormalities, cryptorchidism, hypertonia, hearing loss, and epilepsy."

GeneReviews lists refractive errors among the common findings.

Delayed Bladder Control Enuresis HP:0000805

Show evidence (1 reference)

PMID:38123995 SUPPORT Human Clinical

"The most prevalent medical signs and symptoms include delayed bladder control, sleeping problems, hypermetropia, strabismus, sacral dimple, undescended testes, abnormal muscle tone and airway infections."

Delayed bladder control heads the list of most prevalent symptoms in the unbiased cohort.

Frontal Hair Upsweep OCCASIONAL Frontal upsweep of hair HP:0002236

Show evidence (2 references)

PMID:24214399 SUPPORT Human Clinical

"a frontal hair upsweep and prominent digit pads"

Named in the delineating facial-gestalt description.

PMID:33892622 SUPPORT Human Clinical

"ocular hypertelorism (17/59; 29%), and frontal hair upsweep (16/59; 27%)"

The pooled review quantifies frontal hair upsweep at 27%, mapping to the OCCASIONAL band.

Sacral Dimple HP:0000960

Show evidence (1 reference)

PMID:38123995 SUPPORT Human Clinical

"hypermetropia, strabismus, sacral dimple, undescended testes"

Sacral dimple named among the most prevalent findings.

Structural Brain Abnormality FREQUENT Abnormal brain morphology HP:0012443

Show evidence (2 references)

PMID:33892622 SUPPORT Human Clinical

"Brain abnormalities were evident in about a half of total cases (29/58)"

The pooled review quantifies structural brain abnormality at about 50%, mapping to the FREQUENT band.

PMID:29090079 SUPPORT Human Clinical

"Medical features included non-specific structural brain abnormalities and dysmorphic features"

A prospective cohort independently documents the non-specific nature of the imaging findings.

Aberrant Sensory Responsiveness Sensory behavioral abnormality HP:5200046

Show evidence (2 references)

PMID:34588003 SUPPORT Human Clinical

"Sensory symptoms, in particular sensory seeking, were common."

Prospective standardized sensory assessment documents the sensory phenotype; no numeric rate is given, so frequency is omitted.

PMID:37691105 SUPPORT Model Organism

"Foxp1-cKO mice had a deferred response to the tactile environment. However, the mice exhibited avoidance behavior and hyper-reaction following repeated whisker stimulation, similar to a fight-or-flight response."

A cortex-restricted mouse model reproduces an analogous tactile phenotype; translation of whisker behavior to human sensory experience is indirect, so this is PARTIAL support.

🧬

Genetic Associations

1

FOXP1 Pathogenic Variants (Causative)

Gene: FOXP1 hgnc:3823 relationship_type: CAUSATIVE variant_origin: DE_NOVO

Autosomal dominant inheritance

Show evidence (4 references)

PMID:29090079 SUPPORT Human Clinical

"Haploinsufficiency of the forkhead-box protein P1 (FOXP1) gene leads to a neurodevelopmental disorder termed FOXP1 syndrome."

States haploinsufficiency of FOXP1 as the disease mechanism.

PMID:29090079 SUPPORT Human Clinical

"This study identifies novel FOXP1 mutations associated with FOXP1 syndrome, identifies recurrent mutations, and demonstrates significant clustering of missense mutations in the DNA-binding domain."

Establishes the DNA-binding-domain clustering of missense alleles.

PMID:30385778 SUPPORT In Vitro

"Most of the reported FOXP1 mutations occur on the C-terminus of the protein and cluster around to the forkhead domain. All reported FOXP1 pathogenic variants result in abnormal cellular localization and loss of transcriptional repression activity of the protein product."

Functional characterization of the allele spectrum showing convergent loss of repression.

+ 1 more reference

🔬

Variants

2

FOXP1 c.1574G>A (p.Arg525Gln)

Gene: FOXP1 hgnc:3823

A recurrent missense substitution in the forkhead DNA-binding domain, reported in three unrelated patients. It abolishes transcriptional repression while, uniquely among characterized FOXP1 alleles, preserving normal nuclear localization, evidence that loss of repression rather than mislocalization is the shared pathogenic consequence.

Show evidence (1 reference)

PMID:30385778 SUPPORT In Vitro

"Here we present three patients with the same FOXP1 mutation, c.1574G>A (p.R525Q), that results in the characteristic loss of transcription repression activity."

Identifies the recurrent allele and its functional consequence.

FOXP1 c.1267_1268delGT (p.Val423Hisfs*37)

Gene: FOXP1 hgnc:3823

A de novo frameshift allele identified by clinical exome sequencing in a child with autism, mild intellectual disability, severe hypotonia and severe speech and language impairment. Cellular assays showed disruption of both subcellular localization and transcriptional repression.

Show evidence (1 reference)

PMID:25853299 SUPPORT In Vitro

"Clinical exome sequencing identified a heterozygous de novo FOXP1 variant c.1267_1268delGT (p.V423Hfs*37). Functional analyses using cellular models show that the variant disrupts multiple aspects of FOXP1 activity, including subcellular localization and transcriptional repression properties."

Establishes the allele, its de novo origin, and its functional effect.

💊

Medical Actions

9

Multidisciplinary Supportive Care

Category: Therapeutic Action: supportive care Ontology label: Supportive Care NCIT:C15747

There is no disease-modifying therapy. Management is symptom directed and aims to improve quality of life, maximize function, and reduce complications, delivered by a multidisciplinary team spanning pediatrics, developmental medicine or neurodevelopment, neurology, physiatry, occupational and physical therapy, speech-language pathology, psychiatry, psychology, ophthalmology, and medical genetics. The GeneReviews chapter abstract records no agents or circumstances to avoid for this disorder.

Show evidence (1 reference)

PMID:37733892 SUPPORT Human Clinical

"Supportive care to improve quality of life, maximize function, and reduce complications is recommended. This can include multidisciplinary care by specialists in pediatrics, developmental medicine or neurodevelopment, neurology, physiatry, occupational and physical therapy, speech-language..."

GeneReviews defines the standard of care as multidisciplinary supportive management.

Speech and Language Therapy

Category: Therapeutic Action: speech and language therapy Ontology label: Speech Language Therapy NCIT:C159273

Speech-language pathology is central to management. Because dysarthria rather than pure apraxia dominates the profile, therapy should be targeted at dysarthria and phonology; in one cohort no participant was receiving dysarthria-directed therapy despite being good candidates for it. Alternative and augmentative communication is appropriate for minimally verbal individuals.

Target Phenotypes: Delayed speech and language development HP:0000750 Dysarthria HP:0001260

Show evidence (2 references)

PMID:34109629 SUPPORT Human Clinical

"No participants were receiving speech therapy for dysarthria, but were good candidates for therapy"

Identifies dysarthria-directed speech therapy as an under-delivered, indicated intervention in this population.

PMID:34109629 SUPPORT Human Clinical

"Diagnosis of the speech phenotype associated with FOXP1-related dysfunction will inform early targeted therapy."

Supports phenotype-specific targeting of speech therapy.

Occupational Therapy

Category: Therapeutic Action: occupational therapy Ontology label: Occupational Therapy NCIT:C121351

Occupational therapy supports fine-motor and visual-motor integration deficits, sensory symptoms, and the acquisition of activities of daily living, which remain a major long-term support need.

Show evidence (2 references)

PMID:37733892 SUPPORT Human Clinical

"neurology, physiatry, occupational and physical therapy, speech-language pathology"

GeneReviews includes occupational therapy in the recommended multidisciplinary team.

PMID:41175749 SUPPORT Human Clinical

"We found that individuals with FOXP1 syndrome have great difficulties with both basic and instrumental activities of daily living, but continue to develop their skills into adulthood."

Documents the activities-of-daily-living deficit that occupational therapy targets, and the continued capacity for skill gain that justifies ongoing therapy into adulthood.

Physical Therapy

Category: Therapeutic Action: physical therapy Ontology label: Physical Therapy NCIT:C15302

Physical therapy addresses gross-motor delay and abnormal muscle tone.

Target Phenotypes: Motor delay HP:0001270

Show evidence (1 reference)

PMID:37733892 SUPPORT Human Clinical

"neurology, physiatry, occupational and physical therapy, speech-language pathology"

GeneReviews includes physical therapy in the recommended multidisciplinary team.

Behavioral and Psychiatric Intervention

Category: Therapeutic Action: behavioral intervention Ontology label: Behavioral Intervention NCIT:C15184

Behavioral and psychological intervention addresses the near-universal restricted and repetitive behaviors, anxiety, and externalizing behaviors. Cohort data show that many individuals with formal ADHD or anxiety diagnoses were not receiving treatment for them, so systematic psychiatric assessment is an actionable gap.

Target Phenotypes: Anxiety HP:0000739 Restricted or repetitive behaviors or interests HP:0031432

Show evidence (1 reference)

PMID:34588003 SUPPORT Human Clinical

"Furthermore, many individuals in our cohort who received diagnoses of attention-deficit/hyperactivity disorder or anxiety disorder were not being treated for these symptoms; therefore, our findings suggest that there may be immediate areas for improvements in treatment for some individuals."

Identifies undertreatment of ADHD and anxiety as a concrete management gap.

Pharmacotherapy for ADHD Symptoms

Category: Therapeutic Action: Pharmacotherapy NCIT:C15986

Agent: CNS stimulant NCIT:C47795 methylphenidate CHEBI:6887

Medication for ADHD features, typically CNS stimulants such as methylphenidate, is commonly used in adolescents and adults with FOXP1 syndrome. Caregiver-reported experience indicates that multiple medication trials may be required before benefit is achieved, so a structured trial plan is appropriate. No FOXP1-specific efficacy trial has been performed; prescribing follows general ADHD practice. A tolerability caveat is documented: the investigators of a French psychiatric-phenotyping study record family reports of ineffectiveness and poor tolerance of methylphenidate in this population, so response should not be assumed and stimulant trials warrant close monitoring.

Target Phenotypes: Attention deficit hyperactivity disorder HP:0007018

Show evidence (2 references)

PMID:40066139 SUPPORT Human Clinical

"Medication use was common particularly for features of ADHD, although multiple trials were required for some individuals to achieve benefit."

Documents both the common use of ADHD pharmacotherapy and the practical caveat about multiple trials.

clinicaltrials:NCT06211673 SUPPORT Other

"Additionally, families reported ineffectiveness and poor tolerance of methylphenidate in these patients."

A registered study protocol records caregiver-reported poor methylphenidate efficacy and tolerance, tempering the assumption that standard ADHD pharmacotherapy transfers cleanly to FOXP1 syndrome. This is an uncontrolled clinical observation stated in a trial rationale, not a trial result.

Anticonvulsant Therapy

Category: Therapeutic Action: anticonvulsant therapy Ontology label: Anticonvulsant Therapy NCIT:C64172

Standard anti-seizure medication is used for the subset of individuals with epilepsy. No FOXP1-specific regimen is established.

Target Phenotypes: Seizure HP:0001250

Show evidence (1 reference)

PMID:37733892 SUPPORT Human Clinical

"cryptorchidism, hypertonia, hearing loss, and epilepsy"

GeneReviews establishes epilepsy as a manifestation requiring management; it does not specify an agent, so the treatment is curated as generic anticonvulsant therapy.

Multispecialty Surveillance

Category: Monitoring Action: disease screening and surveillance Ontology label: Disease Screening NCIT:C15419

Regular monitoring by the relevant specialists of existing manifestations, the response to supportive care, and the emergence of new manifestations. In practice this includes developmental, neurologic, ophthalmologic, audiologic, cardiac and renal review appropriate to the documented anomalies of the individual.

Show evidence (1 reference)

PMID:37733892 SUPPORT Human Clinical

"Regular monitoring by the relevant specialists of existing manifestations, the individual's response to supportive care, and the emergence of new manifestations is recommended."

GeneReviews defines the surveillance recommendation.

Genetic Counseling

Category: Counseling / Informational Action: genetic counseling Ontology label: Genetic Counseling NCIT:C15240

Counseling covers the autosomal dominant mechanism, the predominance of de novo variants, the 50% transmission risk from an affected individual, and the approximately 1% sib recurrence risk arising from possible parental germline mosaicism, the basis on which prenatal and preimplantation genetic testing may be offered.

Show evidence (1 reference)

PMID:37733892 SUPPORT Human Clinical

"There is, however, a recurrence risk (~1%) to sibs based on the possibility of parental germline mosaicism; given this risk, prenatal and preimplantation genetic testing may be considered."

GeneReviews supplies the recurrence-risk figure and the reproductive options that counseling must cover.

🔬

Diagnosis

1

Molecular Genetic Diagnosis of FOXP1 Syndrome (Positive)

The diagnosis is molecular. It is established in a proband with supportive clinical findings and a heterozygous pathogenic FOXP1 variant identified by molecular genetic testing, in practice exome or genome sequencing performed for neurodevelopmental delay, or chromosomal microarray when the lesion is a copy-number deletion. The recognizable facial gestalt plus a speech impairment disproportionate to cognitive level are the clinical triggers.

Show evidence (2 references)

PMID:37733892 SUPPORT Human Clinical

"The diagnosis of FOXP1 syndrome is established in a proband with a heterozygous pathogenic variant in FOXP1 identified by molecular genetic testing and supportive clinical findings."

GeneReviews states the diagnostic criterion.

PMID:38123995 SUPPORT Human Clinical

"Patients with FOXP1 syndrome were included, mostly diagnosed via whole-exome sequencing for neurodevelopmental delay."

Documents the ascertainment route in current practice.

📈

Progression

1

Non-regressive lifelong developmental trajectory

Age: Infancy through adulthood (observed 2-54 years)

FOXP1 syndrome follows a static-encephalopathy-like course. Caregiver-report studies spanning childhood to adulthood (age 2-54 years) document continued, if slow, acquisition of adaptive and communication skills into adulthood with no developmental regression, no neuropsychiatric decompensation, and no catatonia. Educational placement typically shifts toward special education by late elementary school, and caregiver concerns move from cognitive and developmental issues in childhood to independence, safety, and housing in adolescence and adulthood.

Show evidence (3 references)

PMID:40066139 SUPPORT Human Clinical

"There was no reported regression or loss of skills, early in development or during adolescence/adulthood."

Directly establishes the absence of regression across the observed age range.

PMID:40066139 SUPPORT Human Clinical

"Cognitive and developmental concerns were reported as primary during childhood and independence/safety and housing concerns became top concerns by adolescence/adulthood."

Characterizes how the burden of the disorder shifts across the lifespan.

PMID:41175749 SUPPORT Human Clinical

"but continue to develop their skills into adulthood"

A second, larger caregiver cohort confirms continued skill acquisition in adulthood.

📊

Prevalence

1

Worldwide (reported literature)

Cases In Literature Ultra Rare

GeneReviews reports more than 200 molecularly confirmed individuals worldwide as of the 2023 chapter revision. No population-based prevalence estimate has been published; Orphanet lists no epidemiology class for ORPHA:391372. The count is ascertainment limited and rising with routine exome/genome sequencing for neurodevelopmental delay.

Show evidence (3 references)

PMID:37733892 SUPPORT Human Clinical

"To date, more than 200 individuals have been identified with FOXP1 syndrome."

GeneReviews gives the cumulative count of reported individuals, the only occurrence figure available for this disorder.

ORPHA:391372 SUPPORT Other

"A rare, genetic, syndromic intellectual disability disorder, with highly variable phenotype"

Orphanet classifies FOXP1 syndrome as a rare disorder but publishes no prevalence class for it.

PMID:33892622 SUPPORT Human Clinical

"Here, we present a review of human studies summarizing the clinical features of individuals with FOXP1 syndrome"

The 2021 aggregation of 62 published individuals is the largest pooled case series and is the denominator for most published frequencies; it is a literature aggregation, not a population sample.

⚖️

Clinical Burden

High

Lifelong intellectual disability with a universal speech and language impairment, near-universal behavioral morbidity, and continuing dependence for activities of daily living into adulthood, with most individuals requiring extensive and often continuous caregiver support. Families rank intellectual disability, impaired communication, behavior problems, lack of age-appropriate self-reliance, attention problems and anxiety as the most burdensome features, a set dominated by cognition, communication and behavior rather than by the congenital malformations that defined the earliest reports. Incontinence, obsessions and a complex sensory profile rank disproportionately high relative to how uniformly they occur. Burden is high but not uniformly severe: skills continue to accrue and there is no regression.

Show evidence (2 references)

PMID:38123995 SUPPORT Human Clinical

"The most burdensome complaints for patients with FOXP1 syndrome, as perceived by parents, include intellectual disability, impaired communication, behaviour problems, lack of age-appropriate self-reliance, attention problems and anxiety."

Directly reports the caregiver-prioritized burden ranking.

PMID:41175749 SUPPORT Human Clinical

"Although most individuals learn to perform some basic daily living tasks independently, the majority heavily rely on their parents, many needing 24-7 supervision to support many aspects of daily life up to adulthood."

Quantifies the ongoing caregiver-support requirement underpinning the HIGH burden level.

🔀

Differential Diagnoses

1

Conditions with similar clinical presentations that must be differentiated from FOXP1 Syndrome:

FOXP2-Related Speech and Language Disorder

Overlapping Features FOXP2 haploinsufficiency causes hereditary developmental verbal dyspraxia. FOXP1 and FOXP2 are paralogs that heterodimerize and have overlapping brain expression, but the disorders are clinically separable: FOXP1 syndrome presents with global developmental delay and intellectual disability plus a complex dysarthria-dominant speech profile, whereas FOXP2 deficiency causes a primary oromotor verbal dyspraxia without obligate intellectual disability.

Show evidence (3 references)

PMID:20571508 SUPPORT Human Clinical

"The nature of the speech deficit is different from the primary oromotor verbal dyspraxia found in patients with FOXP2 deficiency."

States the discriminating feature between the two FOXP-related speech disorders.

PMID:24214399 SUPPORT Human Clinical

"Mutations in FOXP2, located at 7q31, are well known to cause developmental speech and language disorders, particularly developmental verbal dyspraxia (DVD)."

Establishes the FOXP2 phenotype that must be distinguished from FOXP1 syndrome.

PMID:31999079 SUPPORT Other

"These varied sites and timepoints of expression have complicated efforts to link FOXP1 and FOXP2 mutations to their respective developmental disorders, the former affecting global neural functions and the latter specifically affecting speech and language."

A FOXP-family review states the discriminating principle directly: FOXP1 loss affects global neural function whereas FOXP2 loss is specific to speech and language. It also notes that the overlapping, cell-type-specific expression of the two paralogs is precisely what makes the distinction non-trivial.

🔬

Clinical Trials

2

NCT03718923 RECRUITING

Cross-sectional observational deep-phenotyping cohort at the Seaver Autism Center (Icahn School of Medicine at Mount Sinai) characterizing FOXP1-related neurodevelopmental disorders with genetic, medical, neuropsychological, EEG, visual-evoked-potential and eye-tracking measures, with biospecimen collection. Not an interventional treatment trial.

Target Phenotypes: Global developmental delay HP:0001263 Delayed speech and language development HP:0000750 Autism HP:0000717

Show evidence (1 reference)

clinicaltrials:NCT03718923 SUPPORT Human Clinical

"This study seeks to characterize FOXP1-related neurodevelopmental disorders using a number of genetic, medical and neuropsychological measures."

States the study objective and confirms it is observational characterization rather than an intervention.

NCT06211673 COMPLETED

Observational psychiatric phenotyping study at Assistance Publique - Hopitaux de Paris characterizing autism, anxiety, sleep, behavior, sensory profile, adaptive function, agitation, ADHD and psychotic symptoms in individuals with FOXP1 syndrome, motivated by a locally observed prevalence of psychotic disorders and by caregiver reports of poor methylphenidate response.

Target Phenotypes: Anxiety HP:0000739 Attention deficit hyperactivity disorder HP:0007018

Show evidence (1 reference)

clinicaltrials:NCT06211673 SUPPORT Human Clinical

"Therefore, it appears crucial to further characterize the psychiatric phenotype of individuals with FOXP1 syndrome and explore the link between agitation and psychotic prodromes."

States the study rationale and its focus on the psychiatric phenotype.

🐁

Animal Models

5

Forebrain-specific Foxp1 conditional knockout Mus musculus

Forebrain-specific Foxp1 conditional knockout mice show impaired neonatal ultrasonic vocalization together with neocortical cytoarchitectonic alterations caused by defective neuronal positioning and migration. This is the model that links the FOXP1-dependent cortical transcriptional network to a communication phenotype.

Species

Mus musculus

Genotype

Forebrain-specific Foxp1 conditional knockout

Show evidence (1 reference)

PMID:29138280 SUPPORT Model Organism

"We show that deletion of Foxp1 in the developing forebrain leads to impairments in neonatal vocalizations as well as neocortical cytoarchitectonic alterations via neuronal positioning and migration."

Describes the model and its two core phenotypes.

Foxp1 heterozygous null (Foxp1+/-) Mus musculus

Patient-relevant heterozygous Foxp1 mice model the haploinsufficient human genotype. They reveal FoxP1-dependent regulation of autism-related pathways and neuronal-activity genes, altered striatal medium spiny neuron excitability, and ultrasonic vocalization defects.

Species

Mus musculus

Genotype

Foxp1 heterozygous null (Foxp1+/-)

Show evidence (1 reference)

PMID:26494785 SUPPORT Model Organism

"Here, we identify the gene expression program regulated by FoxP1 in both human neural cells and patient-relevant heterozygous Foxp1 mouse brains."

Establishes the heterozygous mouse as the dosage-matched model and its pairing with human neural cells.

Brain-specific Foxp1 knockout Mus musculus

Brain-specific Foxp1 knockout pups show strongly reduced ultrasonic vocalization and loss of the normal sex-specific call rate, independently corroborating a Foxp1 requirement for vocal output.

Species

Mus musculus

Genotype

Brain-specific Foxp1 knockout

Show evidence (1 reference)

PMID:28204507 SUPPORT Model Organism

"Foxp1 KO pups had strongly reduced USV and lacked the sex-specific call rate from WT pups, indicating that Foxp1 is essential for normal USV."

Independent knockout confirmation of the vocalization phenotype.

Cortex-restricted Foxp1 conditional knockout (Foxp1-cKO) Mus musculus

Cortex-specific Foxp1 deletion produces a biphasic tactile phenotype (deferred response then avoidance and hyper-reaction on repeated whisker stimulation), reduced dendritic spine number, disrupted somatosensory barrel formation, absent layer IV c-Fos activation, and increased basolateral amygdala c-Fos. It is the model most directly relevant to the human sensory phenotype. Limitation: the causal thalamocortical-to-amygdala circuit physiology is unresolved, and translation of whisker behavior to human sensory experience is indirect.

Species

Mus musculus

Genotype

Cortex-restricted Foxp1 conditional knockout (Foxp1-cKO)

Show evidence (2 references)

PMID:37691105 SUPPORT Model Organism

"We employed cortex-specific Foxp1 knockout (Foxp1-cKO) mice as a model of autism in this study."

Defines the model system.

PMID:37691105 SUPPORT Model Organism

"It is still unclear how the defective thalamocortical connection gives rise to the hyper-reactive response."

The authors state the principal mechanistic limitation of the model, which is why the downstream sensory edge is curated as indirect.

Spiny-projection-neuron-specific Foxp1 conditional knockout (D1-, D2-, and combined SPN drivers) Mus musculus

Cell-type-restricted striatal Foxp1 deletion, profiled by single-cell RNA-seq of the early postnatal striatum, resolves cell-autonomous from non-cell-autonomous effects and links D2/indirect-pathway SPN misspecification and striosome-matrix disorganization to motor-learning, vocalization and fear-conditioning phenotypes. A postnatal reinstatement variant of this design provides the reversibility proof of concept.

Species

Mus musculus

Genotype

Spiny-projection-neuron-specific Foxp1 conditional knockout (D1-, D2-, and combined SPN drivers)

Show evidence (2 references)

PMID:32130906 SUPPORT Model Organism

"Using this approach, we could also examine the non-cell-autonomous effects produced by disrupting one cell type and the molecular compensation that occurs in other populations."

Describes the specific analytic advantage of the cell-type-restricted knockout series.

PMID:38701209 SUPPORT Model Organism

"Together, this study enhances our understanding of striatal circuit development and provides proof of concept for a therapeutic approach for FOXP1 syndrome and other neurodevelopmental disorders."

The reinstatement model is the current preclinical proof of concept for a FOXP1-restoration therapeutic strategy.

{ }

Source YAML

click to show

name: FOXP1 Syndrome
creation_date: "2026-07-31T00:00:00Z"
category: Mendelian
description: >-
  FOXP1 syndrome is an autosomal dominant neurodevelopmental disorder caused by
  heterozygous, almost always de novo, loss-of-function variants or deletions of
  FOXP1, a forkhead-box transcriptional repressor. Pathogenic alleles are
  predominantly protein truncating; recurrent missense and in-frame changes
  cluster in the forkhead DNA-binding domain, where they disrupt DNA contact or
  the domain swap that mediates FOXP1 dimerization, and the reported alleles
  converge on loss of transcriptional repression activity. FOXP1 directly
  represses neurogenic programs (including Notch/Jagged1) and is required for
  neural stem cell differentiation, cortical radial migration and neuronal
  morphogenesis, and striatal medium spiny neuron identity and excitability;
  reduced dosage in model systems produces neocortical cytoarchitectonic
  alterations and impaired vocalization. Clinically the disorder is
  characterized by global developmental delay, mild-to-severe intellectual
  disability, and a speech and language impairment present in essentially all
  affected individuals regardless of cognitive level - a complex profile with
  prominent dysarthria, apraxic features, and phonological errors. Behavioral
  features (ADHD, anxiety, restricted/repetitive behaviors, autistic features,
  sleep and sensory symptoms) are near-universal, and mild dysmorphism (broad
  forehead, downslanted palpebral fissures, short nose with broad tip, relative
  macrocephaly, frontal hair upsweep, prominent fingertip pads) plus ophthalmic,
  cardiac, renal/urogenital and other congenital anomalies complete the
  spectrum. Longitudinal caregiver studies report no developmental regression.
disease_term:
  preferred_term: FOXP1 syndrome
  term:
    id: MONDO:0013352
    label: intellectual disability-severe speech delay-mild dysmorphism syndrome
parents:
- autosomal dominant syndromic intellectual disability
- neurodevelopmental disorder
synonyms:
- FOXP1-related neurodevelopmental disorder
- FOXP1 haploinsufficiency
- FOXP1-related intellectual disability syndrome
- intellectual disability with language impairment and with or without autistic features

references:
- reference: PMID:37733892
  title: "FOXP1 Syndrome."
  tags:
  - GeneReviews
- reference: PMID:24214399
  title: "FOXP1 mutations cause intellectual disability and a recognizable phenotype."
- reference: PMID:29090079
  title: "Prospective investigation of FOXP1 syndrome."
- reference: PMID:34588003
  title: >-
    Individuals with FOXP1 syndrome present with a complex neurobehavioral
    profile with high rates of ADHD, anxiety, repetitive behaviors, and sensory
    symptoms.
- reference: PMID:34109629
  title: "Severe speech impairment is a distinguishing feature of FOXP1-related disorder."
- reference: PMID:38123995
  title: >-
    Clinical phenotype of FOXP1 syndrome: parent-reported medical signs and
    symptoms in 40 individuals.
- reference: PMID:41175749
  title: >-
    Improving prognostication for individuals with FOXP1 syndrome:
    Parent-reported practical and social skills in 52 individuals.
- reference: PMID:40066139
  title: >-
    Adolescents and adults with FOXP1 syndrome show high rates of anxiety and
    externalizing behaviors but not psychiatric decompensation or skill loss.
- reference: PMID:33892622
  title: >-
    FOXP1 syndrome: a review of the literature and practice parameters for
    medical assessment and monitoring.
- reference: PMID:26494785
  title: "FoxP1 orchestration of ASD-relevant signaling pathways in the striatum."
- reference: PMID:32130906
  title: "Single-Cell Analysis of Foxp1-Driven Mechanisms Essential for Striatal Development."
- reference: PMID:37691105
  title: >-
    Cortex-restricted deletion of Foxp1 impairs barrel formation and induces
    aberrant tactile responses in a mouse model of autism.
- reference: PMID:38701209
  title: >-
    FOXP1 regulates the development of excitatory synaptic inputs onto striatal
    neurons and induces phenotypic reversal with reinstatement.
- reference: PMID:29138280
  title: "Foxp1 regulation of neonatal vocalizations via cortical development."
- reference: PMID:31999079
  title: "FOXP transcription factors in vertebrate brain development, function, and disorders."
- reference: ORPHA:391372
  title: "FOXP1 Syndrome"

inheritance:
- name: Autosomal dominant inheritance
  inheritance_term:
    preferred_term: Autosomal dominant inheritance
    term:
      id: HP:0000006
      label: Autosomal dominant inheritance
  description: >-
    FOXP1 syndrome is autosomal dominant. Nearly all molecularly characterized
    probands carry a de novo pathogenic variant; rare parental somatic and
    germline mosaicism or a complex chromosome rearrangement involving FOXP1 has
    been reported. Sib recurrence risk is approximately 1% because of possible
    parental germline mosaicism.
  penetrance: COMPLETE
  expressivity: VARIABLE
  evidence:
  - reference: PMID:37733892
    reference_title: "FOXP1 Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      FOXP1 syndrome is an autosomal dominant disorder typically caused by a de
      novo pathogenic variant.
    explanation: >-
      GeneReviews states the mode of inheritance and the predominance of de novo
      origin.
  - reference: PMID:37733892
    reference_title: "FOXP1 Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Rarely, a parent of an individual with FOXP1 syndrome has somatic and
      germline mosaicism for the FOXP1 pathogenic variant or a complex
      chromosome arrangement involving FOXP1.
    explanation: >-
      Documents the rare non-de-novo mechanisms that underlie the residual sib
      recurrence risk.
  - reference: PMID:34109629
    reference_title: "Severe speech impairment is a distinguishing feature of FOXP1-related disorder."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      with pathogenic FOXP1 variants (14 truncating, three missense, three
      splice site, one in-frame deletion, eight cytogenic deletions; 28 out of
      29 were de novo variants) were studied.
    explanation: >-
      An independent 29-patient cohort quantifies de novo origin (28/29) and the
      allele spectrum.

prevalence:
- population: Worldwide (reported literature)
  measure_type: CASES_IN_LITERATURE
  prevalence_class: ULTRA_RARE
  notes: >-
    GeneReviews reports more than 200 molecularly confirmed individuals
    worldwide as of the 2023 chapter revision. No population-based prevalence
    estimate has been published; Orphanet lists no epidemiology class for
    ORPHA:391372. The count is ascertainment limited and rising with routine
    exome/genome sequencing for neurodevelopmental delay.
  evidence:
  - reference: PMID:37733892
    reference_title: "FOXP1 Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      To date, more than 200 individuals have been identified with FOXP1
      syndrome.
    explanation: >-
      GeneReviews gives the cumulative count of reported individuals, the only
      occurrence figure available for this disorder.
  - reference: ORPHA:391372
    reference_title: "FOXP1 Syndrome"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      A rare, genetic, syndromic intellectual disability disorder, with highly
      variable phenotype
    explanation: >-
      Orphanet classifies FOXP1 syndrome as a rare disorder but publishes no
      prevalence class for it.
  - reference: PMID:33892622
    reference_title: >-
      FOXP1 syndrome: a review of the literature and practice parameters for
      medical assessment and monitoring.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Here, we present a review of human studies summarizing the clinical
      features of individuals with FOXP1 syndrome
    explanation: >-
      The 2021 aggregation of 62 published individuals is the largest pooled
      case series and is the denominator for most published frequencies; it is a
      literature aggregation, not a population sample.

pathophysiology:
- name: Heterozygous FOXP1 Loss-of-Function Variation
  biological_scale: MOLECULAR
  mechanism_confidence: ESTABLISHED
  description: >-
    The initiating lesion is a heterozygous, usually de novo, pathogenic FOXP1
    variant: whole- or partial-gene deletion, frameshift, nonsense, essential
    splice-site change, in-frame deletion, or missense substitution. Missense
    and in-frame alleles cluster in the C-terminal forkhead DNA-binding domain,
    where they either perturb residues required for DNA contact or interfere
    with the domain swap that mediates FOXP1 dimerization. FOXP1 also
    heterodimerizes with its paralog FOXP2, the classic speech-and-language
    gene, which is one route by which reduced FOXP1 dosage reaches speech
    circuitry.
  genes:
  - preferred_term: FOXP1
    term:
      id: hgnc:3823
      label: FOXP1
  molecular_functions:
  - preferred_term: DNA-binding transcription factor activity
    term:
      id: GO:0003700
      label: DNA-binding transcription factor activity
    modifier: DECREASED
  - preferred_term: FOXP1 domain-swap dimerization
    term:
      id: GO:0042803
      label: protein homodimerization activity
    modifier: ABNORMAL
  evidence:
  - reference: PMID:29090079
    reference_title: "Prospective investigation of FOXP1 syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The majority of pathogenic missense and in-frame mutations, including all
      four missense mutations in our cohort, lie in the DNA-binding domain.
      Through structural analyses, we show that the mutations perturb amino
      acids necessary for binding to the DNA or interfere with the domain
      swapping that mediates FOXP1 dimerization.
    explanation: >-
      Establishes both the mutational clustering in the forkhead domain and the
      two structural mechanisms by which those alleles impair FOXP1 function.
  - reference: PMID:29090079
    reference_title: "Prospective investigation of FOXP1 syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We have identified nine de novo mutations, including three frameshift, one
      nonsense, one mutation in an essential splice site resulting in frameshift
      and insertion of a premature stop codon, three missense, and one in-frame
      deletion.
    explanation: >-
      Documents the de novo origin and the truncating-predominant allele
      spectrum of the initiating lesion.
  downstream:
  - target: Loss of FOXP1 Transcriptional Repression
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:30385778
      reference_title: >-
        Characterization of a recurrent missense mutation in the forkhead
        DNA-binding domain of FOXP1.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: >-
        All reported FOXP1 pathogenic variants result in abnormal cellular
        localization and loss of transcriptional repression activity of the
        protein product.
      explanation: >-
        Functional characterization shows the shared molecular consequence of
        pathogenic FOXP1 alleles is loss of repression activity.

- name: Loss of FOXP1 Transcriptional Repression
  biological_scale: MOLECULAR
  mechanism_confidence: ESTABLISHED
  description: >-
    FOXP1 is a sequence-specific transcriptional repressor. Pathogenic alleles
    converge on loss of repression activity, most often accompanied by abnormal
    subcellular (cytoplasmic or aggregated nuclear) localization; the recurrent
    p.Arg525Gln allele loses repression while retaining normal nuclear
    localization, showing that the repression defect, not mislocalization per
    se, is the shared consequence. Repression is exerted in part through
    interaction with the NuRD chromatin-remodeling complex, an interaction that
    requires SUMOylation of FOXP1 during embryonic brain development.
  biological_processes:
  - preferred_term: negative regulation of transcription by RNA polymerase II
    term:
      id: GO:0000122
      label: negative regulation of transcription by RNA polymerase II
    modifier: DECREASED
  - preferred_term: FOXP1 SUMOylation required for NuRD interaction
    term:
      id: GO:0016925
      label: protein sumoylation
  evidence:
  - reference: PMID:30385778
    reference_title: >-
      Characterization of a recurrent missense mutation in the forkhead
      DNA-binding domain of FOXP1.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Here we present three patients with the same FOXP1 mutation, c.1574G>A
      (p.R525Q), that results in the characteristic loss of transcription
      repression activity. This mutation, however, represents the first reported
      FOXP1 mutation that does not result in cytoplasmic or nuclear aggregation
      of the protein but maintains normal nuclear localization.
    explanation: >-
      Dissociates loss of repression from mislocalization, identifying loss of
      repression as the convergent molecular defect.
  - reference: PMID:25853299
    reference_title: >-
      A de novo FOXP1 variant in a patient with autism, intellectual disability
      and severe speech and language impairment.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Functional analyses using cellular models show that the variant disrupts
      multiple aspects of FOXP1 activity, including subcellular localization and
      transcriptional repression properties.
    explanation: >-
      An independent patient-derived frameshift allele shows the same loss of
      repression in cellular assays.
  - reference: PMID:29138280
    reference_title: "Foxp1 regulation of neonatal vocalizations via cortical development."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      We also uncovered mechanistic insight into Foxp1 function by demonstrating
      that sumoylation of Foxp1 during embryonic brain development is necessary
      for mediating proper interactions between Foxp1 and the NuRD complex.
    explanation: >-
      Identifies the chromatin-remodeling partner through which FOXP1 exerts
      repression in the developing brain.
  downstream:
  - target: Dysregulated Neurodevelopmental Transcriptional Program
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:29141232
      reference_title: >-
        FOXP1 Promotes Embryonic Neural Stem Cell Differentiation by Repressing
        Jagged1 Expression.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: >-
        Here, we demonstrate with RNA and chromatin immunoprecipitation
        sequencing that FOXP1 directly regulates genes controlling neurogenesis.
      explanation: >-
        RNA-seq plus ChIP-seq show FOXP1 occupancy and regulation of neurogenic
        target genes, linking repression loss to program dysregulation.
  - target: Extra-CNS Developmental Consequences of FOXP1 Dosage Reduction
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:28884888
      reference_title: "FOXP1 haploinsufficiency: Phenotypes beyond behavior and intellectual disability?"
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        In mice, Foxp1 plays critical roles in development of the spinal motor
        neurons, lymphocytes, cardiomyocytes, foregut, and skeleton.
      explanation: >-
        FOXP1 is required transcriptionally outside the brain, so loss of its
        repression activity also acts in non-neural lineages. The tissue-specific
        intermediates between loss of repression and each extra-CNS malformation
        are not characterized, hence INDIRECT_UNKNOWN_INTERMEDIATES.

- name: Dysregulated Neurodevelopmental Transcriptional Program
  biological_scale: MOLECULAR
  mechanism_confidence: ESTABLISHED
  description: >-
    Reduced FOXP1 dosage releases repression of its direct targets and
    reconfigures the downstream network. Two arms are best characterized:
    de-repression of Notch pathway genes, notably the ligand Jagged1, which
    sustains Notch signaling and holds progenitors in a proliferative,
    undifferentiated state; and dysregulation of autism-associated signaling
    pathways and neuronal-activity genes, including a striatal neuron-identity
    program that is conserved between mouse brain and human neural progenitors.
    In developing neocortex the Foxp1-regulated networks are specifically
    enriched for neurogenesis and neuronal-migration effectors.
  biological_processes:
  - preferred_term: regulation of transcription by RNA polymerase II
    term:
      id: GO:0006357
      label: regulation of transcription by RNA polymerase II
    modifier: DYSREGULATED
  - preferred_term: Notch signaling pathway
    term:
      id: GO:0007219
      label: Notch signaling pathway
    modifier: INCREASED
  evidence:
  - reference: PMID:29141232
    reference_title: >-
      FOXP1 Promotes Embryonic Neural Stem Cell Differentiation by Repressing
      Jagged1 Expression.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      FOXP1 was found to repress the expression of Notch pathway genes including
      the Notch-ligand Jagged1, resulting in inhibition of Notch signaling.
    explanation: >-
      Identifies Jagged1/Notch de-repression as a specific, mechanistically
      resolved consequence of FOXP1 loss.
  - reference: PMID:26494785
    reference_title: "FoxP1 orchestration of ASD-relevant signaling pathways in the striatum."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      We demonstrate a role for FoxP1 in the transcriptional regulation of
      autism-related pathways as well as genes involved in neuronal activity.
    explanation: >-
      Defines the FOXP1-regulated program in patient-relevant heterozygous Foxp1
      mouse brain and human neural cells.
  - reference: PMID:29138280
    reference_title: "Foxp1 regulation of neonatal vocalizations via cortical development."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Using a genomics approach, we identified the transcriptional networks
      regulated by Foxp1 in the developing neocortex and found that such
      networks are enriched for downstream targets involved in neurogenesis and
      neuronal migration.
    explanation: >-
      Shows the dysregulated program is specifically enriched for the
      neurogenesis and migration effectors that produce the downstream cortical
      phenotype.
  downstream:
  - target: Impaired Neural Progenitor Differentiation
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:29141232
      reference_title: >-
        FOXP1 Promotes Embryonic Neural Stem Cell Differentiation by Repressing
        Jagged1 Expression.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: >-
        Finally, blockade of Jagged1 in FOXP1-knockdown NSCs rescued neuronal
        differentiation in vitro.
      explanation: >-
        Epistatic rescue establishes that Jagged1 de-repression is the effector
        step from transcriptional dysregulation to the differentiation defect.
  - target: Impaired Striatal Medium Spiny Neuron Development
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:26494785
      reference_title: "FoxP1 orchestration of ASD-relevant signaling pathways in the striatum."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        Finally, we demonstrate that FoxP1 has an evolutionarily conserved role
        in regulating pathways involved in striatal neuron identity through gene
        expression studies in human neural progenitors with altered FOXP1
        levels.
      explanation: >-
        Links the dysregulated program directly to striatal neuron identity, and
        shows the link is conserved in human neural progenitors.
  - target: Impaired Cortical Radial Migration and Neuronal Morphogenesis
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:29138280
      reference_title: "Foxp1 regulation of neonatal vocalizations via cortical development."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        We show that deletion of Foxp1 in the developing forebrain leads to
        impairments in neonatal vocalizations as well as neocortical
        cytoarchitectonic alterations via neuronal positioning and migration.
      explanation: >-
        Forebrain-specific conditional knockout ties the Foxp1-dependent
        transcriptional network to a migration/positioning phenotype.

- name: Impaired Neural Progenitor Differentiation
  biological_scale: CELLULAR
  mechanism_confidence: PROVISIONAL
  description: >-
    FOXP1 is expressed in embryonic neural stem cells, and reducing it shifts
    the balance away from neuronal (and astrocytic) differentiation. In utero
    FOXP1 knockdown reduces neural stem cell differentiation and migration
    during corticogenesis, and transplanted FOXP1-knockdown neural stem cells
    fail to differentiate and function normally in vivo. The mechanism is
    established in murine and cellular models; direct confirmation in human
    FOXP1-syndrome brain tissue is lacking.
  cell_types:
  - preferred_term: neural stem cell
    term:
      id: CL:0000047
      label: neural stem cell
  - preferred_term: radial glial cell
    term:
      id: CL:0000681
      label: radial glial cell
  biological_processes:
  - preferred_term: neuron differentiation
    term:
      id: GO:0030182
      label: neuron differentiation
    modifier: DECREASED
  - preferred_term: neural precursor cell proliferation
    term:
      id: GO:0061351
      label: neural precursor cell proliferation
    modifier: ABNORMAL
  evidence:
  - reference: PMID:29141232
    reference_title: >-
      FOXP1 Promotes Embryonic Neural Stem Cell Differentiation by Repressing
      Jagged1 Expression.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Using a murine model of cortical development, FOXP1-knockdown in utero was
      found to reduce NSC differentiation and migration during corticogenesis.
    explanation: >-
      In vivo knockdown demonstrates the progenitor differentiation and
      migration defect that follows FOXP1 loss.
  downstream:
  - target: Neocortical Cytoarchitectonic Alteration
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Reduced and mistimed neuronal output from the ventricular and
      subventricular zone leads to abnormal laminar positioning of cortical
      neurons.
    evidence:
    - reference: PMID:29141232
      reference_title: >-
        FOXP1 Promotes Embryonic Neural Stem Cell Differentiation by Repressing
        Jagged1 Expression.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        Furthermore, transplantation of FOXP1-knockdown NSCs in neonatal mice
        after hypoxia-ischemia challenge demonstrated that FOXP1 is also
        required for neuronal differentiation and functionality in vivo.
      explanation: >-
        Supports the progenitor-to-neuron step in vivo; the laminar consequence
        itself is demonstrated in the conditional-knockout studies.

- name: Impaired Cortical Radial Migration and Neuronal Morphogenesis
  biological_scale: CELLULAR
  mechanism_confidence: ESTABLISHED
  description: >-
    Foxp1 is required for radial migration of newly generated cortical neurons.
    Suppressing Foxp1 in mouse cerebral cortex produces a migration defect that
    is rescued by Foxp1 re-expression, with ectopic neurons persisting in deep
    cortical layers postnatally. Differentiation per se is preserved in that
    model, but the neurons show inhibited axonal growth, a weakened
    multipolar-to-bipolar transition, and altered late dendritic maturation.
  cell_types:
  - preferred_term: cerebral cortex neuron
    term:
      id: CL:0010012
      label: cerebral cortex neuron
  - preferred_term: glutamatergic projection neuron
    term:
      id: CL:0000679
      label: glutamatergic neuron
  biological_processes:
  - preferred_term: cerebral cortex radial glia-guided migration
    term:
      id: GO:0021801
      label: cerebral cortex radial glia-guided migration
    modifier: DECREASED
  - preferred_term: neuron migration
    term:
      id: GO:0001764
      label: neuron migration
    modifier: DECREASED
  evidence:
  - reference: PMID:26010426
    reference_title: >-
      Foxp1 regulates cortical radial migration and neuronal morphogenesis in
      developing cerebral cortex.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Here, we report that suppression of Foxp1 expression in mouse cerebral
      cortex led to a neuronal migration defect, which was rescued by
      overexpression of Foxp1.
    explanation: >-
      Knockdown-plus-rescue is the strongest available demonstration that the
      migration defect is Foxp1 dose dependent.
  - reference: PMID:26010426
    reference_title: >-
      Foxp1 regulates cortical radial migration and neuronal morphogenesis in
      developing cerebral cortex.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      However, morphological analysis showed that the neurons with Foxp1
      deficiency had an inhibited axonal growth in vitro and a weakened
      transition from multipolar to bipolar in vivo.
    explanation: >-
      Identifies the cell-biological substrate of the migration defect and an
      added axon-growth deficit.
  downstream:
  - target: Neocortical Cytoarchitectonic Alteration
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:26010426
      reference_title: >-
        Foxp1 regulates cortical radial migration and neuronal morphogenesis in
        developing cerebral cortex.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        Mice with Foxp1 knockdown exhibited ectopic neurons in deep layers of
        the cortex postnatally.
      explanation: >-
        Ectopic deep-layer neurons are the direct architectural readout of the
        failed radial migration.

- name: Neocortical Cytoarchitectonic Alteration
  biological_scale: TISSUE
  mechanism_confidence: PROVISIONAL
  description: >-
    Mispositioned cortical neurons yield altered neocortical cytoarchitecture
    and circuit assembly. In forebrain-specific Foxp1 conditional knockout mice
    this is accompanied by impaired neonatal vocalization, providing the closest
    model-system correlate of the human speech phenotype. In affected humans,
    imaging shows only non-specific structural brain abnormalities, so the
    correspondence between the murine cytoarchitectonic lesion and human
    cortical pathology is inferred rather than demonstrated.
  cell_types:
  - preferred_term: cerebral cortex neuron
    term:
      id: CL:0010012
      label: cerebral cortex neuron
  biological_processes:
  - preferred_term: cerebral cortex development
    term:
      id: GO:0021987
      label: cerebral cortex development
    modifier: ABNORMAL
  evidence:
  - reference: PMID:29138280
    reference_title: "Foxp1 regulation of neonatal vocalizations via cortical development."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      To elucidate the contribution of FOXP1-mediated signaling to brain
      development and, in particular, neocortical development, we generated
      forebrain-specific Foxp1 conditional knockout mice.
    explanation: >-
      Establishes the model system in which the cytoarchitectonic alteration and
      the vocalization deficit are jointly demonstrated.
  - reference: PMID:29090079
    reference_title: "Prospective investigation of FOXP1 syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Medical features included non-specific structural brain abnormalities and
      dysmorphic features, endocrine and gastrointestinal problems, sleep
      disturbances, and sinopulmonary infections.
    explanation: >-
      Human neuroimaging documents structural brain abnormality but is
      non-specific, so it only partially corroborates the model-derived
      cytoarchitectonic mechanism.
  - reference: PMID:37691105
    reference_title: >-
      Cortex-restricted deletion of Foxp1 impairs barrel formation and induces
      aberrant tactile responses in a mouse model of autism.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Moreover, Foxp1 deficiency in cortical neurons altered the dendrite
      development, reduced the number of dendritic spines, and disrupted barrel
      formation in the somatosensory cortex, suggesting impaired somatosensory
      processing may underlie the aberrant tactile responses.
    explanation: >-
      Extends the cytoarchitectonic phenotype beyond lamination to dendritic and
      columnar (barrel) organization, and links it to a sensory behavioral
      output.
  downstream:
  - target: Impaired Speech Motor and Vocal Communication Output
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Altered cortical circuit assembly in speech-motor and language-associated
      areas.
    evidence:
    - reference: PMID:29138280
      reference_title: "Foxp1 regulation of neonatal vocalizations via cortical development."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        We show that deletion of Foxp1 in the developing forebrain leads to
        impairments in neonatal vocalizations as well as neocortical
        cytoarchitectonic alterations via neuronal positioning and migration.
      explanation: >-
        Directly couples the cortical developmental lesion to a vocalization
        deficit in the same animals.
  - target: Autistic Features and Behavioral Dysregulation
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Reduced dendritic spine density and disrupted somatosensory barrel
      organization, with reduced layer IV cortical activation and increased
      basolateral amygdala activation, produce aberrant sensory responsiveness.
    evidence:
    - reference: PMID:37691105
      reference_title: >-
        Cortex-restricted deletion of Foxp1 impairs barrel formation and induces
        aberrant tactile responses in a mouse model of autism.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        In contrast to the wild-type, c-Fos was activated in the basolateral
        amygdala but not in layer IV of the primary somatosensory cortex of the
        cKO mice.
      explanation: >-
        Identifies a cortex-to-limbic shift in stimulus-evoked activity as a
        candidate substrate for the sensory and behavioral phenotype; the
        authors note the causal circuit physiology is unresolved.
  - target: Global Developmental Delay and Intellectual Disability
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:24214399
      reference_title: "FOXP1 mutations cause intellectual disability and a recognizable phenotype."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Mutations in FOXP1, located at 3p13, have been reported in patients with
        global developmental delay (GDD), intellectual disability (ID), and
        speech defects.
      explanation: >-
        Links FOXP1 loss to the cognitive endpoint; the intervening steps from
        cortical architecture to cognition remain unresolved.

- name: Impaired Striatal Medium Spiny Neuron Development
  biological_scale: CELLULAR
  mechanism_confidence: ESTABLISHED
  description: >-
    FoxP1 is the most highly upregulated gene in the developing mouse whole
    ganglionic eminence, marks medium spiny projection neurons from precursor
    through maturity, and co-localizes with essentially all striatal DARPP-32
    positive projection neurons without labelling interneurons. FoxP1 knockout
    ganglionic eminence fails to generate DARPP-32-positive medium spiny neurons
    in vitro, establishing FoxP1 as required for their differentiation. The same
    expression pattern is present in human fetal brain at equivalent gestational
    stages.
  cell_types:
  - preferred_term: medium spiny neuron
    term:
      id: CL:1001474
      label: medium spiny neuron
  biological_processes:
  - preferred_term: striatum development
    term:
      id: GO:0021756
      label: striatum development
    modifier: ABNORMAL
  - preferred_term: neuron differentiation
    term:
      id: GO:0030182
      label: neuron differentiation
    modifier: DECREASED
  evidence:
  - reference: PMID:27154297
    reference_title: >-
      FoxP1 marks medium spiny neurons from precursors to maturity and is
      required for their differentiation.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Furthermore, DARPP-32 expression was absent from FoxP1 knock-out mouse WGE
      differentiated in vitro, suggesting that FoxP1 is important for the
      development of DARPP-32-positive MSNs.
    explanation: >-
      Loss-of-function evidence that FoxP1 is required for medium spiny neuron
      differentiation.
  - reference: PMID:27154297
    reference_title: >-
      FoxP1 marks medium spiny neurons from precursors to maturity and is
      required for their differentiation.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      FoxP1 expression persisted through into adulthood in the mouse brain,
      where it co-localised with all striatal DARPP-32 positive projection
      neurons and a small population of DARPP-32 negative cells. There was no
      co-localisation of FoxP1 with any interneuron markers.
    explanation: >-
      Establishes the cell-type specificity of FoxP1 within the striatum,
      identifying the medium spiny neuron as the vulnerable population.
  - reference: PMID:32130906
    reference_title: "Single-Cell Analysis of Foxp1-Driven Mechanisms Essential for Striatal Development."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Using single-cell RNA sequencing (RNA-seq), we examine the cellular
      diversity of the early postnatal striatum and show that Foxp1, a
      transcription factor strongly linked to autism and intellectual
      disability, regulates the cellular composition, neurochemical
      architecture, and connectivity of the striatum in a cell-type-dependent
      fashion.
    explanation: >-
      Single-cell profiling of the early postnatal striatum shows the effect of
      Foxp1 loss is cell-type dependent rather than uniform, and extends it from
      neuron identity to neurochemical compartmentalization and connectivity.
  - reference: PMID:32130906
    reference_title: "Single-Cell Analysis of Foxp1-Driven Mechanisms Essential for Striatal Development."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      We also identify Foxp1-regulated target genes within distinct cell types
      and connect these molecular changes to functional and behavioral deficits
      relevant to phenotypes described in patients with FOXP1 loss-of-function
      mutations.
    explanation: >-
      Explicitly bridges the cell-type-specific molecular changes to behavioral
      deficits corresponding to the human loss-of-function phenotype.
  downstream:
  - target: Altered Striatal Circuit Excitability
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:26494785
      reference_title: "FoxP1 orchestration of ASD-relevant signaling pathways in the striatum."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        We show that Foxp1 regulates the excitability of striatal medium spiny
        neurons and that reduction of Foxp1 correlates with defects in
        ultrasonic vocalizations.
      explanation: >-
        Direct electrophysiological demonstration that Foxp1 dose sets medium
        spiny neuron excitability.

- name: Altered Striatal Circuit Excitability
  biological_scale: CELLULAR
  mechanism_confidence: ESTABLISHED
  description: >-
    Beyond specifying medium spiny neuron identity, FoxP1 dose sets the
    intrinsic excitability of these neurons. In patient-relevant heterozygous
    Foxp1 mice, reduced Foxp1 alters medium spiny neuron excitability and
    correlates with defective ultrasonic vocalization; brain-specific Foxp1
    knockout pups have strongly reduced ultrasonic vocalization and lose the
    normal sex-specific call rate. FoxP1 is co-expressed with the androgen
    receptor in striatal medium spiny neurons, and FOXP1 heterodimerizes with
    FOXP2, tying this node to the canonical speech-and-language pathway. The
    proximate mechanism is subtype specific: FOXP1 strengthens and matures the
    long-range cortical and thalamic glutamatergic inputs onto D2
    (indirect-pathway) SPNs and thereby promotes their synaptically driven
    excitability. Critically, postnatal FOXP1 reinstatement in mice rescues the
    electrophysiological, cell-type-specific transcriptional, and behavioral
    abnormalities, so at least part of this node is not a fixed prenatal
    malformation.
  cell_types:
  - preferred_term: medium spiny neuron
    term:
      id: CL:1001474
      label: medium spiny neuron
  biological_processes:
  - preferred_term: regulation of membrane potential
    term:
      id: GO:0042391
      label: regulation of membrane potential
    modifier: ABNORMAL
  evidence:
  - reference: PMID:28204507
    reference_title: "Foxp1 expression is essential for sex-specific murine neonatal ultrasonic vocalization."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Foxp1 KO pups had strongly reduced USV and lacked the sex-specific call
      rate from WT pups, indicating that Foxp1 is essential for normal USV.
    explanation: >-
      Independent knockout model confirms that Foxp1 loss impairs vocal output.
  - reference: PMID:28204507
    reference_title: "Foxp1 expression is essential for sex-specific murine neonatal ultrasonic vocalization."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Since Foxp1 and Foxp2 form heterodimers for transcriptional regulation, we
      investigated USV in neonatal brain-specific Foxp1 KO mice.
    explanation: >-
      Documents the FOXP1-FOXP2 heterodimer that connects FOXP1 dosage to the
      established speech-and-language transcription factor.
  - reference: PMID:38701209
    reference_title: >-
      FOXP1 regulates the development of excitatory synaptic inputs onto
      striatal neurons and induces phenotypic reversal with reinstatement.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      We find a neuron subtype-specific role of FOXP1 in strengthening and
      maturing glutamatergic inputs onto dopamine receptor 2-expressing SPNs (D2
      SPNs). We also find that FOXP1 promotes synaptically driven excitability
      in these neurons.
    explanation: >-
      Resolves the excitability effect to a specific mechanism (maturation of
      long-range cortical and thalamic glutamatergic input) and a specific
      neuron subtype (D2, indirect-pathway SPNs).
  - reference: PMID:38701209
    reference_title: >-
      FOXP1 regulates the development of excitatory synaptic inputs onto
      striatal neurons and induces phenotypic reversal with reinstatement.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Last, we demonstrate that postnatal FOXP1 reinstatement rescues
      electrophysiological deficits, cell type-specific gene expression changes,
      and behavioral phenotypes.
    explanation: >-
      Postnatal rescue shows this node is not an irreversible prenatal
      malformation in mice, establishing it as a candidate therapeutic target;
      the corresponding human window is unknown.
  downstream:
  - target: Impaired Speech Motor and Vocal Communication Output
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Corticostriatal loop dysfunction affecting motor planning and programming
      for speech.
    evidence:
    - reference: PMID:34109629
      reference_title: "Severe speech impairment is a distinguishing feature of FOXP1-related disorder."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        FOXP1-related disorder is characterized by a complex speech and language
        phenotype with prominent dysarthria, broader motor planning and
        programming deficits, and linguistic-based phonological errors.
      explanation: >-
        The human speech profile is dominated by motor planning and programming
        deficits, the functional domain served by corticostriatal circuits.
  - target: Autistic Features and Behavioral Dysregulation
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:26494785
      reference_title: "FoxP1 orchestration of ASD-relevant signaling pathways in the striatum."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        These data support an integral role for FoxP1 in regulating signaling
        pathways vulnerable in autism and the specific regulation of striatal
        pathways important for vocal communication.
      explanation: >-
        Connects the striatal node to autism-relevant pathways; the path from
        striatal excitability to human behavior is not resolved.

- name: Impaired Speech Motor and Vocal Communication Output
  biological_scale: ORGANISM
  mechanism_confidence: ESTABLISHED
  description: >-
    The clinical convergence point that distinguishes FOXP1 syndrome from other
    syndromic intellectual disabilities: speech and language impairment is
    present in essentially every affected individual regardless of cognitive
    level. The profile is complex rather than a pure verbal dyspraxia - all
    verbal patients show dysarthric and apraxic features with persistent
    phonological errors, and in individuals with truncating or splice-site
    variants and small deletions expressive ability is relatively preserved
    compared with comprehension. This differs from the primary oromotor verbal
    dyspraxia of FOXP2 deficiency.
  evidence:
  - reference: PMID:37733892
    reference_title: "FOXP1 Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      speech and language impairment in all individuals regardless of level of
      cognitive abilities
    explanation: >-
      GeneReviews establishes speech and language impairment as the invariant
      feature, independent of cognitive level.
  - reference: PMID:34109629
    reference_title: "Severe speech impairment is a distinguishing feature of FOXP1-related disorder."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      All had atypical speech, with 21 being verbal and eight minimally verbal.
      All verbal patients had dysarthric and apraxic features, with phonological
      deficits in most (14 out of 16).
    explanation: >-
      Standardized speech assessment in 29 patients quantifies the profile and
      its universality.
  - reference: PMID:20571508
    reference_title: >-
      Chiari I malformation, delayed gross motor skills, severe speech delay,
      and epileptiform discharges in a child with FOXP1 haploinsufficiency.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The nature of the speech deficit is different from the primary oromotor
      verbal dyspraxia found in patients with FOXP2 deficiency.
    explanation: >-
      Contrasts the FOXP1 speech phenotype with the FOXP2 phenotype, supporting
      it as a distinct mechanism-level endpoint.

- name: Global Developmental Delay and Intellectual Disability
  biological_scale: ORGANISM
  mechanism_confidence: ESTABLISHED
  description: >-
    Impaired cortical and striatal development produces early motor and language
    milestone delay and mild-to-severe intellectual disability, present in
    essentially all affected individuals. Longitudinal caregiver report finds
    continued, if slow, acquisition of adaptive skills into adulthood, with no
    developmental regression, neuropsychiatric decompensation, or catatonia,
    distinguishing FOXP1 syndrome from regressive neurodevelopmental disorders.
  evidence:
  - reference: PMID:38123995
    reference_title: >-
      Clinical phenotype of FOXP1 syndrome: parent-reported medical signs and
      symptoms in 40 individuals.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      All patients had developmental problems, including cognitive,
      communication, social-emotional and motor delays.
    explanation: >-
      An unbiased 40-person cohort establishes the universality of multi-domain
      developmental delay.
  - reference: PMID:40066139
    reference_title: >-
      Adolescents and adults with FOXP1 syndrome show high rates of anxiety and
      externalizing behaviors but not psychiatric decompensation or skill loss.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      There were no reports of developmental regression, neuropsychiatric
      decompensation or catatonia.
    explanation: >-
      Establishes the non-regressive natural history, an important negative
      finding for counseling and for the mechanistic model.
  downstream:
  - target: Dependence in Activities of Daily Living
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:41175749
      reference_title: >-
        Improving prognostication for individuals with FOXP1 syndrome:
        Parent-reported practical and social skills in 52 individuals.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        We found that individuals with FOXP1 syndrome have great difficulties
        with both basic and instrumental activities of daily living, but
        continue to develop their skills into adulthood.
      explanation: >-
        Quantifies the functional consequence of the cognitive and communication
        deficits across the lifespan.

- name: Autistic Features and Behavioral Dysregulation
  biological_scale: ORGANISM
  mechanism_confidence: PROVISIONAL
  description: >-
    A complex neurobehavioral profile rather than a single behavioral diagnosis.
    Restricted and repetitive behaviors are near-universal even in individuals
    who do not meet criteria for autism spectrum disorder; ADHD is the most
    common formal psychiatric diagnosis, followed by anxiety, with sensory
    symptoms (particularly sensory seeking) common. The behavioral phenotype
    persists into adolescence and adulthood as anxiety plus externalizing
    behavior. The mechanistic path from FOXP1-dependent striatal and cortical
    circuits to these behaviors is supported by model systems but not
    established in humans.
  evidence:
  - reference: PMID:34588003
    reference_title: >-
      Individuals with FOXP1 syndrome present with a complex neurobehavioral
      profile with high rates of ADHD, anxiety, repetitive behaviors, and
      sensory symptoms.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In addition, 24% of the cohort met criteria for ASD. Seventy-five percent
      of individuals met DSM-5 criteria for attention-deficit/hyperactivity
      disorder and 38% for an anxiety disorder. Repetitive behaviors were almost
      universally present (95%) even without a diagnosis of ASD.
    explanation: >-
      Quantifies each component of the behavioral phenotype in a prospectively
      assessed cohort.
  - reference: PMID:29090079
    reference_title: "Prospective investigation of FOXP1 syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Individuals with FOXP1 syndrome presented with delays in early motor and
      language milestones, language impairment (expressive language > receptive
      language), ASD symptoms, visual-motor integration deficits, and complex
      psychiatric presentations characterized by anxiety, obsessive-compulsive
      traits, attention deficits, and externalizing symptoms.
    explanation: >-
      The first prospective standardized characterization of the composite
      behavioral phenotype.

- name: Extra-CNS Developmental Consequences of FOXP1 Dosage Reduction
  biological_scale: ORGANISM
  mechanism_confidence: PROVISIONAL
  description: >-
    FOXP1 is required outside the brain. In mice it has critical roles in spinal
    motor neuron, lymphocyte, cardiomyocyte, foregut and skeletal development,
    and reduced dosage in humans is associated with cardiac malformations,
    congenital anomalies of the kidney and urinary tract, cryptorchidism,
    ophthalmic anomalies, and recurrent sinopulmonary or airway infections.
    Which of these are obligate consequences of FOXP1 dosage versus variable
    stochastic developmental effects is unresolved; single-patient reports of
    lung and skeletal disease remain unreplicated.
  evidence:
  - reference: PMID:28884888
    reference_title: "FOXP1 haploinsufficiency: Phenotypes beyond behavior and intellectual disability?"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In humans FOXP1 mutations have been associated with language and speech
      defects, intellectual disability, autism spectrum disorder, facial
      dysmorphisms, and congenital anomalies of the kidney and urinary tract.
    explanation: >-
      Sets out the established extra-CNS human associations that motivate the
      node. The murine requirement is cited separately, as MODEL_ORGANISM
      evidence, on the causal edge into this node.
  - reference: PMID:28884888
    reference_title: "FOXP1 haploinsufficiency: Phenotypes beyond behavior and intellectual disability?"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Although attribution of these traits to mutation of FOXP1 requires
      ascertainment of additional patients, we hypothesize that the variable
      expression of these additional features might arise by means of stochastic
      developmental variation.
    explanation: >-
      The authors themselves flag the unreplicated single-patient features as
      provisional, which is why this node carries PROVISIONAL confidence.
  - reference: ORPHA:391372
    reference_title: "FOXP1 Syndrome"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Brain, cardiac, urogenital and ocular malformations may be associated."
    explanation: >-
      Orphanet independently records the organ systems affected by congenital
      malformation in FOXP1 syndrome.

- name: Dependence in Activities of Daily Living
  biological_scale: ORGANISM
  mechanism_confidence: ESTABLISHED
  description: >-
    The lifetime functional endpoint. Most individuals acquire some basic
    self-care tasks independently, but the majority rely heavily on caregivers,
    and many require continuous supervision into adulthood. Skills continue to
    accrue rather than decline, so the trajectory is one of slow gain against a
    persistent support requirement.
  evidence:
  - reference: PMID:41175749
    reference_title: >-
      Improving prognostication for individuals with FOXP1 syndrome:
      Parent-reported practical and social skills in 52 individuals.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Although most individuals learn to perform some basic daily living tasks
      independently, the majority heavily rely on their parents, many needing
      24-7 supervision to support many aspects of daily life up to adulthood.
    explanation: >-
      Directly quantifies the level of ongoing support required, the practical
      endpoint families ask about.

phenotypes:
- category: Neurologic
  name: Global Developmental Delay
  description: >-
    Delays in early motor and language milestones affecting all developmental
    domains, present in essentially every affected individual.
  phenotype_term:
    preferred_term: Global developmental delay
    term:
      id: HP:0001263
      label: Global developmental delay
  frequency: VERY_FREQUENT
  evidence:
  - reference: PMID:38123995
    reference_title: >-
      Clinical phenotype of FOXP1 syndrome: parent-reported medical signs and
      symptoms in 40 individuals.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      All patients had developmental problems, including cognitive,
      communication, social-emotional and motor delays.
    explanation: >-
      Forty of forty individuals in an unbiased cohort had multi-domain
      developmental delay, supporting the VERY_FREQUENT band.
  - reference: PMID:33892622
    reference_title: >-
      FOXP1 syndrome: a review of the literature and practice parameters for
      medical assessment and monitoring.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Gross and fine motor delays were present in virtually all cases (59/61; 97%).
    explanation: >-
      The pooled 62-person literature review independently reports 97% for the motor domain, consistent with the VERY_FREQUENT band.

- category: Neurologic
  name: Intellectual Disability
  description: >-
    Mild-to-severe intellectual deficits. Severity is variable and does not
    predict the degree of speech impairment.
  phenotype_term:
    preferred_term: Intellectual disability
    term:
      id: HP:0001249
      label: Intellectual disability
  frequency: VERY_FREQUENT
  evidence:
  - reference: PMID:37733892
    reference_title: "FOXP1 Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      FOXP1 syndrome is characterized by delays in early motor and language
      milestones, mild-to-severe intellectual deficits, speech and language
      impairment in all individuals regardless of level of cognitive abilities,
      and behavior abnormalities
    explanation: >-
      GeneReviews lists mild-to-severe intellectual deficits as a defining
      characteristic of the syndrome.
  - reference: PMID:34588003
    reference_title: >-
      Individuals with FOXP1 syndrome present with a complex neurobehavioral
      profile with high rates of ADHD, anxiety, repetitive behaviors, and
      sensory symptoms.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Previous observations of intellectual disability, motor delays, and
      language deficits were confirmed.
    explanation: >-
      Prospective replication of intellectual disability in a second cohort.
  - reference: PMID:33892622
    reference_title: >-
      FOXP1 syndrome: a review of the literature and practice parameters for
      medical assessment and monitoring.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      present in 90% (55/61) of cases evaluated
    explanation: >-
      The pooled review quantifies intellectual disability or global developmental delay at 90%, mapping to the VERY_FREQUENT band.

- category: Neurologic
  name: Speech and Language Impairment
  description: >-
    Moderate-to-severe speech and language impairment present in all affected
    individuals regardless of cognitive level. This is the distinguishing
    feature of the disorder.
  phenotype_term:
    preferred_term: Delayed speech and language development
    term:
      id: HP:0000750
      label: Delayed speech and language development
  frequency: OBLIGATE
  diagnostic: true
  evidence:
  - reference: PMID:37733892
    reference_title: "FOXP1 Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      speech and language impairment in all individuals regardless of level of
      cognitive abilities
    explanation: >-
      GeneReviews states the impairment is present in all individuals,
      supporting the OBLIGATE band.
  - reference: PMID:34109629
    reference_title: "Severe speech impairment is a distinguishing feature of FOXP1-related disorder."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      All had atypical speech, with 21 being verbal and eight minimally verbal.
    explanation: >-
      Standardized speech assessment found atypical speech in 29 of 29 patients.
  - reference: PMID:33892622
    reference_title: >-
      FOXP1 syndrome: a review of the literature and practice parameters for
      medical assessment and monitoring.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Speech and language delays were reported in all the cases (60/60; 100%)
    explanation: >-
      A third, independent aggregation reports 60/60 (100%), the quantitative basis for the OBLIGATE band.

- category: Neurologic
  name: Expressive Language Delay
  description: >-
    Expressive speech is the most severely affected language domain in the
    classic description. In individuals with truncating or splice-site variants
    and small deletions, however, expressive ability is relatively preserved
    compared with comprehension, so the expressive/receptive profile is genotype
    dependent.
  phenotype_term:
    preferred_term: Expressive language delay
    term:
      id: HP:0002474
      label: Expressive language delay
  evidence:
  - reference: PMID:24214399
    reference_title: "FOXP1 mutations cause intellectual disability and a recognizable phenotype."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Review of our patient and others reported in the literature reveals an
      emerging phenotype of GDD/ID with moderate to severe speech delay where
      expressive speech is most severely affected.
    explanation: >-
      The delineating literature review identifies expressive speech as the most
      severely affected domain.
  - reference: PMID:34109629
    reference_title: "Severe speech impairment is a distinguishing feature of FOXP1-related disorder."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In the 21 individuals who carried truncating or splice site variants and
      small deletions, expressive abilities were relatively preserved compared
      with comprehension.
    explanation: >-
      Qualifies the classic expressive-predominant claim; formal testing shows a
      genotype-dependent expressive and receptive relationship.

- category: Neurologic
  name: Dysarthria
  description: >-
    Dysarthria impairing intelligibility is the dominant feature of the speech
    motor profile and is frequently untreated because it is not recognized.
  phenotype_term:
    preferred_term: Dysarthria
    term:
      id: HP:0001260
      label: Dysarthria
  frequency: FREQUENT
  evidence:
  - reference: PMID:34109629
    reference_title: "Severe speech impairment is a distinguishing feature of FOXP1-related disorder."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      All verbal patients had dysarthric and apraxic features, with phonological
      deficits in most (14 out of 16).
    explanation: >-
      All 21 verbal patients out of the 29-patient cohort (72%) had dysarthric
      features, supporting the FREQUENT band.
  - reference: PMID:33892622
    reference_title: >-
      FOXP1 syndrome: a review of the literature and practice parameters for
      medical assessment and monitoring.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Articulation problems 3/3 9/9 9/11 - - 1/3 - 1/1 - 32/48 (67%)
    explanation: >-
      The pooled review reports articulation problems in 67%, independently supporting the FREQUENT band for the motor-speech deficit.

- category: Neurologic
  name: Speech Apraxia
  description: >-
    Features of speech apraxia occur alongside persistent phonological errors.
    Unlike FOXP2 deficiency, primary oromotor verbal dyspraxia is not the
    distinguishing feature of the FOXP1 speech profile.
  phenotype_term:
    preferred_term: Speech apraxia
    term:
      id: HP:0011098
      label: Speech apraxia
  frequency: FREQUENT
  evidence:
  - reference: PMID:34109629
    reference_title: "Severe speech impairment is a distinguishing feature of FOXP1-related disorder."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Features of speech apraxia occur alongside persistent phonological errors.
    explanation: >-
      The authors' summary of the speech profile documents apraxic features in
      the cohort.
  - reference: PMID:24214399
    reference_title: "FOXP1 mutations cause intellectual disability and a recognizable phenotype."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "DVD appears not to be a distinct feature in this group."
    explanation: >-
      Earlier literature review found developmental verbal dyspraxia not to be a
      distinguishing feature, so apraxic features are curated as present but not
      defining.

- category: Neurologic
  name: Oromotor Dysfunction
  description: >-
    Oromotor dysfunction contributes to both the speech impairment and to
    feeding difficulties.
  phenotype_term:
    preferred_term: Oromotor dysfunction
    term:
      id: HP:0007301
      label: Oromotor apraxia
  evidence:
  - reference: PMID:37733892
    reference_title: "FOXP1 Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Other common findings are oromotor dysfunction (contributing to speech and
      feeding difficulties), refractive errors, strabismus, cardiac
      abnormalities, renal abnormalities, cryptorchidism, hypertonia, hearing
      loss, and epilepsy.
    explanation: >-
      GeneReviews lists oromotor dysfunction among the common findings; the
      collective wording does not support a specific frequency band, so
      frequency is omitted.

- category: Neurologic
  name: Motor Delay
  description: >-
    Delayed early gross and fine motor milestones, including delayed gross motor
    skills and visual-motor integration deficits.
  phenotype_term:
    preferred_term: Motor delay
    term:
      id: HP:0001270
      label: Motor delay
  frequency: VERY_FREQUENT
  evidence:
  - reference: PMID:29090079
    reference_title: "Prospective investigation of FOXP1 syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Individuals with FOXP1 syndrome presented with delays in early motor and
      language milestones, language impairment (expressive language > receptive
      language), ASD symptoms, visual-motor integration deficits
    explanation: >-
      Prospective standardized assessment documents motor milestone delay across
      the cohort.
  - reference: PMID:38123995
    reference_title: >-
      Clinical phenotype of FOXP1 syndrome: parent-reported medical signs and
      symptoms in 40 individuals.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      All patients had developmental problems, including cognitive,
      communication, social-emotional and motor delays.
    explanation: >-
      All 40 individuals had motor delay, supporting the VERY_FREQUENT band.

- category: Neurologic
  name: Hypotonia
  description: >-
    Hypotonia is described in the Orphanet clinical definition and in individual
    reports; abnormal muscle tone in either direction is among the most
    prevalent parent-reported signs.
  phenotype_term:
    preferred_term: Hypotonia
    term:
      id: HP:0001252
      label: Hypotonia
  frequency: OCCASIONAL
  evidence:
  - reference: ORPHA:391372
    reference_title: "FOXP1 Syndrome"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      mild to severe global development delay, severe speech and language
      impairment, mild to severe intellectual disability, dysphagia, hypotonia
    explanation: >-
      Orphanet includes hypotonia in the core clinical description.
  - reference: PMID:25853299
    reference_title: >-
      A de novo FOXP1 variant in a patient with autism, intellectual disability
      and severe speech and language impairment.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We report on a female child with a history of severe hypotonia, autism
      spectrum disorder and mild intellectual disability with severe
      speech/language impairment.
    explanation: >-
      Case report with a functionally validated FOXP1 frameshift documents
      severe hypotonia.
  - reference: PMID:33892622
    reference_title: >-
      FOXP1 syndrome: a review of the literature and practice parameters for
      medical assessment and monitoring.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      (18/62; 29%) and feeding issues (13/62; 21%)
    explanation: >-
      The pooled review quantifies a history of hypotonia at 29%, mapping to the OCCASIONAL band (5-29%).

- category: Neurologic
  name: Hypertonia
  description: >-
    Hypertonia is listed by GeneReviews among the common non-behavioral
    findings; parent-reported cohorts describe abnormal muscle tone generally.
  phenotype_term:
    preferred_term: Hypertonia
    term:
      id: HP:0001276
      label: Hypertonia
  evidence:
  - reference: PMID:37733892
    reference_title: "FOXP1 Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "cryptorchidism, hypertonia, hearing loss, and epilepsy"
    explanation: >-
      GeneReviews lists hypertonia among the common findings; the collective
      wording does not license a specific frequency band.
  - reference: PMID:38123995
    reference_title: >-
      Clinical phenotype of FOXP1 syndrome: parent-reported medical signs and
      symptoms in 40 individuals.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The most prevalent medical signs and symptoms include delayed bladder
      control, sleeping problems, hypermetropia, strabismus, sacral dimple,
      undescended testes, abnormal muscle tone and airway infections.
    explanation: >-
      Supports abnormal muscle tone as highly prevalent without specifying the
      direction of the abnormality.

- category: Neurologic
  name: Seizures
  description: >-
    Epilepsy is listed by GeneReviews among the common findings; epileptiform
    discharges were among the presenting features in an early FOXP1-deletion
    case report.
  phenotype_term:
    preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
  frequency: OCCASIONAL
  evidence:
  - reference: PMID:37733892
    reference_title: "FOXP1 Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "cryptorchidism, hypertonia, hearing loss, and epilepsy"
    explanation: >-
      GeneReviews includes epilepsy among the common findings; no quantitative
      frequency is given, so frequency is omitted.
  - reference: PMID:20571508
    reference_title: >-
      Chiari I malformation, delayed gross motor skills, severe speech delay,
      and epileptiform discharges in a child with FOXP1 haploinsufficiency.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      This patient presented with speech and motor developmental delays, a
      Chiari I malformation, and epileptiform discharges.
    explanation: >-
      Documents epileptiform activity in a patient with an isolated FOXP1
      deletion.
  - reference: PMID:33892622
    reference_title: >-
      FOXP1 syndrome: a review of the literature and practice parameters for
      medical assessment and monitoring.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Seizures were reported in some cases (7/59; 12%).
    explanation: >-
      The pooled review quantifies seizures at 12%, mapping to OCCASIONAL and confirming that epilepsy is a minority rather than a defining feature.

- category: Neurologic
  name: Chiari Type I Malformation
  description: >-
    Chiari I malformation was reported in the index patient with an isolated
    FOXP1 deletion; structural brain abnormalities in FOXP1 syndrome cohorts are
    otherwise non-specific.
  phenotype_term:
    preferred_term: Chiari type I malformation
    term:
      id: HP:0007099
      label: Chiari type I malformation
  evidence:
  - reference: PMID:20571508
    reference_title: >-
      Chiari I malformation, delayed gross motor skills, severe speech delay,
      and epileptiform discharges in a child with FOXP1 haploinsufficiency.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In this study, we report the case of a patient with a single deletion of
      FOXP1. This patient presented with speech and motor developmental delays,
      a Chiari I malformation, and epileptiform discharges.
    explanation: >-
      Single-patient report; recorded without a frequency because it is not
      established as a recurrent feature.

- category: Behavioral
  name: Autism Spectrum Disorder
  description: >-
    Autism spectrum disorder or autistic features. In prospectively assessed
    cohorts a minority meet full diagnostic criteria, although autistic traits
    are far more widespread; standardized ASD testing shows high sensitivity but
    low specificity against expert consensus diagnosis in this population.
  phenotype_term:
    preferred_term: Autism
    term:
      id: HP:0000717
      label: Autism
  frequency: OCCASIONAL
  evidence:
  - reference: PMID:34588003
    reference_title: >-
      Individuals with FOXP1 syndrome present with a complex neurobehavioral
      profile with high rates of ADHD, anxiety, repetitive behaviors, and
      sensory symptoms.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In addition, 24% of the cohort met criteria for ASD."
    explanation: >-
      A direct quantitative estimate of 24% maps to the OCCASIONAL band (5-29%).
  - reference: PMID:34588003
    reference_title: >-
      Individuals with FOXP1 syndrome present with a complex neurobehavioral
      profile with high rates of ADHD, anxiety, repetitive behaviors, and
      sensory symptoms.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Notably, standardized testing for ASD showed high sensitivity, but low
      specificity, when compared to expert consensus diagnosis.
    explanation: >-
      Cautions that instrument-based ASD rates in this population overcall the
      diagnosis relative to expert consensus.
  - reference: PMID:33892622
    reference_title: >-
      FOXP1 syndrome: a review of the literature and practice parameters for
      medical assessment and monitoring.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      ASD features - 4/8 14/20 - - - 1/1 1/1 - 28/56 (50%)
    explanation: >-
      The pooled literature review reports ASD *features* in 50%, roughly double
      the 24% who met formal DSM-5 criteria on prospective expert-consensus
      assessment. The curated frequency follows the stricter prospective
      diagnosis; this item records the higher retrospective trait-level figure
      rather than silently averaging the two.

- category: Behavioral
  name: Attention Deficit Hyperactivity Disorder
  description: >-
    ADHD is the most common formal psychiatric diagnosis in FOXP1 syndrome and
    is frequently undertreated; medication use for ADHD features is common in
    adolescents and adults, though multiple trials may be needed.
  phenotype_term:
    preferred_term: Attention deficit hyperactivity disorder
    term:
      id: HP:0007018
      label: Attention deficit hyperactivity disorder
  frequency: FREQUENT
  evidence:
  - reference: PMID:34588003
    reference_title: >-
      Individuals with FOXP1 syndrome present with a complex neurobehavioral
      profile with high rates of ADHD, anxiety, repetitive behaviors, and
      sensory symptoms.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Seventy-five percent of individuals met DSM-5 criteria for
      attention-deficit/hyperactivity disorder and 38% for an anxiety disorder.
    explanation: >-
      Seventy-five percent maps to the FREQUENT band (30-79%).

- category: Behavioral
  name: Anxiety
  description: >-
    Anxiety disorders are common in childhood and remain among the most
    prominent psychiatric features in adolescence and adulthood.
  phenotype_term:
    preferred_term: Anxiety
    term:
      id: HP:0000739
      label: Anxiety
  frequency: FREQUENT
  evidence:
  - reference: PMID:34588003
    reference_title: >-
      Individuals with FOXP1 syndrome present with a complex neurobehavioral
      profile with high rates of ADHD, anxiety, repetitive behaviors, and
      sensory symptoms.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Seventy-five percent of individuals met DSM-5 criteria for
      attention-deficit/hyperactivity disorder and 38% for an anxiety disorder.
    explanation: >-
      38% meeting criteria for an anxiety disorder maps to the FREQUENT band.
  - reference: PMID:40066139
    reference_title: >-
      Adolescents and adults with FOXP1 syndrome show high rates of anxiety and
      externalizing behaviors but not psychiatric decompensation or skill loss.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Anxiety and externalizing behaviors were common in this cohort and
      psychiatric features, such as psychosis or bipolar symptoms, were present
      in two participants.
    explanation: >-
      Confirms persistence of anxiety into adolescence and adulthood.
  - reference: PMID:33892622
    reference_title: >-
      FOXP1 syndrome: a review of the literature and practice parameters for
      medical assessment and monitoring.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Behavioral problems 2/2 9/9 12/19 - 1/1 2/3 - 1/1 - 32/56 (57%)
    explanation: >-
      The pooled review documents psychiatric comorbidity (ADHD, aggression, obsessive-compulsive traits, mood disorders and anxiety) in 57%.

- category: Behavioral
  name: Restricted and Repetitive Behaviors
  description: >-
    Restricted and repetitive behaviors are almost universal, occurring even in
    individuals who do not meet criteria for autism spectrum disorder.
  phenotype_term:
    preferred_term: Restricted or repetitive behaviors or interests
    term:
      id: HP:0031432
      label: Restricted or repetitive behaviors or interests
  frequency: VERY_FREQUENT
  evidence:
  - reference: PMID:34588003
    reference_title: >-
      Individuals with FOXP1 syndrome present with a complex neurobehavioral
      profile with high rates of ADHD, anxiety, repetitive behaviors, and
      sensory symptoms.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Repetitive behaviors were almost universally present (95%) even without a
      diagnosis of ASD.
    explanation: >-
      95% maps to the VERY_FREQUENT band (80-100%).

- category: Behavioral
  name: Sleep Disturbance
  description: >-
    Sleeping problems are among the most prevalent parent-reported symptoms and
    are listed by GeneReviews among the behavior abnormalities.
  phenotype_term:
    preferred_term: Sleep disturbance
    term:
      id: HP:0002360
      label: Sleep disturbance
  evidence:
  - reference: PMID:38123995
    reference_title: >-
      Clinical phenotype of FOXP1 syndrome: parent-reported medical signs and
      symptoms in 40 individuals.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The most prevalent medical signs and symptoms include delayed bladder
      control, sleeping problems, hypermetropia, strabismus, sacral dimple,
      undescended testes, abnormal muscle tone and airway infections.
    explanation: >-
      Sleeping problems rank among the most prevalent symptoms; no numeric rate
      is given, so frequency is omitted.
  - reference: PMID:29090079
    reference_title: "Prospective investigation of FOXP1 syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Medical features included non-specific structural brain abnormalities and
      dysmorphic features, endocrine and gastrointestinal problems, sleep
      disturbances, and sinopulmonary infections.
    explanation: >-
      Independent prospective cohort confirms sleep disturbance.

- category: Ophthalmologic
  name: Refractive Error
  description: >-
    Refractive errors are a common ophthalmologic finding; hypermetropia is the
    specific error most often reported by parents.
  phenotype_term:
    preferred_term: Abnormality of refraction
    term:
      id: HP:0000539
      label: Abnormality of refraction
  evidence:
  - reference: PMID:37733892
    reference_title: "FOXP1 Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Other common findings are oromotor dysfunction (contributing to speech and
      feeding difficulties), refractive errors, strabismus, cardiac
      abnormalities, renal abnormalities, cryptorchidism, hypertonia, hearing
      loss, and epilepsy.
    explanation: >-
      GeneReviews lists refractive errors among the common findings.

- category: Ophthalmologic
  name: Hypermetropia
  description: Hyperopia is among the most prevalent parent-reported findings.
  phenotype_term:
    preferred_term: Hypermetropia
    term:
      id: HP:0000540
      label: Hypermetropia
  evidence:
  - reference: PMID:38123995
    reference_title: >-
      Clinical phenotype of FOXP1 syndrome: parent-reported medical signs and
      symptoms in 40 individuals.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The most prevalent medical signs and symptoms include delayed bladder
      control, sleeping problems, hypermetropia, strabismus, sacral dimple,
      undescended testes, abnormal muscle tone and airway infections.
    explanation: >-
      Hypermetropia is explicitly named among the most prevalent findings.

- category: Ophthalmologic
  name: Strabismus
  description: Strabismus is a recurrent ophthalmologic finding.
  phenotype_term:
    preferred_term: Strabismus
    term:
      id: HP:0000486
      label: Strabismus
  frequency: OCCASIONAL
  evidence:
  - reference: PMID:38123995
    reference_title: >-
      Clinical phenotype of FOXP1 syndrome: parent-reported medical signs and
      symptoms in 40 individuals.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The most prevalent medical signs and symptoms include delayed bladder
      control, sleeping problems, hypermetropia, strabismus, sacral dimple,
      undescended testes, abnormal muscle tone and airway infections.
    explanation: >-
      Strabismus is explicitly named among the most prevalent findings.
  - reference: PMID:37733892
    reference_title: "FOXP1 Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "refractive errors, strabismus, cardiac"
    explanation: GeneReviews includes strabismus among the common findings.
  - reference: PMID:33892622
    reference_title: >-
      FOXP1 syndrome: a review of the literature and practice parameters for
      medical assessment and monitoring.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      myopia (29/58; 50%), and strabismus (11/60; 18%) were reported in a significant number of cases.
    explanation: >-
      The pooled review quantifies strabismus at 18%, mapping to the OCCASIONAL band.

- category: Cardiovascular
  name: Congenital Cardiac Malformation
  description: >-
    Cardiac abnormalities are a recognized congenital malformation in FOXP1
    syndrome, consistent with the requirement for Foxp1 in cardiomyocyte
    development in mice.
  phenotype_term:
    preferred_term: Abnormal heart morphology
    term:
      id: HP:0001627
      label: Abnormal heart morphology
  frequency: FREQUENT
  evidence:
  - reference: PMID:37733892
    reference_title: "FOXP1 Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      abnormalities, renal abnormalities, cryptorchidism
    explanation: GeneReviews lists cardiac abnormalities among the common findings.
  - reference: ORPHA:391372
    reference_title: "FOXP1 Syndrome"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Brain, cardiac, urogenital and ocular malformations may be associated."
    explanation: Orphanet independently records cardiac malformation.
  - reference: PMID:33892622
    reference_title: >-
      FOXP1 syndrome: a review of the literature and practice parameters for
      medical assessment and monitoring.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Congenital heart defect - 2/9 (iv) 9/19 (v) - - 1/3 (vi) - - - 17/56 (30%)
    explanation: >-
      The pooled review quantifies congenital heart defects at 30%, mapping to the FREQUENT band.

- category: Renal
  name: Renal and Urinary Tract Anomaly
  description: >-
    Congenital anomalies of the kidney and urinary tract are an established
    extra-CNS association of FOXP1 haploinsufficiency.
  phenotype_term:
    preferred_term: Abnormality of the kidney
    term:
      id: HP:0000077
      label: Abnormality of the kidney
  evidence:
  - reference: PMID:28884888
    reference_title: "FOXP1 haploinsufficiency: Phenotypes beyond behavior and intellectual disability?"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In humans FOXP1 mutations have been associated with language and speech
      defects, intellectual disability, autism spectrum disorder, facial
      dysmorphisms, and congenital anomalies of the kidney and urinary tract.
    explanation: >-
      Explicitly names congenital anomalies of the kidney and urinary tract as
      an established FOXP1 association.
  - reference: PMID:37733892
    reference_title: "FOXP1 Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "renal abnormalities, cryptorchidism"
    explanation: GeneReviews lists renal abnormalities among the common findings.

- category: Genitourinary
  name: Cryptorchidism
  description: Undescended testes are among the most prevalent findings in affected males.
  phenotype_term:
    preferred_term: Cryptorchidism
    term:
      id: HP:0000028
      label: Cryptorchidism
  frequency: OCCASIONAL
  evidence:
  - reference: PMID:38123995
    reference_title: >-
      Clinical phenotype of FOXP1 syndrome: parent-reported medical signs and
      symptoms in 40 individuals.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      sacral dimple, undescended testes, abnormal muscle tone and airway
      infections
    explanation: Undescended testes named among the most prevalent findings.
  - reference: PMID:37733892
    reference_title: "FOXP1 Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "renal abnormalities, cryptorchidism, hypertonia"
    explanation: GeneReviews lists cryptorchidism among the common findings.
  - reference: PMID:33892622
    reference_title: >-
      FOXP1 syndrome: a review of the literature and practice parameters for
      medical assessment and monitoring.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      cryptorchidism (9/41 males; 22%), and micropenis
    explanation: >-
      The pooled review quantifies cryptorchidism at 22% of affected males, mapping to the OCCASIONAL band.

- category: Genitourinary
  name: Delayed Bladder Control
  description: >-
    Delayed acquisition of bladder control was the single most prevalent
    parent-reported medical symptom, and incontinence is ranked as
    disproportionately burdensome by families.
  phenotype_term:
    preferred_term: Enuresis
    term:
      id: HP:0000805
      label: Enuresis
  evidence:
  - reference: PMID:38123995
    reference_title: >-
      Clinical phenotype of FOXP1 syndrome: parent-reported medical signs and
      symptoms in 40 individuals.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The most prevalent medical signs and symptoms include delayed bladder
      control, sleeping problems, hypermetropia, strabismus, sacral dimple,
      undescended testes, abnormal muscle tone and airway infections.
    explanation: >-
      Delayed bladder control heads the list of most prevalent symptoms in the
      unbiased cohort.

- category: Gastrointestinal
  name: Feeding Difficulties
  description: >-
    Feeding difficulties arise from oromotor dysfunction and are a target of
    supportive nutritional management.
  phenotype_term:
    preferred_term: Feeding difficulties
    term:
      id: HP:0011968
      label: Feeding difficulties
  frequency: OCCASIONAL
  evidence:
  - reference: PMID:37733892
    reference_title: "FOXP1 Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Other common findings are oromotor dysfunction (contributing to speech and
      feeding difficulties)
    explanation: >-
      GeneReviews explicitly attributes feeding difficulties to oromotor
      dysfunction.
  - reference: PMID:33892622
    reference_title: >-
      FOXP1 syndrome: a review of the literature and practice parameters for
      medical assessment and monitoring.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      (18/62; 29%) and feeding issues (13/62; 21%)
    explanation: >-
      The pooled review quantifies feeding issues at 21%, mapping to the OCCASIONAL band.

- category: Gastrointestinal
  name: Dysphagia
  description: Dysphagia is part of the core Orphanet clinical description.
  phenotype_term:
    preferred_term: Dysphagia
    term:
      id: HP:0002015
      label: Dysphagia
  evidence:
  - reference: ORPHA:391372
    reference_title: "FOXP1 Syndrome"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      mild to severe intellectual disability, dysphagia, hypotonia
    explanation: Orphanet includes dysphagia in the clinical definition.

- category: Craniofacial
  name: Broad and Prominent Forehead
  description: >-
    A broad, prominent forehead is the single most frequent dysmorphic feature
    and the anchor of the recognizable FOXP1 facial gestalt. Curated against
    HP:0011220 (Prominent forehead) because that is the descriptor scored in the
    quantified cohort; the delineating literature describes the same feature as
    a broad forehead.
  phenotype_term:
    preferred_term: Broad, prominent forehead
    term:
      id: HP:0011220
      label: Prominent forehead
  frequency: VERY_FREQUENT
  evidence:
  - reference: PMID:33892622
    reference_title: >-
      FOXP1 syndrome: a review of the literature and practice parameters for
      medical assessment and monitoring.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      prominent forehead (48/59; 81%), short nose with a broad tip or base (41/59; 69%), down slanting
    explanation: >-
      The pooled review quantifies prominent forehead at 81%, the most frequent dysmorphic feature, mapping to the VERY_FREQUENT band.
  - reference: PMID:24214399
    reference_title: "FOXP1 mutations cause intellectual disability and a recognizable phenotype."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Facial features include a broad forehead, downslanting palpebral fissures,
      a short nose with broad tip, relative or true macrocephaly, a frontal hair
      upsweep and prominent digit pads.
    explanation: >-
      The delineating paper defines the recognizable facial phenotype and calls
      the same feature a broad forehead.
  - reference: ORPHA:391372
    reference_title: "FOXP1 Syndrome"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Facial gestalt typically features a broad, prominent forehead
    explanation: >-
      Orphanet uses both descriptors for the same feature, supporting the choice
      of the Prominent forehead term with a combined preferred term.

- category: Craniofacial
  name: Downslanted Palpebral Fissures
  description: Downslanting palpebral fissures are part of the FOXP1 facial gestalt.
  phenotype_term:
    preferred_term: Downslanted palpebral fissures
    term:
      id: HP:0000494
      label: Downslanted palpebral fissures
  frequency: FREQUENT
  evidence:
  - reference: PMID:24214399
    reference_title: "FOXP1 mutations cause intellectual disability and a recognizable phenotype."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Facial features include a broad forehead, downslanting palpebral fissures,
      a short nose with broad tip
    explanation: Named in the delineating facial-gestalt description.
  - reference: PMID:33892622
    reference_title: >-
      FOXP1 syndrome: a review of the literature and practice parameters for
      medical assessment and monitoring.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      fissures (24/59; 41%), ptosis (22/59; 37%), thick
    explanation: >-
      The pooled review quantifies down-slanting palpebral fissures at 41%, mapping to the FREQUENT band.

- category: Craniofacial
  name: Short Nose with Broad Tip
  description: A short nose with a broad or bulbous tip is characteristic.
  phenotype_term:
    preferred_term: Short nose
    term:
      id: HP:0003196
      label: Short nose
  frequency: FREQUENT
  evidence:
  - reference: PMID:24214399
    reference_title: "FOXP1 mutations cause intellectual disability and a recognizable phenotype."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      a short nose with broad tip, relative or true macrocephaly
    explanation: Named in the delineating facial-gestalt description.
  - reference: PMID:33892622
    reference_title: >-
      FOXP1 syndrome: a review of the literature and practice parameters for
      medical assessment and monitoring.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      short nose with a broad tip or base (41/59; 69%), down slanting
    explanation: >-
      The pooled review quantifies short nose with a broad tip or base at 69%, mapping to the FREQUENT band.

- category: Craniofacial
  name: Relative or True Macrocephaly
  description: >-
    The head can appear too large for the body; both relative and true
    macrocephaly are described.
  phenotype_term:
    preferred_term: Macrocephaly
    term:
      id: HP:0000256
      label: Macrocephaly
  frequency: OCCASIONAL
  evidence:
  - reference: PMID:24214399
    reference_title: "FOXP1 mutations cause intellectual disability and a recognizable phenotype."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      a short nose with broad tip, relative or true macrocephaly, a frontal hair
      upsweep and prominent digit pads.
    explanation: Named in the delineating facial-gestalt description.
  - reference: ORPHA:391372
    reference_title: "FOXP1 Syndrome"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "dysphagia, hypotonia, relative to true macrocephaly"
    explanation: Orphanet independently records relative-to-true macrocephaly.
  - reference: PMID:33892622
    reference_title: >-
      FOXP1 syndrome: a review of the literature and practice parameters for
      medical assessment and monitoring.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      macrocephaly (9/59; 15%), and broad nasal
    explanation: >-
      The pooled review scores frank macrocephaly in only 15% of dysmorphology examinations, so this feature is curated as OCCASIONAL despite its prominence in the classic gestalt description.

- category: Craniofacial
  name: Frontal Hair Upsweep
  description: A frontal hair upsweep is part of the recognizable gestalt.
  phenotype_term:
    preferred_term: Frontal upsweep of hair
    term:
      id: HP:0002236
      label: Frontal upsweep of hair
  frequency: OCCASIONAL
  evidence:
  - reference: PMID:24214399
    reference_title: "FOXP1 mutations cause intellectual disability and a recognizable phenotype."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      a frontal hair upsweep and prominent digit pads
    explanation: Named in the delineating facial-gestalt description.
  - reference: PMID:33892622
    reference_title: >-
      FOXP1 syndrome: a review of the literature and practice parameters for
      medical assessment and monitoring.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      ocular hypertelorism (17/59; 29%), and frontal hair upsweep (16/59; 27%)
    explanation: >-
      The pooled review quantifies frontal hair upsweep at 27%, mapping to the OCCASIONAL band.

- category: Craniofacial
  name: Hypertelorism
  description: Hypertelorism is part of the Orphanet facial gestalt description.
  phenotype_term:
    preferred_term: Hypertelorism
    term:
      id: HP:0000316
      label: Hypertelorism
  frequency: OCCASIONAL
  evidence:
  - reference: ORPHA:391372
    reference_title: "FOXP1 Syndrome"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Facial gestalt typically features a broad, prominent forehead,
      hypertelorism, downslanting palpebral fissures, ptosis, a short bulbous
      nose with broad tip
    explanation: The Orphanet facial-gestalt description names hypertelorism.
  - reference: PMID:33892622
    reference_title: >-
      FOXP1 syndrome: a review of the literature and practice parameters for
      medical assessment and monitoring.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      ocular hypertelorism (17/59; 29%), and frontal hair upsweep (16/59; 27%)
    explanation: >-
      The pooled review quantifies ocular hypertelorism at 29%, mapping to the OCCASIONAL band.

- category: Craniofacial
  name: Ptosis
  description: Ptosis is part of the Orphanet facial gestalt description.
  phenotype_term:
    preferred_term: Ptosis
    term:
      id: HP:0000508
      label: Ptosis
  frequency: FREQUENT
  evidence:
  - reference: ORPHA:391372
    reference_title: "FOXP1 Syndrome"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      hypertelorism, downslanting palpebral fissures, ptosis, a short bulbous
      nose with broad tip
    explanation: The Orphanet facial-gestalt description names ptosis.
  - reference: PMID:33892622
    reference_title: >-
      FOXP1 syndrome: a review of the literature and practice parameters for
      medical assessment and monitoring.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      fissures (24/59; 41%), ptosis (22/59; 37%), thick
    explanation: >-
      The pooled review quantifies ptosis at 37%, mapping to the FREQUENT band.

- category: Musculoskeletal
  name: Prominent Fingertip Pads
  description: Bulging or prominent digit pads are a recurrent minor anomaly.
  phenotype_term:
    preferred_term: Prominent fingertip pads
    term:
      id: HP:0001212
      label: Prominent fingertip pads
  evidence:
  - reference: PMID:24214399
    reference_title: "FOXP1 mutations cause intellectual disability and a recognizable phenotype."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      a frontal hair upsweep and prominent digit pads
    explanation: Named in the delineating description of the recognizable phenotype.

- category: Musculoskeletal
  name: Sacral Dimple
  description: Sacral dimple is among the most prevalent parent-reported findings.
  phenotype_term:
    preferred_term: Sacral dimple
    term:
      id: HP:0000960
      label: Sacral dimple
  evidence:
  - reference: PMID:38123995
    reference_title: >-
      Clinical phenotype of FOXP1 syndrome: parent-reported medical signs and
      symptoms in 40 individuals.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      hypermetropia, strabismus, sacral dimple, undescended testes
    explanation: Sacral dimple named among the most prevalent findings.

- category: Otologic
  name: Hearing Impairment
  description: Hearing loss is listed by GeneReviews among the common findings.
  phenotype_term:
    preferred_term: Hearing impairment
    term:
      id: HP:0000365
      label: Hearing impairment
  frequency: OCCASIONAL
  evidence:
  - reference: PMID:37733892
    reference_title: "FOXP1 Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "cryptorchidism, hypertonia, hearing loss, and epilepsy"
    explanation: GeneReviews lists hearing loss among the common findings.
  - reference: PMID:33892622
    reference_title: >-
      FOXP1 syndrome: a review of the literature and practice parameters for
      medical assessment and monitoring.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Hearing loss was also reported (8/48; 17%).
    explanation: >-
      The pooled review quantifies hearing loss at 17%, mapping to the OCCASIONAL band.

- category: Immunologic
  name: Recurrent Respiratory Infections
  description: >-
    Airway and sinopulmonary infections recur in FOXP1 syndrome, consistent with
    the requirement for Foxp1 in lymphocyte development in mice.
  phenotype_term:
    preferred_term: Recurrent respiratory infections
    term:
      id: HP:0002205
      label: Recurrent respiratory infections
  evidence:
  - reference: PMID:38123995
    reference_title: >-
      Clinical phenotype of FOXP1 syndrome: parent-reported medical signs and
      symptoms in 40 individuals.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      undescended testes, abnormal muscle tone and airway infections
    explanation: Airway infections named among the most prevalent findings.
  - reference: PMID:29090079
    reference_title: "Prospective investigation of FOXP1 syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      endocrine and gastrointestinal problems, sleep disturbances, and
      sinopulmonary infections
    explanation: Independent prospective cohort confirms sinopulmonary infections.

- category: Neurologic
  name: Structural Brain Abnormality
  description: >-
    Non-specific structural brain abnormalities are seen in roughly half of
    imaged individuals and include dilated lateral ventricles, white-matter
    abnormalities, arachnoid cysts, large cisterna magna, corpus callosum
    defects, frontal atrophy, cerebellar defects, and Chiari I malformation. The
    findings are heterogeneous and not diagnostic.
  phenotype_term:
    preferred_term: Abnormal brain morphology
    term:
      id: HP:0012443
      label: Abnormal brain morphology
  frequency: FREQUENT
  evidence:
  - reference: PMID:33892622
    reference_title: >-
      FOXP1 syndrome: a review of the literature and practice parameters for
      medical assessment and monitoring.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Brain abnormalities were evident in about a half of total cases (29/58)
    explanation: >-
      The pooled review quantifies structural brain abnormality at about 50%,
      mapping to the FREQUENT band.
  - reference: PMID:29090079
    reference_title: "Prospective investigation of FOXP1 syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Medical features included non-specific structural brain abnormalities and
      dysmorphic features
    explanation: >-
      A prospective cohort independently documents the non-specific nature of
      the imaging findings.

- category: Musculoskeletal
  name: Contractures and Spasticity
  description: >-
    Spasticity and joint contractures, particularly of the upper extremities,
    are recurrent and can significantly impair function.
  phenotype_term:
    preferred_term: Flexion contracture
    term:
      id: HP:0001371
      label: Flexion contracture
  frequency: OCCASIONAL
  evidence:
  - reference: PMID:33892622
    reference_title: >-
      FOXP1 syndrome: a review of the literature and practice parameters for
      medical assessment and monitoring.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Spastic/contractures - - 10/19 - - - - 1/1 - 16/56 (29%)
    explanation: >-
      The pooled review quantifies spasticity/contractures at 29%, mapping to
      the OCCASIONAL band.

- category: Ophthalmologic
  name: Myopia
  description: >-
    Myopia is the single most frequently reported refractive error in the pooled
    literature, alongside hypermetropia and amblyopia.
  phenotype_term:
    preferred_term: Myopia
    term:
      id: HP:0000545
      label: Myopia
  frequency: FREQUENT
  evidence:
  - reference: PMID:33892622
    reference_title: >-
      FOXP1 syndrome: a review of the literature and practice parameters for
      medical assessment and monitoring.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      myopia (29/58; 50%), and strabismus (11/60; 18%) were reported in a
      significant number of cases.
    explanation: >-
      The pooled review quantifies myopia at 50%, mapping to the FREQUENT band.

- category: Growth
  name: Short Stature
  description: Short stature is described in a minority of individuals.
  phenotype_term:
    preferred_term: Short stature
    term:
      id: HP:0004322
      label: Short stature
  frequency: OCCASIONAL
  evidence:
  - reference: PMID:33892622
    reference_title: >-
      FOXP1 syndrome: a review of the literature and practice parameters for
      medical assessment and monitoring.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Short stature (8/60; 13%) and obesity (3/60; 5%) were
    explanation: >-
      The pooled review quantifies short stature at 13%, mapping to the
      OCCASIONAL band.

- category: Growth
  name: Obesity
  description: >-
    Obesity is reported in a small minority and motivates routine height,
    weight, BMI and pubertal monitoring.
  phenotype_term:
    preferred_term: Obesity
    term:
      id: HP:0001513
      label: Obesity
  frequency: OCCASIONAL
  evidence:
  - reference: PMID:33892622
    reference_title: >-
      FOXP1 syndrome: a review of the literature and practice parameters for
      medical assessment and monitoring.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Short stature (8/60; 13%) and obesity (3/60; 5%) were
    explanation: >-
      The pooled review quantifies obesity at 5%, the lower edge of the
      OCCASIONAL band.

- category: Genitourinary
  name: Micropenis
  description: Micropenis is reported in a small minority of affected males.
  phenotype_term:
    preferred_term: Micropenis
    term:
      id: HP:0000054
      label: Micropenis
  frequency: OCCASIONAL
  evidence:
  - reference: PMID:33892622
    reference_title: >-
      FOXP1 syndrome: a review of the literature and practice parameters for
      medical assessment and monitoring.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      cryptorchidism (9/41 males; 22%), and micropenis
    explanation: >-
      The pooled review reports micropenis in 3/41 males (7%), mapping to the
      OCCASIONAL band.

- category: Otologic
  name: Recurrent Otitis Media
  description: Recurrent ear infections are reported in a minority of individuals.
  phenotype_term:
    preferred_term: Recurrent otitis media
    term:
      id: HP:0000403
      label: Recurrent otitis media
  frequency: OCCASIONAL
  evidence:
  - reference: PMID:33892622
    reference_title: >-
      FOXP1 syndrome: a review of the literature and practice parameters for
      medical assessment and monitoring.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Recurrent ear infections were reported in some cases (7/60; 12%).
    explanation: >-
      The pooled review quantifies recurrent ear infections at 12%, mapping to
      the OCCASIONAL band.

- category: Craniofacial
  name: Thick Vermilion Border
  description: A thick vermilion border is part of the Orphanet facial gestalt.
  phenotype_term:
    preferred_term: Thick vermilion border
    term:
      id: HP:0012471
      label: Thick vermilion border
  evidence:
  - reference: ORPHA:391372
    reference_title: "FOXP1 Syndrome"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      a short bulbous nose with broad tip, thick vermilion border, wide, and
      open mouth with downturned corners
    explanation: >-
      Orphanet's facial-gestalt description names a thick vermilion border.

- category: Behavioral
  name: Aberrant Sensory Responsiveness
  description: >-
    Sensory symptoms are common, with sensory seeking particularly prominent in
    prospectively assessed cohorts. A cortex-restricted Foxp1 mouse model
    reproduces a biphasic tactile phenotype (delayed initial response followed
    by avoidance and hyper-reaction to repeated stimulation), providing a
    candidate cortical substrate. Bound at the sensory-behavioral grouping level
    because the claim spans both sensory seeking (the prominent human finding,
    HP:4000079) and hyper-reactivity/avoidance, rather than seeking alone.
  phenotype_term:
    preferred_term: Sensory symptoms and sensory seeking
    term:
      id: HP:5200046
      label: Sensory behavioral abnormality
  evidence:
  - reference: PMID:34588003
    reference_title: >-
      Individuals with FOXP1 syndrome present with a complex neurobehavioral
      profile with high rates of ADHD, anxiety, repetitive behaviors, and
      sensory symptoms.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Sensory symptoms, in particular sensory seeking, were common.
    explanation: >-
      Prospective standardized sensory assessment documents the sensory
      phenotype; no numeric rate is given, so frequency is omitted.
  - reference: PMID:37691105
    reference_title: >-
      Cortex-restricted deletion of Foxp1 impairs barrel formation and induces
      aberrant tactile responses in a mouse model of autism.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Foxp1-cKO mice had a deferred response to the tactile environment.
      However, the mice exhibited avoidance behavior and hyper-reaction
      following repeated whisker stimulation, similar to a fight-or-flight
      response.
    explanation: >-
      A cortex-restricted mouse model reproduces an analogous tactile
      phenotype; translation of whisker behavior to human sensory experience is
      indirect, so this is PARTIAL support.

genetic:
- name: FOXP1 Pathogenic Variants
  gene_term:
    preferred_term: FOXP1
    term:
      id: hgnc:3823
      label: FOXP1
  association: Causative
  presence: Positive
  relationship_type: CAUSATIVE
  variant_origin: DE_NOVO
  notes: >-
    FOXP1 (3p13) encodes a forkhead-box transcriptional repressor. Pathogenic
    alleles are heterozygous and, in the large majority of molecularly tested
    probands, de novo. The spectrum comprises whole- and partial-gene deletions
    (including cytogenetically visible 3p13-14.1 deletions and intragenic
    deletions), frameshift and nonsense variants, essential splice-site changes,
    in-frame deletions, and missense substitutions; balanced rearrangements
    disrupting FOXP1 have also been reported. Missense and in-frame alleles
    cluster in the C-terminal forkhead DNA-binding domain. All reported
    pathogenic alleles studied functionally converge on loss of transcriptional
    repression activity, supporting haploinsufficiency as the disease mechanism.
    Rare parental somatic-plus-germline mosaicism gives an approximately 1% sib
    recurrence risk.
  inheritance:
  - name: Autosomal dominant inheritance
    inheritance_term:
      preferred_term: Autosomal dominant inheritance
      term:
        id: HP:0000006
        label: Autosomal dominant inheritance
    description: >-
      Autosomal dominant, almost always de novo; each child of an affected
      individual has a 50% chance of inheriting the variant.
    evidence:
    - reference: PMID:37733892
      reference_title: "FOXP1 Syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Each child of an individual with FOXP1 syndrome has a 50% chance of
        inheriting the FOXP1 pathogenic variant.
      explanation: GeneReviews states the dominant transmission risk.
  evidence:
  - reference: PMID:29090079
    reference_title: "Prospective investigation of FOXP1 syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Haploinsufficiency of the forkhead-box protein P1 (FOXP1) gene leads to a
      neurodevelopmental disorder termed FOXP1 syndrome.
    explanation: >-
      States haploinsufficiency of FOXP1 as the disease mechanism.
  - reference: PMID:29090079
    reference_title: "Prospective investigation of FOXP1 syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      This study identifies novel FOXP1 mutations associated with FOXP1
      syndrome, identifies recurrent mutations, and demonstrates significant
      clustering of missense mutations in the DNA-binding domain.
    explanation: >-
      Establishes the DNA-binding-domain clustering of missense alleles.
  - reference: PMID:30385778
    reference_title: >-
      Characterization of a recurrent missense mutation in the forkhead
      DNA-binding domain of FOXP1.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Most of the reported FOXP1 mutations occur on the C-terminus of the
      protein and cluster around to the forkhead domain. All reported FOXP1
      pathogenic variants result in abnormal cellular localization and loss of
      transcriptional repression activity of the protein product.
    explanation: >-
      Functional characterization of the allele spectrum showing convergent loss
      of repression.
  - reference: PMID:34109629
    reference_title: "Severe speech impairment is a distinguishing feature of FOXP1-related disorder."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      14 truncating, three missense, three splice site, one in-frame deletion,
      eight cytogenic deletions; 28 out of 29 were de novo variants
    explanation: >-
      Quantifies the variant-class distribution and the de novo rate in a
      29-patient cohort.

variants:
- name: FOXP1 c.1574G>A (p.Arg525Gln)
  description: >-
    A recurrent missense substitution in the forkhead DNA-binding domain,
    reported in three unrelated patients. It abolishes transcriptional
    repression while, uniquely among characterized FOXP1 alleles, preserving
    normal nuclear localization, evidence that loss of repression rather than
    mislocalization is the shared pathogenic consequence.
  gene:
    preferred_term: FOXP1
    term:
      id: hgnc:3823
      label: FOXP1
  evidence:
  - reference: PMID:30385778
    reference_title: >-
      Characterization of a recurrent missense mutation in the forkhead
      DNA-binding domain of FOXP1.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Here we present three patients with the same FOXP1 mutation, c.1574G>A
      (p.R525Q), that results in the characteristic loss of transcription
      repression activity.
    explanation: >-
      Identifies the recurrent allele and its functional consequence.
- name: FOXP1 c.1267_1268delGT (p.Val423Hisfs*37)
  description: >-
    A de novo frameshift allele identified by clinical exome sequencing in a
    child with autism, mild intellectual disability, severe hypotonia and severe
    speech and language impairment. Cellular assays showed disruption of both
    subcellular localization and transcriptional repression.
  gene:
    preferred_term: FOXP1
    term:
      id: hgnc:3823
      label: FOXP1
  evidence:
  - reference: PMID:25853299
    reference_title: >-
      A de novo FOXP1 variant in a patient with autism, intellectual disability
      and severe speech and language impairment.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Clinical exome sequencing identified a heterozygous de novo FOXP1 variant
      c.1267_1268delGT (p.V423Hfs*37). Functional analyses using cellular models
      show that the variant disrupts multiple aspects of FOXP1 activity,
      including subcellular localization and transcriptional repression
      properties.
    explanation: >-
      Establishes the allele, its de novo origin, and its functional effect.

diagnosis:
- name: Molecular Genetic Diagnosis of FOXP1 Syndrome
  description: >-
    The diagnosis is molecular. It is established in a proband with supportive
    clinical findings and a heterozygous pathogenic FOXP1 variant identified by
    molecular genetic testing, in practice exome or genome sequencing performed
    for neurodevelopmental delay, or chromosomal microarray when the lesion is a
    copy-number deletion. The recognizable facial gestalt plus a speech
    impairment disproportionate to cognitive level are the clinical triggers.
  presence: Positive
  evidence:
  - reference: PMID:37733892
    reference_title: "FOXP1 Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The diagnosis of FOXP1 syndrome is established in a proband with a
      heterozygous pathogenic variant in FOXP1 identified by molecular genetic
      testing and supportive clinical findings.
    explanation: GeneReviews states the diagnostic criterion.
  - reference: PMID:38123995
    reference_title: >-
      Clinical phenotype of FOXP1 syndrome: parent-reported medical signs and
      symptoms in 40 individuals.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Patients with FOXP1 syndrome were included, mostly diagnosed via
      whole-exome sequencing for neurodevelopmental delay.
    explanation: >-
      Documents the ascertainment route in current practice.

definitions:
- name: GeneReviews Molecular Diagnostic Criterion for FOXP1 Syndrome
  definition_type: DIAGNOSTIC_CRITERIA
  derivation_basis: ESTABLISHED_CRITERIA
  description: >-
    Diagnosis requires supportive clinical findings (global developmental delay
    with speech and language impairment out of proportion to cognitive level,
    behavior abnormalities, and mild dysmorphism) together with a heterozygous
    pathogenic FOXP1 variant on molecular genetic testing. There are no
    consensus clinical-only criteria; the molecular finding is required.
  inclusion_criteria:
  - preferred_term: Heterozygous pathogenic FOXP1 variant
    description: >-
      A heterozygous pathogenic or likely pathogenic FOXP1 variant (sequence
      variant, or whole- or partial-gene deletion) identified by molecular
      genetic testing.
  - preferred_term: Supportive clinical findings
    term:
      id: HP:0001263
      label: Global developmental delay
    description: >-
      Supportive clinical findings, including global developmental delay and
      speech and language impairment.
  evidence:
  - reference: PMID:37733892
    reference_title: "FOXP1 Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The diagnosis of FOXP1 syndrome is established in a proband with a
      heterozygous pathogenic variant in FOXP1 identified by molecular genetic
      testing and supportive clinical findings.
    explanation: >-
      The GeneReviews diagnostic statement is the source of both inclusion
      criteria.

treatments:
- name: Multidisciplinary Supportive Care
  description: >-
    There is no disease-modifying therapy. Management is symptom directed and
    aims to improve quality of life, maximize function, and reduce
    complications, delivered by a multidisciplinary team spanning pediatrics,
    developmental medicine or neurodevelopment, neurology, physiatry,
    occupational and physical therapy, speech-language pathology, psychiatry,
    psychology, ophthalmology, and medical genetics. The GeneReviews chapter
    abstract records no agents or circumstances to avoid for this disorder.
  action_category: THERAPEUTIC
  therapeutic_modality: OTHER
  treatment_term:
    preferred_term: supportive care
    term:
      id: NCIT:C15747
      label: Supportive Care
  evidence:
  - reference: PMID:37733892
    reference_title: "FOXP1 Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Supportive care to improve quality of life, maximize function, and reduce
      complications is recommended. This can include multidisciplinary care by
      specialists in pediatrics, developmental medicine or neurodevelopment,
      neurology, physiatry, occupational and physical therapy, speech-language
      pathology, psychiatry, psychology, ophthalmology, and medical genetics.
    explanation: >-
      GeneReviews defines the standard of care as multidisciplinary supportive
      management.

- name: Speech and Language Therapy
  description: >-
    Speech-language pathology is central to management. Because dysarthria
    rather than pure apraxia dominates the profile, therapy should be targeted
    at dysarthria and phonology; in one cohort no participant was receiving
    dysarthria-directed therapy despite being good candidates for it.
    Alternative and augmentative communication is appropriate for minimally
    verbal individuals.
  action_category: THERAPEUTIC
  therapeutic_modality: BEHAVIORAL
  treatment_term:
    preferred_term: speech and language therapy
    term:
      id: NCIT:C159273
      label: Speech Language Therapy
  target_phenotypes:
  - preferred_term: Delayed speech and language development
    term:
      id: HP:0000750
      label: Delayed speech and language development
  - preferred_term: Dysarthria
    term:
      id: HP:0001260
      label: Dysarthria
  evidence:
  - reference: PMID:34109629
    reference_title: "Severe speech impairment is a distinguishing feature of FOXP1-related disorder."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      No participants were receiving speech therapy for dysarthria, but were
      good candidates for therapy
    explanation: >-
      Identifies dysarthria-directed speech therapy as an under-delivered,
      indicated intervention in this population.
  - reference: PMID:34109629
    reference_title: "Severe speech impairment is a distinguishing feature of FOXP1-related disorder."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Diagnosis of the speech phenotype associated with FOXP1-related
      dysfunction will inform early targeted therapy.
    explanation: >-
      Supports phenotype-specific targeting of speech therapy.

- name: Occupational Therapy
  description: >-
    Occupational therapy supports fine-motor and visual-motor integration
    deficits, sensory symptoms, and the acquisition of activities of daily
    living, which remain a major long-term support need.
  action_category: THERAPEUTIC
  therapeutic_modality: BEHAVIORAL
  treatment_term:
    preferred_term: occupational therapy
    term:
      id: NCIT:C121351
      label: Occupational Therapy
  evidence:
  - reference: PMID:37733892
    reference_title: "FOXP1 Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      neurology, physiatry, occupational and physical therapy, speech-language
      pathology
    explanation: >-
      GeneReviews includes occupational therapy in the recommended
      multidisciplinary team.
  - reference: PMID:41175749
    reference_title: >-
      Improving prognostication for individuals with FOXP1 syndrome:
      Parent-reported practical and social skills in 52 individuals.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We found that individuals with FOXP1 syndrome have great difficulties with
      both basic and instrumental activities of daily living, but continue to
      develop their skills into adulthood.
    explanation: >-
      Documents the activities-of-daily-living deficit that occupational therapy
      targets, and the continued capacity for skill gain that justifies ongoing
      therapy into adulthood.

- name: Physical Therapy
  description: >-
    Physical therapy addresses gross-motor delay and abnormal muscle tone.
  action_category: THERAPEUTIC
  therapeutic_modality: BEHAVIORAL
  treatment_term:
    preferred_term: physical therapy
    term:
      id: NCIT:C15302
      label: Physical Therapy
  target_phenotypes:
  - preferred_term: Motor delay
    term:
      id: HP:0001270
      label: Motor delay
  evidence:
  - reference: PMID:37733892
    reference_title: "FOXP1 Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      neurology, physiatry, occupational and physical therapy, speech-language
      pathology
    explanation: >-
      GeneReviews includes physical therapy in the recommended multidisciplinary
      team.

- name: Behavioral and Psychiatric Intervention
  description: >-
    Behavioral and psychological intervention addresses the near-universal
    restricted and repetitive behaviors, anxiety, and externalizing behaviors.
    Cohort data show that many individuals with formal ADHD or anxiety diagnoses
    were not receiving treatment for them, so systematic psychiatric assessment
    is an actionable gap.
  action_category: THERAPEUTIC
  therapeutic_modality: BEHAVIORAL
  treatment_term:
    preferred_term: behavioral intervention
    term:
      id: NCIT:C15184
      label: Behavioral Intervention
  target_phenotypes:
  - preferred_term: Anxiety
    term:
      id: HP:0000739
      label: Anxiety
  - preferred_term: Restricted or repetitive behaviors or interests
    term:
      id: HP:0031432
      label: Restricted or repetitive behaviors or interests
  evidence:
  - reference: PMID:34588003
    reference_title: >-
      Individuals with FOXP1 syndrome present with a complex neurobehavioral
      profile with high rates of ADHD, anxiety, repetitive behaviors, and
      sensory symptoms.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Furthermore, many individuals in our cohort who received diagnoses of
      attention-deficit/hyperactivity disorder or anxiety disorder were not
      being treated for these symptoms; therefore, our findings suggest that
      there may be immediate areas for improvements in treatment for some
      individuals.
    explanation: >-
      Identifies undertreatment of ADHD and anxiety as a concrete management
      gap.

- name: Pharmacotherapy for ADHD Symptoms
  description: >-
    Medication for ADHD features, typically CNS stimulants such as
    methylphenidate, is commonly used in adolescents and adults with FOXP1
    syndrome. Caregiver-reported experience indicates that multiple medication
    trials may be required before benefit is achieved, so a structured trial
    plan is appropriate. No FOXP1-specific efficacy trial has been performed;
    prescribing follows general ADHD practice. A tolerability caveat is
    documented: the investigators of a French psychiatric-phenotyping study
    record family reports of ineffectiveness and poor tolerance of
    methylphenidate in this population, so response should not be assumed and
    stimulant trials warrant close monitoring.
  action_category: THERAPEUTIC
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: CNS stimulant
      term:
        id: NCIT:C47795
        label: CNS Stimulant
    - preferred_term: methylphenidate
      term:
        id: CHEBI:6887
        label: methylphenidate
  target_phenotypes:
  - preferred_term: Attention deficit hyperactivity disorder
    term:
      id: HP:0007018
      label: Attention deficit hyperactivity disorder
  evidence:
  - reference: PMID:40066139
    reference_title: >-
      Adolescents and adults with FOXP1 syndrome show high rates of anxiety and
      externalizing behaviors but not psychiatric decompensation or skill loss.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Medication use was common particularly for features of ADHD, although
      multiple trials were required for some individuals to achieve benefit.
    explanation: >-
      Documents both the common use of ADHD pharmacotherapy and the practical
      caveat about multiple trials.
  - reference: clinicaltrials:NCT06211673
    reference_title: "Psychiatric Phenotype Characterization of Individuals With FOXP1 Syndrome"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Additionally, families reported ineffectiveness and poor tolerance of
      methylphenidate in these patients.
    explanation: >-
      A registered study protocol records caregiver-reported poor
      methylphenidate efficacy and tolerance, tempering the assumption that
      standard ADHD pharmacotherapy transfers cleanly to FOXP1 syndrome. This is
      an uncontrolled clinical observation stated in a trial rationale, not a
      trial result.

- name: Anticonvulsant Therapy
  description: >-
    Standard anti-seizure medication is used for the subset of individuals with
    epilepsy. No FOXP1-specific regimen is established.
  action_category: THERAPEUTIC
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: anticonvulsant therapy
    term:
      id: NCIT:C64172
      label: Anticonvulsant Therapy
  target_phenotypes:
  - preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
  evidence:
  - reference: PMID:37733892
    reference_title: "FOXP1 Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "cryptorchidism, hypertonia, hearing loss, and epilepsy"
    explanation: >-
      GeneReviews establishes epilepsy as a manifestation requiring management;
      it does not specify an agent, so the treatment is curated as generic
      anticonvulsant therapy.

- name: Multispecialty Surveillance
  description: >-
    Regular monitoring by the relevant specialists of existing manifestations,
    the response to supportive care, and the emergence of new manifestations. In
    practice this includes developmental, neurologic, ophthalmologic,
    audiologic, cardiac and renal review appropriate to the documented anomalies
    of the individual.
  action_category: MONITORING
  therapeutic_modality: OTHER
  treatment_term:
    preferred_term: disease screening and surveillance
    term:
      id: NCIT:C15419
      label: Disease Screening
  evidence:
  - reference: PMID:37733892
    reference_title: "FOXP1 Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Regular monitoring by the relevant specialists of existing manifestations,
      the individual's response to supportive care, and the emergence of new
      manifestations is recommended.
    explanation: GeneReviews defines the surveillance recommendation.

- name: Genetic Counseling
  description: >-
    Counseling covers the autosomal dominant mechanism, the predominance of de
    novo variants, the 50% transmission risk from an affected individual, and
    the approximately 1% sib recurrence risk arising from possible parental
    germline mosaicism, the basis on which prenatal and preimplantation genetic
    testing may be offered.
  action_category: COUNSELING_INFORMATIONAL
  therapeutic_modality: OTHER
  treatment_term:
    preferred_term: genetic counseling
    term:
      id: NCIT:C15240
      label: Genetic Counseling
  evidence:
  - reference: PMID:37733892
    reference_title: "FOXP1 Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      There is, however, a recurrence risk (~1%) to sibs based on the
      possibility of parental germline mosaicism; given this risk, prenatal and
      preimplantation genetic testing may be considered.
    explanation: >-
      GeneReviews supplies the recurrence-risk figure and the reproductive
      options that counseling must cover.

progression:
- phase: Non-regressive lifelong developmental trajectory
  age_range: Infancy through adulthood (observed 2-54 years)
  notes: >-
    FOXP1 syndrome follows a static-encephalopathy-like course. Caregiver-report
    studies spanning childhood to adulthood (age 2-54 years) document continued,
    if slow, acquisition of adaptive and communication skills into adulthood
    with no developmental regression, no neuropsychiatric decompensation, and no
    catatonia. Educational placement typically shifts toward special education
    by late elementary school, and caregiver concerns move from cognitive and
    developmental issues in childhood to independence, safety, and housing in
    adolescence and adulthood.
  evidence:
  - reference: PMID:40066139
    reference_title: >-
      Adolescents and adults with FOXP1 syndrome show high rates of anxiety and
      externalizing behaviors but not psychiatric decompensation or skill loss.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      There was no reported regression or loss of skills, early in development
      or during adolescence/adulthood.
    explanation: >-
      Directly establishes the absence of regression across the observed age
      range.
  - reference: PMID:40066139
    reference_title: >-
      Adolescents and adults with FOXP1 syndrome show high rates of anxiety and
      externalizing behaviors but not psychiatric decompensation or skill loss.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Cognitive and developmental concerns were reported as primary during
      childhood and independence/safety and housing concerns became top concerns
      by adolescence/adulthood.
    explanation: >-
      Characterizes how the burden of the disorder shifts across the lifespan.
  - reference: PMID:41175749
    reference_title: >-
      Improving prognostication for individuals with FOXP1 syndrome:
      Parent-reported practical and social skills in 52 individuals.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      but continue to develop their skills into adulthood
    explanation: >-
      A second, larger caregiver cohort confirms continued skill acquisition in
      adulthood.

clinical_burden:
  burden_level: HIGH
  rationale: >-
    Lifelong intellectual disability with a universal speech and language
    impairment, near-universal behavioral morbidity, and continuing dependence
    for activities of daily living into adulthood, with most individuals
    requiring extensive and often continuous caregiver support. Families rank
    intellectual disability, impaired communication, behavior problems, lack of
    age-appropriate self-reliance, attention problems and anxiety as the most
    burdensome features, a set dominated by cognition, communication and
    behavior rather than by the congenital malformations that defined the
    earliest reports. Incontinence, obsessions and a complex sensory profile
    rank disproportionately high relative to how uniformly they occur. Burden is
    high but not uniformly severe: skills continue to accrue and there is no
    regression.
  evidence:
  - reference: PMID:38123995
    reference_title: >-
      Clinical phenotype of FOXP1 syndrome: parent-reported medical signs and
      symptoms in 40 individuals.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The most burdensome complaints for patients with FOXP1 syndrome, as
      perceived by parents, include intellectual disability, impaired
      communication, behaviour problems, lack of age-appropriate self-reliance,
      attention problems and anxiety.
    explanation: >-
      Directly reports the caregiver-prioritized burden ranking.
  - reference: PMID:41175749
    reference_title: >-
      Improving prognostication for individuals with FOXP1 syndrome:
      Parent-reported practical and social skills in 52 individuals.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Although most individuals learn to perform some basic daily living tasks
      independently, the majority heavily rely on their parents, many needing
      24-7 supervision to support many aspects of daily life up to adulthood.
    explanation: >-
      Quantifies the ongoing caregiver-support requirement underpinning the HIGH
      burden level.

animal_models:
- species: Mus musculus
  genotype: Forebrain-specific Foxp1 conditional knockout
  description: >-
    Forebrain-specific Foxp1 conditional knockout mice show impaired neonatal
    ultrasonic vocalization together with neocortical cytoarchitectonic
    alterations caused by defective neuronal positioning and migration. This is
    the model that links the FOXP1-dependent cortical transcriptional network to
    a communication phenotype.
  evidence:
  - reference: PMID:29138280
    reference_title: "Foxp1 regulation of neonatal vocalizations via cortical development."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      We show that deletion of Foxp1 in the developing forebrain leads to
      impairments in neonatal vocalizations as well as neocortical
      cytoarchitectonic alterations via neuronal positioning and migration.
    explanation: >-
      Describes the model and its two core phenotypes.
- species: Mus musculus
  genotype: Foxp1 heterozygous null (Foxp1+/-)
  description: >-
    Patient-relevant heterozygous Foxp1 mice model the haploinsufficient human
    genotype. They reveal FoxP1-dependent regulation of autism-related pathways
    and neuronal-activity genes, altered striatal medium spiny neuron
    excitability, and ultrasonic vocalization defects.
  evidence:
  - reference: PMID:26494785
    reference_title: "FoxP1 orchestration of ASD-relevant signaling pathways in the striatum."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Here, we identify the gene expression program regulated by FoxP1 in both
      human neural cells and patient-relevant heterozygous Foxp1 mouse brains.
    explanation: >-
      Establishes the heterozygous mouse as the dosage-matched model and its
      pairing with human neural cells.
- species: Mus musculus
  genotype: Brain-specific Foxp1 knockout
  description: >-
    Brain-specific Foxp1 knockout pups show strongly reduced ultrasonic
    vocalization and loss of the normal sex-specific call rate, independently
    corroborating a Foxp1 requirement for vocal output.
  evidence:
  - reference: PMID:28204507
    reference_title: "Foxp1 expression is essential for sex-specific murine neonatal ultrasonic vocalization."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Foxp1 KO pups had strongly reduced USV and lacked the sex-specific call
      rate from WT pups, indicating that Foxp1 is essential for normal USV.
    explanation: >-
      Independent knockout confirmation of the vocalization phenotype.

- species: Mus musculus
  genotype: Cortex-restricted Foxp1 conditional knockout (Foxp1-cKO)
  description: >-
    Cortex-specific Foxp1 deletion produces a biphasic tactile phenotype
    (deferred response then avoidance and hyper-reaction on repeated whisker
    stimulation), reduced dendritic spine number, disrupted somatosensory barrel
    formation, absent layer IV c-Fos activation, and increased basolateral
    amygdala c-Fos. It is the model most directly relevant to the human sensory
    phenotype. Limitation: the causal thalamocortical-to-amygdala circuit
    physiology is unresolved, and translation of whisker behavior to human
    sensory experience is indirect.
  evidence:
  - reference: PMID:37691105
    reference_title: >-
      Cortex-restricted deletion of Foxp1 impairs barrel formation and induces
      aberrant tactile responses in a mouse model of autism.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      We employed cortex-specific Foxp1 knockout (Foxp1-cKO) mice as a model of
      autism in this study.
    explanation: Defines the model system.
  - reference: PMID:37691105
    reference_title: >-
      Cortex-restricted deletion of Foxp1 impairs barrel formation and induces
      aberrant tactile responses in a mouse model of autism.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      It is still unclear how the defective thalamocortical connection gives
      rise to the hyper-reactive response.
    explanation: >-
      The authors state the principal mechanistic limitation of the model, which
      is why the downstream sensory edge is curated as indirect.
- species: Mus musculus
  genotype: >-
    Spiny-projection-neuron-specific Foxp1 conditional knockout (D1-, D2-, and
    combined SPN drivers)
  description: >-
    Cell-type-restricted striatal Foxp1 deletion, profiled by single-cell
    RNA-seq of the early postnatal striatum, resolves cell-autonomous from
    non-cell-autonomous effects and links D2/indirect-pathway SPN
    misspecification and striosome-matrix disorganization to motor-learning,
    vocalization and fear-conditioning phenotypes. A postnatal reinstatement
    variant of this design provides the reversibility proof of concept.
  evidence:
  - reference: PMID:32130906
    reference_title: "Single-Cell Analysis of Foxp1-Driven Mechanisms Essential for Striatal Development."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Using this approach, we could also examine the non-cell-autonomous effects
      produced by disrupting one cell type and the molecular compensation that
      occurs in other populations.
    explanation: >-
      Describes the specific analytic advantage of the cell-type-restricted
      knockout series.
  - reference: PMID:38701209
    reference_title: >-
      FOXP1 regulates the development of excitatory synaptic inputs onto
      striatal neurons and induces phenotypic reversal with reinstatement.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Together, this study enhances our understanding of striatal circuit
      development and provides proof of concept for a therapeutic approach for
      FOXP1 syndrome and other neurodevelopmental disorders.
    explanation: >-
      The reinstatement model is the current preclinical proof of concept for a
      FOXP1-restoration therapeutic strategy.

clinical_trials:
- name: NCT03718923
  status: RECRUITING
  description: >-
    Cross-sectional observational deep-phenotyping cohort at the Seaver Autism
    Center (Icahn School of Medicine at Mount Sinai) characterizing
    FOXP1-related neurodevelopmental disorders with genetic, medical,
    neuropsychological, EEG, visual-evoked-potential and eye-tracking measures,
    with biospecimen collection. Not an interventional treatment trial.
  target_phenotypes:
  - preferred_term: Global developmental delay
    term:
      id: HP:0001263
      label: Global developmental delay
  - preferred_term: Delayed speech and language development
    term:
      id: HP:0000750
      label: Delayed speech and language development
  - preferred_term: Autism
    term:
      id: HP:0000717
      label: Autism
  evidence:
  - reference: clinicaltrials:NCT03718923
    reference_title: "The Seaver Autism Center for Research and Treatment - Assessment Core"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      This study seeks to characterize FOXP1-related neurodevelopmental
      disorders using a number of genetic, medical and neuropsychological
      measures.
    explanation: >-
      States the study objective and confirms it is observational
      characterization rather than an intervention.
- name: NCT06211673
  status: COMPLETED
  description: >-
    Observational psychiatric phenotyping study at Assistance Publique -
    Hopitaux de Paris characterizing autism, anxiety, sleep, behavior, sensory
    profile, adaptive function, agitation, ADHD and psychotic symptoms in
    individuals with FOXP1 syndrome, motivated by a locally observed prevalence
    of psychotic disorders and by caregiver reports of poor methylphenidate
    response.
  target_phenotypes:
  - preferred_term: Anxiety
    term:
      id: HP:0000739
      label: Anxiety
  - preferred_term: Attention deficit hyperactivity disorder
    term:
      id: HP:0007018
      label: Attention deficit hyperactivity disorder
  evidence:
  - reference: clinicaltrials:NCT06211673
    reference_title: "Psychiatric Phenotype Characterization of Individuals With FOXP1 Syndrome"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Therefore, it appears crucial to further characterize the psychiatric
      phenotype of individuals with FOXP1 syndrome and explore the link between
      agitation and psychotic prodromes.
    explanation: >-
      States the study rationale and its focus on the psychiatric phenotype.

differential_diagnoses:
- name: FOXP2-Related Speech and Language Disorder
  description: >-
    FOXP2 haploinsufficiency causes hereditary developmental verbal dyspraxia.
    FOXP1 and FOXP2 are paralogs that heterodimerize and have overlapping brain
    expression, but the disorders are clinically separable: FOXP1 syndrome
    presents with global developmental delay and intellectual disability plus a
    complex dysarthria-dominant speech profile, whereas FOXP2 deficiency causes
    a primary oromotor verbal dyspraxia without obligate intellectual
    disability.
  evidence:
  - reference: PMID:20571508
    reference_title: >-
      Chiari I malformation, delayed gross motor skills, severe speech delay,
      and epileptiform discharges in a child with FOXP1 haploinsufficiency.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The nature of the speech deficit is different from the primary oromotor
      verbal dyspraxia found in patients with FOXP2 deficiency.
    explanation: >-
      States the discriminating feature between the two FOXP-related speech
      disorders.
  - reference: PMID:24214399
    reference_title: "FOXP1 mutations cause intellectual disability and a recognizable phenotype."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Mutations in FOXP2, located at 7q31, are well known to cause developmental
      speech and language disorders, particularly developmental verbal dyspraxia
      (DVD).
    explanation: >-
      Establishes the FOXP2 phenotype that must be distinguished from FOXP1
      syndrome.
  - reference: PMID:31999079
    reference_title: "FOXP transcription factors in vertebrate brain development, function, and disorders."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      These varied sites and timepoints of expression have complicated efforts
      to link FOXP1 and FOXP2 mutations to their respective developmental
      disorders, the former affecting global neural functions and the latter
      specifically affecting speech and language.
    explanation: >-
      A FOXP-family review states the discriminating principle directly: FOXP1
      loss affects global neural function whereas FOXP2 loss is specific to
      speech and language. It also notes that the overlapping,
      cell-type-specific expression of the two paralogs is precisely what makes
      the distinction non-trivial.

discussions:
- discussion_id: foxp1_postnatal_reinstatement_window
  kind: HUMAN_MODEL_MISMATCH
  status: OPEN
  prompt: >-
    Postnatal FOXP1 reinstatement rescues electrophysiological, behavioral and
    cell-type-specific transcriptional phenotypes in mice. Does a
    comparable postnatal window of reversibility exist in humans, in whom the
    disorder is diagnosed after several years of atypical development and in
    whom cortical and striatal circuit maturation follows a much longer
    timescale?
  attaches_to:
  - pathophysiology#Altered Striatal Circuit Excitability
  rationale: >-
    This is a translational-validity question rather than an absence of
    evidence. Strong in vivo mouse evidence exists that the striatal arm of the
    mechanism is postnatally reversible, which would reclassify FOXP1 syndrome
    from a fixed prenatal malformation disorder to a partially modifiable
    circuit disorder and would justify FOXP1-restoration strategies. But mouse
    reinstatement occurs early in a short developmental program, whereas human
    diagnosis typically follows years of atypical development; delivery to the
    relevant cell types, dosage and isoform control, off-target transcriptional
    effects, and the human timing window are all unresolved. The cortical arm of
    the mechanism (lamination, barrel formation, dendritic spines) has not been
    shown to be reversible at all.
  proposed_experiments:
  - experiment_id: exp_foxp1_reinstatement_age_series
    name: Age-series mapping of the FOXP1 reinstatement window in mice
    description: >-
      Reinstate FOXP1 at a graded series of postnatal ages in the same
      conditional model and measure D2 SPN glutamatergic input strength,
      synaptically driven excitability, and the corresponding behavioral
      readouts at each timepoint. The objective is the shape of the closing
      window, not a single permissive early timepoint, because only a rate of
      closure can be extrapolated to the much longer human developmental
      timescale.
  - experiment_id: exp_foxp1_cortical_arm_reversibility
    name: Test whether the cortical arm is reversible under the same protocol
    description: >-
      Apply the same postnatal reinstatement protocol to cortex-restricted
      Foxp1 loss and assay laminar positioning, somatosensory barrel
      organization, dendritic spine density, and tactile behavior. A negative
      result would confine the reversibility claim to the striatal arm and would
      materially change what a FOXP1-restoration therapy could be expected to
      achieve.
  - experiment_id: exp_foxp1_dose_response_ipsc
    name: FOXP1 dose-response in patient-derived and isogenic human neurons
    description: >-
      Use patient-derived iPSC neurons and isogenic corrected lines to establish
      the FOXP1 dose-response relationship, determining whether a normal
      transcriptional state is reachable without overexpression toxicity and
      which isoforms must be restored. FOXP1 is dosage sensitive in both
      directions, so a human dose window is a prerequisite for any restoration
      strategy.
  evidence:
  - reference: PMID:38701209
    reference_title: >-
      FOXP1 regulates the development of excitatory synaptic inputs onto
      striatal neurons and induces phenotypic reversal with reinstatement.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Last, we demonstrate that postnatal FOXP1 reinstatement rescues
      electrophysiological deficits, cell type-specific gene expression changes,
      and behavioral phenotypes.
    explanation: >-
      The mouse result that creates the translational question; it is
      model-organism evidence with no human counterpart.
  - reference: PMID:40066139
    reference_title: >-
      Adolescents and adults with FOXP1 syndrome show high rates of anxiety and
      externalizing behaviors but not psychiatric decompensation or skill loss.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Caregivers reported continued development in adaptive skills even into
      adulthood.
    explanation: >-
      Continued human skill acquisition into adulthood is weakly consistent with
      retained plasticity, but it is not evidence that the underlying circuit
      deficit is reversible.

notes: >-
  Frequency bands are asserted only where a quantitative or explicitly universal
  statement is available. Most bands are anchored on the pooled 62-person
  literature review (PMID:33892622) or on the prospective Mount Sinai cohorts
  (PMID:29090079, PMID:34588003, PMID:40066139): speech/language 60/60 (100%),
  motor delay 59/61 (97%), ID/GDD 55/61 (90%), prominent forehead 48/59 (81%),
  ADHD 75%, short nose with broad tip 41/59 (69%), articulation problems 32/48
  (67%), psychiatric comorbidity 32/56 (57%), brain abnormality 29/58 (50%),
  myopia 29/58 (50%), downslanted palpebral fissures 24/59 (41%), anxiety 38%,
  ptosis 22/59 (37%), congenital heart defect 17/56 (30%), hypotonia 18/62
  (29%), hypertelorism 17/59 (29%), contractures 16/56 (29%), frontal hair
  upsweep 16/59 (27%), ASD 24%, cryptorchidism 9/41 males (22%), feeding issues
  13/62 (21%), strabismus 11/60 (18%), hearing loss 8/48 (17%), macrocephaly
  9/59 (15%), short stature 8/60 (13%), seizures 7/59 (12%), recurrent ear
  infections 7/60 (12%), micropenis 3/41 males (7%), obesity 3/60 (5%).
  Two ASD figures exist and are deliberately not averaged: 24% met formal DSM-5
  criteria on prospective expert-consensus assessment, whereas 50% had ASD
  *features* on retrospective literature aggregation; the curated band follows
  the stricter prospective figure with the higher figure retained as a PARTIAL
  evidence item. GeneReviews lists oromotor dysfunction, refractive errors,
  strabismus, cardiac abnormalities, renal abnormalities, cryptorchidism,
  hypertonia, hearing loss and epilepsy collectively as "other common findings";
  because the qualifier applies to the group rather than to each item, frequency
  is deliberately omitted for those phenotypes.

  No conforms_to module reference is asserted. The candidate modules were
  reviewed and none fits: FOXP1 syndrome is a transcription-factor
  haploinsufficiency neurodevelopmental disorder whose mechanism (loss of
  transcriptional repression, leading to impaired cortical migration and
  striatal medium spiny neuron differentiation) is not represented by any
  current kb/modules entry. The epilepsy_excitation_inhibition_imbalance module
  was considered for the seizure arm, but epilepsy is a minority, non-defining
  feature here and this entry does not curate an excitation/inhibition-imbalance
  node, so declaring conformance would be unsupported.

  The 2010 index case (PMID:20571508) contributes Chiari I malformation and
  epileptiform discharges as single-patient observations; both are curated
  without a frequency. The lung disease resembling neuroendocrine cell
  hyperplasia of infancy and the skeletal undertubulation phenotype reported in
  PMID:28884888 are deliberately NOT curated as phenotypes: they are
  unreplicated single-patient findings that the authors themselves attribute to
  possible stochastic developmental variation. They are represented only in the
  Extra-CNS pathophysiology node description and its PARTIAL evidence item.

  Deep research: an Edison/Falcon deep-research run
  (research/FOXP1_Syndrome-deep-research-falcon.md, 2026-07-31) was used as a
  lead source only. Its NEC preflight passed (report gene FOXP1, MONDO:0013352,
  3p14.1 - matching the intended entity). Every DR-sourced item was
  independently re-derived: DOIs were resolved to PMIDs via the PMC ID
  converter, abstracts were fetched with just fetch-reference, and all snippets
  were verified as exact substrings of the cached text. Two DR suggestions were
  rejected on verification: HP:0002167 was proposed for speech apraxia (the
  correct term is HP:0011098; HP:0002167 is Neurological speech impairment), and
  HP:0000431 was proposed for "wide nasal tip" when its actual label is Wide
  nasal bridge. The DR report also stated that no Orphanet code could be
  established; ORPHA:391372 was confirmed independently from the MONDO record
  and the Orphadata cache. Cytoband is reported as 3p13 by PMID:24214399 and
  3p14.1 by the pooled review; the entry quotes the sourced 3p13 statement.

📚

References & Deep Research

References

16

PMID:37733892

FOXP1 Syndrome.

No top-level findings curated for this source.

PMID:24214399

FOXP1 mutations cause intellectual disability and a recognizable phenotype.

No top-level findings curated for this source.

PMID:29090079

Prospective investigation of FOXP1 syndrome.

No top-level findings curated for this source.

PMID:34588003

Individuals with FOXP1 syndrome present with a complex neurobehavioral profile with high rates of ADHD, anxiety, repetitive behaviors, and sensory symptoms.

No top-level findings curated for this source.

PMID:34109629

Severe speech impairment is a distinguishing feature of FOXP1-related disorder.

No top-level findings curated for this source.

PMID:38123995

Clinical phenotype of FOXP1 syndrome: parent-reported medical signs and symptoms in 40 individuals.

No top-level findings curated for this source.

PMID:41175749

Improving prognostication for individuals with FOXP1 syndrome: Parent-reported practical and social skills in 52 individuals.

No top-level findings curated for this source.

PMID:40066139

Adolescents and adults with FOXP1 syndrome show high rates of anxiety and externalizing behaviors but not psychiatric decompensation or skill loss.

No top-level findings curated for this source.

PMID:33892622

FOXP1 syndrome: a review of the literature and practice parameters for medical assessment and monitoring.

No top-level findings curated for this source.

PMID:26494785

FoxP1 orchestration of ASD-relevant signaling pathways in the striatum.

No top-level findings curated for this source.

PMID:32130906

Single-Cell Analysis of Foxp1-Driven Mechanisms Essential for Striatal Development.

No top-level findings curated for this source.

PMID:37691105

Cortex-restricted deletion of Foxp1 impairs barrel formation and induces aberrant tactile responses in a mouse model of autism.

No top-level findings curated for this source.

PMID:38701209

FOXP1 regulates the development of excitatory synaptic inputs onto striatal neurons and induces phenotypic reversal with reinstatement.

No top-level findings curated for this source.

PMID:29138280

Foxp1 regulation of neonatal vocalizations via cortical development.

No top-level findings curated for this source.

PMID:31999079

FOXP transcription factors in vertebrate brain development, function, and disorders.

No top-level findings curated for this source.

ORPHA:391372

FOXP1 Syndrome

No top-level findings curated for this source.

Deep Research

1

Falcon ▸

FOXP1 Syndrome: Disease-Characteristics Research Report

Edison Scientific Literature 13 citations 2026-07-31T17:50:23.702674

FOXP1 Syndrome: Disease-Characteristics Research Report

Scope and evidence date. This report prioritizes human clinical evidence and 2023–2024 mechanistic work retrieved for this review. FOXP1 syndrome remains ultra-rare; much of its clinical literature consists of case reports, small series, and one aggregated 62-person review. Frequencies should therefore be treated as provisional and potentially affected by ascertainment and missing-data assumptions. The most recent retrieved human research is largely observational phenotyping rather than therapeutic trials.

Executive summary

FOXP1 syndrome is a congenital, lifelong Mendelian neurodevelopmental disorder caused by heterozygous disruption of FOXP1 at chromosome 3p14.1, usually through a de novo loss-of-function sequence variant or deletion. The core phenotype is global developmental delay/intellectual disability with disproportionately severe speech-language impairment; motor delay, autism-related features, behavioral/psychiatric morbidity, hypotonia, and variable congenital brain, cardiac, genitourinary, ophthalmologic, and hearing abnormalities also occur. In the principal 62-person literature aggregation, speech-language delay occurred in 60/60, motor delay in 59/61, intellectual disability/developmental delay in 55/61, ASD symptoms in 28/56, and psychiatric comorbidity in 32/56. These are aggregated disease-level data, not EHR-derived estimates. (lozano2021foxp1syndromea pages 1-2, lozano2021foxp1syndromea pages 11-13, lozano2021foxp1syndromea pages 2-3, lozano2021foxp1syndromea pages 3-4)

The established disease mechanism is FOXP1 haploinsufficiency, disrupting a dosage-sensitive nuclear transcriptional regulator during development. Mouse single-cell and circuit studies implicate cortical development, striatal spiny projection neuron specification—especially D2/indirect-pathway neurons—glutamatergic synapse maturation, neuronal excitability, and corticostriatal/thalamocortical organization. A major 2024 advance was proof that postnatal FOXP1 reinstatement can reverse electrophysiologic, cell-type-specific transcriptional, and behavioral abnormalities in mice; this is compelling preclinical evidence, but not evidence of efficacy or safety in humans. (anderson2020singlecellanalysisof pages 1-4, khandelwal2024foxp1regulatesthe pages 1-2, li2023cortexrestricteddeletionof pages 1-2)

Domain	Best-supported finding	Quantitative data	Evidence type/date
Core neurodevelopmental phenotype	FOXP1 syndrome is a neurodevelopmental disorder with global developmental delay/intellectual disability and especially prominent speech-language impairment.	Developmental delay/intellectual disability 55/61 (90%); speech/language delay 60/60 (100%); gross/fine motor delay 59/61 (97%); articulation problems 32/48 (67%) (lozano2021foxp1syndromea pages 11-13, lozano2021foxp1syndromea pages 3-4)	Human aggregated disease-level review of 62 independent individuals; 2021 (lozano2021foxp1syndromea pages 1-2, lozano2021foxp1syndromea pages 11-13)
Behavioral/psychiatric phenotype	Autism-related and psychiatric features are common but variable.	ASD symptoms 28/56 (50%); psychiatric comorbidities 32/56 (57%); hypotonia 18/62 (29%); feeding issues 13/62 (21%) (lozano2021foxp1syndromea pages 11-13, lozano2021foxp1syndromea pages 3-4)	Human aggregated disease-level review; 2021 (lozano2021foxp1syndromea pages 11-13)
Associated medical findings	Multisystem involvement extends beyond neurodevelopment, supporting syndromic evaluation.	Seizures 12%; brain abnormalities ~50%; cardiac defects 30%; hypertonia/muscle spasms 34%; contractures 29%; short stature 13%; obesity 5% (lozano2021foxp1syndromea pages 13-15)	Human aggregated disease-level review; 2021 (lozano2021foxp1syndromea pages 13-15)
Dysmorphology	Mild but recurrent craniofacial features are frequent.	Prominent forehead 48/59 (81%); short nose/broad tip 41/59 (69%); down-slanting palpebral fissures 24/59 (41%); ptosis 22/59 (37%) (lozano2021foxp1syndromea pages 1-2, lozano2021foxp1syndromea pages 7-9)	Human aggregated disease-level review; 2021 (lozano2021foxp1syndromea pages 1-2, lozano2021foxp1syndromea pages 7-9)
Genetics/inheritance	Disease is caused by disruptive FOXP1 variants/deletions, usually de novo, consistent with haploinsufficiency; rare parental balanced rearrangements or mosaic recurrence risk must be considered.	Review captured 62 individuals: 18 deletion cases and 44 sequence-variant cases; sex ratio 41 male:21 female; age 4 months-31 years, mean 11.4 years; recurrence risk for apparent de novo events noted as low but above population baseline because of possible germline mosaicism (~1%) (lozano2021foxp1syndromea pages 1-2, lozano2021foxp1syndromea pages 2-3)	Human genetics review and counseling recommendations; 2021 (lozano2021foxp1syndromea pages 1-2, lozano2021foxp1syndromea pages 2-3)
Diagnostic pathway	First-line workup is chromosomal microarray plus sequencing; parental studies are important because CMA misses balanced rearrangements and structural events can involve FOXP1.	Recommended tests: CMA for 3p14 deletions, NGS/WES/WGS for sequence variants, parental karyotype and/or metaphase FISH to assess balanced insertion/inversion; RNA-seq/optical genome mapping can aid structural-variant interpretation in unresolved NDD cases (lozano2021foxp1syndromea pages 2-3, lozano2021foxp1syndromea pages 15-16)	Practice-parameter review; 2021, plus NDD genome/RNA workflow evidence noting prior FOXP1 breakpoint example; 2024 (lozano2021foxp1syndromea pages 2-3, lozano2021foxp1syndromea pages 15-16)
Current management	No disease-modifying standard therapy; care is supportive and multidisciplinary with developmental, neurologic, cardiac, sensory, and educational surveillance.	Recommended: speech/language therapy, OT/PT, behavior therapy/ABA, AAC for nonverbal or minimally verbal individuals, neuropsychological reevaluation at least every 3 years, EEG when seizures suspected, brain imaging, hearing/vision assessment, echocardiography/ECG, and specialist referrals as indicated (lozano2021foxp1syndromea pages 13-15, lozano2021foxp1syndromea pages 16-17, lozano2021foxp1syndromea pages 11-13)	Multidisciplinary practice recommendations; 2021 (lozano2021foxp1syndromea pages 13-15, lozano2021foxp1syndromea pages 16-17, lozano2021foxp1syndromea pages 11-13)
2023 cortical model	Cortex-specific Foxp1 loss causes abnormal tactile processing and disrupted somatosensory circuit development, supporting a cortical contribution to sensory symptoms.	Foxp1-cKO mice showed delayed tactile response, avoidance/hyper-reaction to repeated whisker stimulation, reduced c-Fos in layer IV somatosensory cortex, increased c-Fos in basolateral amygdala, fewer dendritic spines, and disrupted barrel formation (li2023cortexrestricteddeletionof pages 1-2)	Mouse conditional knockout study; Molecular Autism, 2023 (li2023cortexrestricteddeletionof pages 1-2)
2024 postnatal reinstatement result	Postnatal FOXP1 restoration in striatal neurons rescued electrophysiologic, gene-expression, and behavioral abnormalities, providing proof-of-concept for therapeutic reversibility.	Study concluded that postnatal FOXP1 reinstatement rescues electrophysiological deficits, cell type-specific gene-expression changes, and behavioral phenotypes, with strongest effects described in D2 SPNs (khandelwal2024foxp1regulatesthe pages 1-2)	Mouse mechanistic/rescue study; Science Advances, 2024 (khandelwal2024foxp1regulatesthe pages 1-2)
Mechanistic/circuit insight	FOXP1 is a key regulator of striatal development and SPN subtype specification, linking molecular dysregulation to motor, vocalization, and limbic phenotypes relevant to human disease.	Single-cell RNA-seq profiled 62,778 striatal cells at postnatal day 9 across 4 genotypes; Foxp1 deletion altered cellular composition, neurochemical architecture, and behaviors including motor learning, ultrasonic vocalizations, and fear conditioning (anderson2020singlecellanalysisof pages 1-4)	Mouse single-cell systems study; 2020 (anderson2020singlecellanalysisof pages 1-4)
Observational studies	Current human research is focused on deep phenotyping rather than interventional treatment trials.	NCT03718923: recruiting observational cohort, estimated n=50, started 2016, primary completion estimated 2028; NCT06211673: completed observational psychiatric phenotyping study, n=25 (NCT03718923 chunk 1, NCT03718923 chunk 2, NCT06211673 chunk 2)	ClinicalTrials.gov observational studies; updated through 2024-2026 registry records (NCT06211673 chunk 2, NCT03718923 chunk 1, NCT03718923 chunk 2)

Table: This table summarizes the strongest currently retrieved evidence on FOXP1 syndrome across phenotype, genetics, diagnostics, management, mechanistic models, and active observational studies. It is designed as a compact knowledge-base-ready snapshot anchored to available context citations.

1. Disease information

Definition and classification

FOXP1 syndrome is a syndromic neurodevelopmental disorder due to heterozygous FOXP1 disruption. Synonyms include FOXP1-related neurodevelopmental disorder, FOXP1 haploinsufficiency syndrome, and intellectual disability–severe speech delay–mild dysmorphism syndrome. Open Targets maps the latter to MONDO:0013352 and associates it specifically with FOXP1/ENSG00000114861. (lozano2021foxp1syndromea pages 1-2, OpenTargets Search: FOXP1 syndrome-FOXP1)

Identifiers suitable for the knowledge base

MONDO: MONDO:0013352.
OMIM phenotype: commonly catalogued as Intellectual developmental disorder with language impairment and with or without autistic features; OMIM 613670 should be verified directly before production ingestion because the retrieved primary evidence did not itself display the OMIM record.
Gene: FOXP1; approved name forkhead box P1; Ensembl ENSG00000114861.
Orphanet: a dedicated ORPHA number was not established from the retrieved evidence and should be left unpopulated pending direct Orphanet validation.
ICD-10/ICD-11: no syndrome-specific code was identified. Coding generally uses manifestations such as intellectual developmental disorder, developmental speech/language disorder, ASD, hypotonia, or congenital anomalies.
MeSH: no disease-specific MeSH heading was established; relevant headings include Neurodevelopmental Disorders, Intellectual Disability, Developmental Disabilities, Communication Disorders, and Autism Spectrum Disorder. ClinicalTrials.gov maps the studied condition to MeSH D000067877, D008607, D007859, and D002658 for ASD, intellectual disability, learning disability, and developmental disability, respectively. (NCT03718923 chunk 2)

Data provenance. Published frequencies are aggregated from case reports and case series. The 2021 review included 62 independent individuals, ages 4 months–31 years, rather than longitudinal EHR records. Current studies collect standardized participant-level medical, genetic, neuropsychological, EEG, eye-tracking, and biospecimen data, but are observational. (NCT03718923 chunk 1, lozano2021foxp1syndromea pages 2-3)

2. Etiology, risk, and protective factors

Causal factors

The primary cause is a heterozygous germline pathogenic variant or chromosomal rearrangement disrupting FOXP1. Reported classes include whole/partial-gene deletions, nonsense, frameshift, splice-altering, missense, and in-frame variants, as well as structural rearrangements with a FOXP1 breakpoint. The common biological endpoint is reduced normal FOXP1 dosage or function. In the 62-person review, 18 had deletions and 44 had sequence variants. (lozano2021foxp1syndromea pages 1-2, lozano2021foxp1syndromea pages 2-3)

Genetic risk

Most affected individuals have a de novo event; the inheritance model is autosomal dominant.
Rare familial recurrence can arise from a parental balanced insertion/inversion or presumed germline mosaicism.
For an apparently de novo event, the cited counseling estimate was approximately 1% recurrence risk, reflecting possible parental germline mosaicism; if a parent carries the pathogenic variant or balanced rearrangement, recurrence may be substantially higher and is rearrangement-specific. (lozano2021foxp1syndromea pages 1-2, lozano2021foxp1syndromea pages 2-3)
Penetrance for clearly disruptive variants appears high, but formal age-stratified penetrance estimates are unavailable. Expressivity is variable.
No founder variant, carrier-frequency estimate, anticipation, or consanguinity effect is established.

Environmental, lifestyle, infectious, and protective factors

No toxin, infection, diet, smoking, alcohol, occupational exposure, or lifestyle factor is known to cause FOXP1 syndrome. No validated genetic or environmental protective factor has been identified. Likewise, no FOXP1-specific gene–environment interaction has been demonstrated. General prenatal and pediatric health measures may affect overall outcome but do not prevent the causal genetic disorder. Claims from multifactorial ASD should not be transferred to this monogenic syndrome without direct evidence.

3. Phenotypes

Core neurodevelopmental and behavioral phenotype

Speech/language impairment: 60/60 (100%) in the aggregated review; usually apparent in early childhood and often the most disproportionate deficit. Expressive language, articulation, motor-speech production, and intelligibility may be affected. Severity ranges from delayed phrase speech to minimally verbal communication. Suggested HPO: HP:0000750 Delayed speech and language development, HP:0002167 Speech apraxia, HP:0001263 Global developmental delay. (lozano2021foxp1syndromea pages 11-13, lozano2021foxp1syndromea pages 3-4)
Developmental delay/intellectual disability: 55/61 (90%); generally congenital/early-childhood onset, chronic, and variable in severity. Suggested HPO: HP:0001249 Intellectual disability, HP:0001263. (lozano2021foxp1syndromea pages 11-13)
Motor delay: 59/61 (97%); gross and fine motor development may be impaired, with gait and coordination consequences. Suggested HPO: HP:0001270 Motor delay, HP:0002194 Delayed gross motor development, HP:0010862 Delayed fine motor development. (lozano2021foxp1syndromea pages 11-13, lozano2021foxp1syndromea pages 3-4)
Articulation difficulty: 32/48 (67%). Suggested HPO: HP:0001618 Dysarthria or HP:0002167 where formal motor-speech assessment supports those labels. (lozano2021foxp1syndromea pages 3-4)
ASD symptoms/features: 28/56 (50%), not universal. Suggested HPO: HP:0000717 Autism, HP:0000729 Autistic behavior. (lozano2021foxp1syndromea pages 11-13)
Psychiatric/behavioral comorbidity: 32/56 (57%), including ADHD symptoms, anxiety, aggression, repetitive behavior, sensory abnormalities, and sleep concerns. Suggested HPO: HP:0007018 Attention deficit hyperactivity disorder, HP:0000739 Anxiety, HP:0000718 Aggressive behavior, HP:0002360 Sleep disturbance, HP:0000733 Stereotypic behavior. (lozano2021foxp1syndromea pages 13-15, lozano2021foxp1syndromea pages 11-13, NCT06211673 chunk 2)

Neurologic and musculoskeletal findings

Hypotonia: 18/62 (29%), commonly infantile/childhood; may contribute to feeding and motor delay. HPO: HP:0001252 Hypotonia. (lozano2021foxp1syndromea pages 11-13, lozano2021foxp1syndromea pages 3-4)
Hypertonia/muscle spasms: approximately 34%; contractures: approximately 29%. HPO: HP:0001276 Hypertonia; HP:0001371 Flexion contracture. (lozano2021foxp1syndromea pages 13-15)
Seizures: approximately 12%, indicating that epilepsy is a minority rather than defining feature. HPO: HP:0001250 Seizure. EEG is indicated clinically, not as a universal molecular biomarker. (lozano2021foxp1syndromea pages 13-15)
Brain MRI abnormalities: about 50% among reported/imaged cases, including ventricular dilation, white-matter abnormalities, arachnoid cyst, corpus-callosum or cerebellar abnormalities, and Chiari I malformation. Findings are heterogeneous and not diagnostic. HPO terms may include HP:0002119 Ventriculomegaly, HP:0001273 Abnormality of the corpus callosum, and HP:0002308 Arnold–Chiari malformation. (lozano2021foxp1syndromea pages 13-15)

Feeding, growth, congenital anomalies, and dysmorphism

Feeding/swallowing problems: 13/62 (21%), especially early in life. HPO: HP:0011968 Feeding difficulties, HP:0002015 Dysphagia when documented. (lozano2021foxp1syndromea pages 11-13, lozano2021foxp1syndromea pages 3-4)
Cardiac defects: approximately 30%; genitourinary anomalies are variably reported. HPO should follow the specific lesion rather than a generic syndrome assertion. (lozano2021foxp1syndromea pages 13-15, lozano2021foxp1syndromea pages 16-17)
Growth: short stature approximately 13%; obesity approximately 5%. HPO: HP:0004322 Short stature; HP:0001513 Obesity. (lozano2021foxp1syndromea pages 13-15)
Recurrent dysmorphism included prominent forehead 48/59 (81%), short nose with broad tip 41/59 (69%), down-slanting palpebral fissures 24/59 (41%), and ptosis 22/59 (37%). HPO: HP:0011220 Prominent forehead, HP:0003196 Short nose, HP:0000431 Wide nasal tip, HP:0000494 Downslanted palpebral fissures, HP:0000508 Ptosis. (lozano2021foxp1syndromea pages 1-2, lozano2021foxp1syndromea pages 7-9)

Functional and quality-of-life impact

Severe communication impairment, intellectual/adaptive limitations, motor delay, behavioral dysregulation, sensory differences, and need for educational support can substantially restrict independent daily living and caregiver/family functioning. However, no syndrome-specific EQ-5D, SF-36, PROMIS, utility-weight, or caregiver-burden estimate was retrieved. Adaptive behavior is being measured with instruments such as Vineland in current observational research. (NCT06211673 chunk 2, NCT03718923 chunk 1)

4. Genetic and molecular information

Gene and protein

FOXP1, located at 3p14.1, encodes a forkhead-box family transcription factor. It is broadly expressed and has developmental roles in brain, heart, lung, and immune tissues. In the nervous system, expression is prominent in cortex, hippocampus, and striatum. The protein functions primarily in the nucleus as a DNA-binding transcriptional regulator/repressor and can participate in FOXP-family homo-/heterodimeric complexes. (lozano2021foxp1syndromea pages 1-2, khandelwal2024foxp1regulatesthe pages 1-2, li2023cortexrestricteddeletionof pages 1-2)

Suggested annotations include GO:0003677 DNA binding, GO:0003700 DNA-binding transcription-factor activity, GO:0006355 regulation of DNA-templated transcription, and GO:0005634 nucleus. Exact GO annotations should be imported from the current GO/UniProt records rather than inferred solely from this report.

Pathogenic variants and interpretation

Established disease mechanism: loss of function/haploinsufficiency.
Variant classes: deletion/CNV, nonsense, frameshift, canonical or noncanonical splice, missense, in-frame deletion, inversion/insertion/translocation disrupting FOXP1.
Origin: usually constitutional germline and de novo. Somatic FOXP1 alterations in cancer are a separate disease context and should not be conflated with FOXP1 syndrome.
Population frequency: truly pathogenic high-impact alleles are expected to be absent or exceptionally rare in population databases. Variant-level gnomAD frequencies must be checked individually; no single frequency can describe the heterogeneous pathogenic spectrum.
Classification: use ACMG/AMP criteria with de novo status, predicted loss of function in a haploinsufficient gene, segregation, population rarity, phenotype match, and functional RNA/protein evidence. A VUS does not confirm the syndrome.
Genotype–phenotype: deletions, truncating variants, and missense variants had broadly similar developmental severity in the review; large 3p deletions may be more severe because neighboring genes are also lost. Robust variant-specific prognostic rules are not established. (lozano2021foxp1syndromea pages 16-17, lozano2021foxp1syndromea pages 15-16)

No reproducible modifier gene or protective allele is established. No syndrome-specific DNA-methylation episignature, histone signature, metabolomic profile, lipidomic signature, or validated circulating biomarker was identified.

5. Environmental information

FOXP1 syndrome is not an environmental, lifestyle-associated, toxicologic, or infectious disease. Environmental supports—early language exposure, accessible communication, education, rehabilitation, sleep care, and treatment of hearing/vision abnormalities—may modify functional outcome but are not etiologic or proven protective against occurrence. There is no zoonotic or transmissible component.

6. Mechanism and pathophysiology

Causal chain

Upstream: pathogenic germline FOXP1 variant/deletion → reduced functional FOXP1 dosage or defective DNA-binding/transcriptional regulation.

Intermediate developmental effects: altered expression of neuronal differentiation, ion-channel, synaptic, and ASD-associated gene programs → disturbed neuronal positioning/lamination, striatal cell-type specification, dendritic spine/barrel formation, and maturation of glutamatergic inputs.

Circuit effects: abnormal cortical and thalamic inputs to striatum; altered D2 spiny projection-neuron intrinsic and synaptically driven excitability; disturbed striosome–matrix architecture; impaired somatosensory cortex–amygdala responses.

Downstream clinical manifestations: speech/communication impairment, intellectual and adaptive disability, motor-learning deficits, social/behavioral differences, abnormal sensory responses, and variable congenital organ abnormalities. Human causation is strongest for the gene-to-syndrome relationship; the detailed cell/circuit chain is principally based on mouse experiments. (co2020foxptranscriptionfactors pages 13-15, anderson2020singlecellanalysisof pages 1-4, khandelwal2024foxp1regulatesthe pages 1-2, li2023cortexrestricteddeletionof pages 1-2)

Striatal single-cell and synaptic mechanisms

A 2020 study profiled 62,778 postnatal-day-9 striatal cells across control and D1-, D2-, or combined SPN-specific Foxp1 conditional knockouts. Foxp1 loss changed striatal cellular composition and neurochemical architecture, impaired indirect-pathway SPN specification, produced non-cell-autonomous and compensatory effects in other populations, and connected cell-type-specific transcriptional changes to motor learning, ultrasonic vocalization, and fear-conditioning phenotypes. Relevant cell types are GABAergic spiny projection neurons, particularly DRD2-positive indirect-pathway SPNs, plus cortical/thalamic glutamatergic afferents, astrocytes, oligodendrocyte precursors, interneurons, and neurogenic progenitors. (anderson2020singlecellanalysisof pages 1-4)

Suggested terms: GO:0099536 synaptic signaling, GO:0007268 chemical synaptic transmission, GO:0050804 modulation of chemical synaptic transmission, GO:0030154 cell differentiation, GO:0007399 nervous-system development; CL:0000540 neuron, CL:0000120 granule cell/related neuronal subclasses only if anatomically appropriate, and a current CL term for striatal medium spiny neuron should be validated before ingestion.

The 2024 Science Advances study found that FOXP1 strengthens and matures glutamatergic input onto D2 SPNs, promotes synaptically driven excitability, and regulates post-synaptic candidate genes identified by single-nucleus RNA sequencing. Crucially, postnatal reinstatement rescued electrophysiologic abnormalities, cell-type-specific expression changes, and behavioral phenotypes. This suggests that at least some downstream circuitry remains biologically reversible after prenatal development, creating a possible postnatal therapeutic window. It does not establish an approved gene therapy, optimal dose, delivery vector, human therapeutic window, or safety profile. Published 3 May 2024; DOI: https://doi.org/10.1126/sciadv.adm7039. (khandelwal2024foxp1regulatesthe pages 1-2)

Direct abstract quote: “postnatal FOXP1 reinstatement rescues electrophysiological deficits, cell type-specific gene expression changes, and behavioral phenotypes.” (khandelwal2024foxp1regulatesthe pages 1-2)

Cortical and sensory mechanisms

Cortex-specific Foxp1 knockout mice showed delayed tactile responses followed by avoidance/hyper-reaction to repeated whisker stimulation. They had reduced dendritic spines and disrupted barrel formation in primary somatosensory cortex, reduced c-Fos activation in cortical layer IV, and increased c-Fos in basolateral amygdala. This supports altered thalamocortical sensory processing with downstream limbic hyper-reactivity, although the authors explicitly note that the causal electrophysiology of the thalamocortical–amygdala circuit remains unresolved. Published September 2023; DOI: https://doi.org/10.1186/s13229-023-00567-0. (li2023cortexrestricteddeletionof pages 1-2)

Earlier cortical/hippocampal deletion models showed impaired neonatal vocalization, cortical lamination/neuronal migration defects, spatial-memory and motor-learning deficits, social impairment, and reduced CA1 long-term potentiation. These findings support developmental cortical and hippocampal contributions alongside striatal pathology. (co2020foxptranscriptionfactors pages 13-15)

Other biological systems and omics gaps

FOXP1’s broad developmental expression is compatible with cardiac and genitourinary anomalies, but the precise human tissue-specific causal chains remain less resolved than the neural mechanism. No consistent immune deficiency, autoimmunity, inflammation, metabolic enzyme defect, mitochondrial disorder, oxidative tissue-injury mechanism, proteomic signature, metabolomic profile, lipidomic signature, human spatial transcriptomic atlas, or human disease single-cell dataset was identified. Existing advanced-technology evidence is mainly mouse scRNA-seq/snRNA-seq and electrophysiology.

7. Anatomical structures affected

Primary system: central nervous system, especially cerebral cortex, basal ganglia/striatum, hippocampus, thalamocortical and corticostriatal connections, corpus callosum, white matter, and variably cerebellum. Suggested UBERON: UBERON:0000955 brain, UBERON:0001870 frontal cortex/cerebral cortex mapping should be validated, UBERON:0002435 striatum, UBERON:0002421 hippocampal formation, UBERON:0001897 dorsal thalamus, UBERON:0002336 corpus callosum, UBERON:0002037 cerebellum.
Secondary organs: heart and genitourinary tract, with variable eye, ear/hearing, gastrointestinal, dental/palatal, and musculoskeletal involvement. (lozano2021foxp1syndromea pages 13-15, lozano2021foxp1syndromea pages 16-17)
Tissue: nervous tissue; developing cortical and striatal neural circuits.
Cells: cortical pyramidal/excitatory neurons; striatal GABAergic D1 and D2 SPNs, with a particularly strong D2-SPN effect; cortical layer-IV neurons; amygdala neurons. (anderson2020singlecellanalysisof pages 1-4, khandelwal2024foxp1regulatesthe pages 1-2, li2023cortexrestricteddeletionof pages 1-2)
Subcellular: nucleus for FOXP1 transcriptional activity; post-synaptic structures and dendritic spines as downstream sites. Suggested GO-CC: GO:0005634 nucleus, GO:0045211 postsynaptic membrane, GO:0043197 dendritic spine.
Lateralization: no consistent unilateral or asymmetric pattern is established.

8. Temporal development

FOXP1 syndrome is congenital in origin but often recognized during infancy or early childhood when hypotonia, feeding difficulty, delayed milestones, or absent/delayed speech emerge. The onset is insidious/developmental rather than acute. It is chronic and lifelong, with no established staging system, relapsing-remitting pattern, spontaneous remission, or end-stage phase. Skills may improve with maturation and intervention, but core communication, cognitive, adaptive, and motor vulnerabilities commonly persist. Regression is not established as a defining feature.

The critical biological period begins prenatally with brain and organ development and continues postnatally during synaptic/circuit maturation. Mouse rescue evidence indicates that prenatal absence does not make every phenotype irreversible, but the human intervention window is unknown. (lozano2021foxp1syndromea pages 11-13, khandelwal2024foxp1regulatesthe pages 1-2)

9. Inheritance and population

Inheritance: autosomal dominant, usually de novo.
Penetrance: likely high for clearly pathogenic disruptive alleles, but not formally quantified.
Expressivity: variable, especially for ASD, epilepsy, congenital anomalies, and behavioral morbidity.
Mosaicism: parental germline mosaicism is a recognized recurrence consideration; test parents where possible.
Anticipation/founder effect/consanguinity: not demonstrated.
Prevalence/incidence: no reliable population prevalence or annual incidence was identified. “Fewer than reported cases” should not be converted into a prevalence estimate because genomic ascertainment is incomplete.
Sex: the 62-case review included 41 males and 21 females, but this approximately 2:1 ratio may reflect ascertainment and is not proof of sex-linked biology. FOXP1 is autosomal. Ages ranged from 4 months to 31 years, mean 11.4 years. (lozano2021foxp1syndromea pages 2-3)
Ethnicity/geography: no validated population enrichment or geographic clustering is known.

10. Diagnostics

Recommended molecular pathway

In unexplained developmental delay/ID, severe speech-language impairment, ASD, or multiple congenital anomalies, obtain chromosomal microarray to detect 3p14/FOXP1 deletions and other CNVs.
Perform trio exome/genome sequencing or a comprehensive neurodevelopmental/ID/ASD panel including FOXP1 to detect SNVs and small indels.
If suspicion remains after nondiagnostic testing, genome sequencing and structural-variant analysis are useful for intronic, breakpoint, inversion, insertion, or complex rearrangements. RNA sequencing of an accessible tissue may demonstrate aberrant splicing/expression, although this is an adjunct rather than a validated stand-alone diagnostic biomarker.
Confirm reportable variants orthogonally as required by the laboratory and perform parental testing to establish de novo status/segregation.
When a deletion or suspected rearrangement is found, consider parental karyotype and/or metaphase FISH, because CMA does not detect balanced rearrangements. (lozano2021foxp1syndromea pages 2-3, lozano2021foxp1syndromea pages 15-16, lozano2021foxp1syndromea pages 16-17, lozano2021foxp1syndromea pages 1-2)

Karyotype/FISH alone are not sufficiently sensitive for most sequence variants. Mitochondrial DNA and repeat-expansion tests are not FOXP1-specific. Prenatal diagnosis and PGT-M are technically possible once the familial pathogenic variant or rearrangement is known.

Clinical assessment after diagnosis

Recommended baseline evaluation includes clinical genetics/dysmorphology; developmental, cognitive, adaptive, speech-language, motor, behavioral, and ASD assessment; neurology and tone examination; hearing and ophthalmology; cardiac examination with echocardiogram/ECG; and targeted renal/genitourinary, gastrointestinal, sleep, endocrine/nutrition, dental, and orthopedic evaluation. EEG is appropriate for suspected seizures, with overnight video EEG preferred when needed; MRI can evaluate structural abnormalities but is not diagnostic and sedation risk must be considered. (lozano2021foxp1syndromea pages 13-15, lozano2021foxp1syndromea pages 15-16, lozano2021foxp1syndromea pages 11-13)

No biochemical enzyme assay, blood protein, metabolite, biopsy, pathology, PET, or liquid-biopsy marker diagnoses FOXP1 syndrome.

Differential diagnosis

The phenotype overlaps many monogenic NDDs and CNV syndromes. Molecular testing should distinguish FOXP1 syndrome from FOXP2-related speech/language disorder, CNTNAP2-related disorders, SHANK3/Phelan–McDermid syndrome, SYNGAP1-, GRIN2B-, SCN2A-, CHD8-, ARID1B-, and DYRK1A-related NDDs, Kleefstra syndrome, Pitt–Hopkins syndrome, Angelman syndrome, Rett/MECP2-related disorders, and broader 3p deletion syndromes. The particularly severe speech-language phenotype is suggestive but not pathognomonic. Large 3p deletions require evaluation for contiguous-gene effects.

Screening

There is no population or newborn screening program. Cascade testing is appropriate for identified parental rearrangements/variants and at-risk relatives. Routine carrier screening is not applicable to a predominantly de novo dominant disorder.

11. Outcome and prognosis

FOXP1 syndrome causes substantial lifelong morbidity through communication, intellectual/adaptive, motor, behavioral, and sometimes multisystem disability. Many individuals require continuing educational, communication, and daily-living support. Developmental gains are possible, and early therapy is clinically favored, but controlled treatment-response rates and validated prognostic models are absent. Large deletions may be associated with greater severity; no variant, biomarker, MRI feature, or baseline score reliably predicts an individual trajectory. (lozano2021foxp1syndromea pages 16-17)

No syndrome-specific survival curve, 5-/10-year survival, mortality rate, or life-expectancy estimate was identified. Available reports include adults up to age 31, but that does not prove normal life expectancy. Mortality is not recognized as the defining outcome; prognosis is more strongly determined by neurodevelopmental disability and the severity of cardiac, neurologic, feeding, or other complications. Formal disease-specific QoL data are unavailable.

12. Treatment and current implementation

Standard care

There is no approved disease-modifying therapy. Treatment is individualized and symptom-directed:

early developmental intervention; speech-language therapy, including motor-speech assessment;
augmentative and alternative communication (AAC) for minimally verbal/nonverbal individuals;
occupational and physical therapy for fine/gross motor skills, hypotonia, gait, contractures, and adaptive function;
behavioral interventions, including structured behavioral therapy/ABA when appropriate;
individualized education plans and periodic comprehensive neuropsychological reassessment, recommended at least every three years;
standard evidence-based treatment for epilepsy, ADHD, anxiety, aggression, sleep disturbance, reflux/constipation, feeding difficulty, hearing/vision impairment, and cardiac/genitourinary anomalies. No FOXP1-specific pharmacogenomic rule exists. (lozano2021foxp1syndromea pages 13-15, lozano2021foxp1syndromea pages 11-13)

Suggested NCIt intervention concepts include Speech and Language Therapy, Occupational Therapy, Physical Therapy, Behavioral Therapy, Augmentative and Alternative Communication, Special Education, Genetic Counseling, and syndrome-independent drugs/procedures for specific comorbidities. Exact NCIt identifiers should be validated against the current thesaurus.

Advanced/experimental therapies

No human FOXP1 gene replacement, CRISPR editing, ASO, siRNA, mRNA, cell therapy, or targeted small-molecule trial was identified. The 2024 mouse reinstatement study provides a mechanistic rationale for postnatal FOXP1-restoration strategies, but delivery to the appropriate brain cell types, dosage control, isoform selection, off-target transcriptional effects, immunogenicity, and developmental timing remain unresolved. (khandelwal2024foxp1regulatesthe pages 1-2)

Clinical studies

NCT03718923, Mount Sinai: recruiting, cross-sectional observational cohort, estimated enrollment 50, age ≥2 years, with ADOS, cognitive/developmental testing, neurology/genetics assessment, EEG, visual-evoked potential, eye tracking, blood/saliva, and possible iPSC generation. Registry URL: https://clinicaltrials.gov/study/NCT03718923. This is not an interventional treatment trial. (NCT03718923 chunk 1)
NCT06211673, Assistance Publique–Hôpitaux de Paris: completed observational psychiatric phenotyping, enrollment 25, assessing autism, anxiety, sleep, behavior, sensory profile, adaptive function, agitation, ADHD, and psychotic symptoms. Registry URL: https://clinicaltrials.gov/study/NCT06211673. (NCT06211673 chunk 2)

13. Prevention

Primary prevention by diet, lifestyle, medication, vaccination, or environmental avoidance is not available. Vaccination follows ordinary schedules; FOXP1 syndrome is not infectious.

Reproductive prevention/choice: genetic counseling, parental testing, prenatal diagnosis by CVS/amniocentesis, and PGT-M/PGT-SR may be considered once the familial sequence variant or structural rearrangement is defined. Counseling must distinguish an apparently de novo event with low residual mosaic recurrence risk from an inherited variant or balanced parental rearrangement. (lozano2021foxp1syndromea pages 2-3)

Secondary prevention: prompt genomic diagnosis and early developmental intervention; no newborn biochemical screening exists.

Tertiary prevention: surveillance and treatment of seizures, feeding/swallowing problems, cardiac/renal anomalies, hearing/vision impairment, sleep/behavioral conditions, contractures, and educational/communication needs. (lozano2021foxp1syndromea pages 13-15, lozano2021foxp1syndromea pages 15-16)

14. Other species and natural disease

FOXP1 orthologs are evolutionarily conserved across vertebrates and have major developmental functions. Relevant experimental species include Mus musculus (NCBI Taxonomy 10090) and human cellular systems (Homo sapiens, Taxonomy 9606). No well-established naturally occurring veterinary FOXP1 syndrome, breed predisposition, OMIA phenotype, zoonotic transmission, or cross-species infectious susceptibility was identified. Therefore, animal evidence should be labeled engineered model, not natural disease.

15. Model organisms

Mouse models

Foxp1+/− heterozygous mouse: patient-relevant haploinsufficiency model; shows abnormal neonatal ultrasonic vocalization, adult hyperactivity, impaired grip strength, and hippocampal/striatal dysregulation of ASD-associated genes. It models dosage loss but cannot reproduce the full diversity of human variants or language. (co2020foxptranscriptionfactors pages 13-15)
Cortical/hippocampal conditional knockout: impaired neonatal vocalization, cortical lamination and neuronal migration, memory, motor learning, social behavior, and CA1 long-term potentiation. Useful for cortical/hippocampal contributions but represents more complete regional loss than typical human heterozygosity. (co2020foxptranscriptionfactors pages 13-15)
D1-, D2-, and combined-SPN conditional knockouts: resolve cell-autonomous and non-cell-autonomous striatal mechanisms. The 2020 scRNA-seq design profiled 62,778 cells and linked D2/iSPN specification and striosome–matrix defects to motor, vocalization, and fear phenotypes. (anderson2020singlecellanalysisof pages 1-4)
Cortex-specific sensory model (2023): demonstrates reduced spines/barrel formation and abnormal tactile/amygdala responses; limitation is unresolved circuit electrophysiology and uncertain direct translation from whisker behavior to human sensory experience. (li2023cortexrestricteddeletionof pages 1-2)
Conditional postnatal reinstatement/deletion model (2024): combines electrophysiology, snRNA-seq, behavior, and temporal restoration to test reversibility. It is the strongest current therapeutic proof of concept but remains preclinical. (khandelwal2024foxp1regulatesthe pages 15-16, khandelwal2024foxp1regulatesthe pages 1-2)

Cellular and omics models

Human neural-cell work and mouse bulk/single-cell transcriptomics implicate synaptic and neuronal-activity pathways. NCT03718923 permits participant blood to be used for iPSC generation, offering a route to patient-derived neurons and isogenic correction studies, but no validated FOXP1 patient-organoid therapeutic-screening platform was established in the retrieved evidence. (co2020foxptranscriptionfactors pages 13-15, NCT03718923 chunk 1)

Key recent developments and expert interpretation

2023 sensory-circuit evidence: cortex-restricted Foxp1 loss linked atypical tactile behavior to reduced dendritic spines, malformed barrel cortex, reduced layer-IV activation, and increased basolateral-amygdala activation. This expands the mechanism beyond speech and striatum while explicitly leaving the causal circuit physiology unresolved. (li2023cortexrestricteddeletionof pages 1-2)
2024 reversibility evidence: postnatal FOXP1 reinstatement reversed molecular, electrophysiologic, and behavioral abnormalities in mice. The expert interpretation is that FOXP1 syndrome may not be exclusively a fixed prenatal malformation disorder; some downstream circuit dysfunction remains modifiable. Translation nevertheless requires rigorous dose, timing, biodistribution, and safety studies. (khandelwal2024foxp1regulatesthe pages 1-2)
Human implementation remains phenotyping-led: active/recent studies are observational, emphasizing standardized psychiatric, developmental, sensory, EEG, eye-tracking, genetic, and biospecimen characterization rather than therapeutic intervention. (NCT06211673 chunk 2, NCT03718923 chunk 1)
Major evidence gaps: unbiased prevalence, adulthood/aging natural history, mortality, QoL, longitudinal developmental trajectories, variant-specific prognosis, human molecular biomarkers, and controlled treatment outcomes remain unavailable. The field’s most authoritative clinical recommendation is therefore coordinated multidisciplinary surveillance and early individualized rehabilitation rather than genotype-specific pharmacotherapy. (lozano2021foxp1syndromea pages 15-16, lozano2021foxp1syndromea pages 16-17)

Selected sources and publication dates

Lozano R, et al. FOXP1 syndrome: a review of the literature and practice parameters for medical assessment and monitoring. Journal of Neurodevelopmental Disorders. Published April 2021. DOI/URL: https://doi.org/10.1186/s11689-021-09358-1. (lozano2021foxp1syndromea pages 1-2)
Anderson AG, et al. Single-Cell Analysis of Foxp1-Driven Mechanisms Essential for Striatal Development. Cell Reports. 2020. The retrieved full text provides the single-cell design and findings. (anderson2020singlecellanalysisof pages 1-4)
Li X, et al. Cortex-restricted deletion of Foxp1 impairs barrel formation and induces aberrant tactile responses in a mouse model of autism. Molecular Autism. Published September 2023. DOI/URL: https://doi.org/10.1186/s13229-023-00567-0. (li2023cortexrestricteddeletionof pages 1-2)
Khandelwal N, et al. FOXP1 regulates the development of excitatory synaptic inputs onto striatal neurons and induces phenotypic reversal with reinstatement. Science Advances. Published 3 May 2024. DOI/URL: https://doi.org/10.1126/sciadv.adm7039. (khandelwal2024foxp1regulatesthe pages 1-2)
ClinicalTrials.gov. NCT03718923, FOXP1 syndrome deep phenotyping: https://clinicaltrials.gov/study/NCT03718923. (NCT03718923 chunk 1)
ClinicalTrials.gov. NCT06211673, psychiatric phenotype characterization: https://clinicaltrials.gov/study/NCT06211673. (NCT06211673 chunk 2)

Evidence caution: PMID numbers should be imported from PubMed/NCBI records during database curation. The retrieved corpus supplied PubMed IDs for several foundational FOXP1 association papers through Open Targets—e.g., PMID 20950788, 20848658, 22670142, 24214399, 25853299, 26647308, 28735298, 28884888, 29090079, 29330474, 29463886, and 30092897—but did not provide a reliable one-to-one PMID mapping for every title above; assigning unverified PMIDs would risk database error. (OpenTargets Search: FOXP1 syndrome-FOXP1)

References

(lozano2021foxp1syndromea pages 1-2): Reymundo Lozano, Catherine Gbekie, Paige M. Siper, Shubhika Srivastava, Jeffrey M. Saland, Swathi Sethuram, Lara Tang, Elodie Drapeau, Yitzchak Frank, Joseph D. Buxbaum, and Alexander Kolevzon. Foxp1 syndrome: a review of the literature and practice parameters for medical assessment and monitoring. Journal of Neurodevelopmental Disorders, Apr 2021. URL: https://doi.org/10.1186/s11689-021-09358-1, doi:10.1186/s11689-021-09358-1. This article has 78 citations and is from a peer-reviewed journal.
(lozano2021foxp1syndromea pages 11-13): Reymundo Lozano, Catherine Gbekie, Paige M. Siper, Shubhika Srivastava, Jeffrey M. Saland, Swathi Sethuram, Lara Tang, Elodie Drapeau, Yitzchak Frank, Joseph D. Buxbaum, and Alexander Kolevzon. Foxp1 syndrome: a review of the literature and practice parameters for medical assessment and monitoring. Journal of Neurodevelopmental Disorders, Apr 2021. URL: https://doi.org/10.1186/s11689-021-09358-1, doi:10.1186/s11689-021-09358-1. This article has 78 citations and is from a peer-reviewed journal.
(lozano2021foxp1syndromea pages 2-3): Reymundo Lozano, Catherine Gbekie, Paige M. Siper, Shubhika Srivastava, Jeffrey M. Saland, Swathi Sethuram, Lara Tang, Elodie Drapeau, Yitzchak Frank, Joseph D. Buxbaum, and Alexander Kolevzon. Foxp1 syndrome: a review of the literature and practice parameters for medical assessment and monitoring. Journal of Neurodevelopmental Disorders, Apr 2021. URL: https://doi.org/10.1186/s11689-021-09358-1, doi:10.1186/s11689-021-09358-1. This article has 78 citations and is from a peer-reviewed journal.
(lozano2021foxp1syndromea pages 3-4): Reymundo Lozano, Catherine Gbekie, Paige M. Siper, Shubhika Srivastava, Jeffrey M. Saland, Swathi Sethuram, Lara Tang, Elodie Drapeau, Yitzchak Frank, Joseph D. Buxbaum, and Alexander Kolevzon. Foxp1 syndrome: a review of the literature and practice parameters for medical assessment and monitoring. Journal of Neurodevelopmental Disorders, Apr 2021. URL: https://doi.org/10.1186/s11689-021-09358-1, doi:10.1186/s11689-021-09358-1. This article has 78 citations and is from a peer-reviewed journal.
(anderson2020singlecellanalysisof pages 1-4): Ashley G. Anderson, Ashwinikumar Kulkarni, Matthew Harper, and Genevieve Konopka. Single-cell analysis of foxp1-driven mechanisms essential for striatal development. Cell reports, 30:3051-3066.e7, Apr 2020. URL: https://doi.org/10.1101/611780, doi:10.1101/611780. This article has 74 citations and is from a highest quality peer-reviewed journal.
(khandelwal2024foxp1regulatesthe pages 1-2): Nitin Khandelwal, Ashwinikumar Kulkarni, Newaz I. Ahmed, Matthew Harper, Genevieve Konopka, and Jay R. Gibson. Foxp1 regulates the development of excitatory synaptic inputs onto striatal neurons and induces phenotypic reversal with reinstatement. Science Advances, May 2024. URL: https://doi.org/10.1126/sciadv.adm7039, doi:10.1126/sciadv.adm7039. This article has 15 citations and is from a highest quality peer-reviewed journal.
(li2023cortexrestricteddeletionof pages 1-2): Xue Li, Shishuai Hao, Shimin Zou, Xiaomeng Tu, Weixi Kong, Tian Jiang, and Jie-Guang Chen. Cortex-restricted deletion of foxp1 impairs barrel formation and induces aberrant tactile responses in a mouse model of autism. Molecular Autism, Sep 2023. URL: https://doi.org/10.1186/s13229-023-00567-0, doi:10.1186/s13229-023-00567-0. This article has 12 citations and is from a peer-reviewed journal.
(lozano2021foxp1syndromea pages 13-15): Reymundo Lozano, Catherine Gbekie, Paige M. Siper, Shubhika Srivastava, Jeffrey M. Saland, Swathi Sethuram, Lara Tang, Elodie Drapeau, Yitzchak Frank, Joseph D. Buxbaum, and Alexander Kolevzon. Foxp1 syndrome: a review of the literature and practice parameters for medical assessment and monitoring. Journal of Neurodevelopmental Disorders, Apr 2021. URL: https://doi.org/10.1186/s11689-021-09358-1, doi:10.1186/s11689-021-09358-1. This article has 78 citations and is from a peer-reviewed journal.
(lozano2021foxp1syndromea pages 7-9): Reymundo Lozano, Catherine Gbekie, Paige M. Siper, Shubhika Srivastava, Jeffrey M. Saland, Swathi Sethuram, Lara Tang, Elodie Drapeau, Yitzchak Frank, Joseph D. Buxbaum, and Alexander Kolevzon. Foxp1 syndrome: a review of the literature and practice parameters for medical assessment and monitoring. Journal of Neurodevelopmental Disorders, Apr 2021. URL: https://doi.org/10.1186/s11689-021-09358-1, doi:10.1186/s11689-021-09358-1. This article has 78 citations and is from a peer-reviewed journal.
(lozano2021foxp1syndromea pages 15-16): Reymundo Lozano, Catherine Gbekie, Paige M. Siper, Shubhika Srivastava, Jeffrey M. Saland, Swathi Sethuram, Lara Tang, Elodie Drapeau, Yitzchak Frank, Joseph D. Buxbaum, and Alexander Kolevzon. Foxp1 syndrome: a review of the literature and practice parameters for medical assessment and monitoring. Journal of Neurodevelopmental Disorders, Apr 2021. URL: https://doi.org/10.1186/s11689-021-09358-1, doi:10.1186/s11689-021-09358-1. This article has 78 citations and is from a peer-reviewed journal.
(lozano2021foxp1syndromea pages 16-17): Reymundo Lozano, Catherine Gbekie, Paige M. Siper, Shubhika Srivastava, Jeffrey M. Saland, Swathi Sethuram, Lara Tang, Elodie Drapeau, Yitzchak Frank, Joseph D. Buxbaum, and Alexander Kolevzon. Foxp1 syndrome: a review of the literature and practice parameters for medical assessment and monitoring. Journal of Neurodevelopmental Disorders, Apr 2021. URL: https://doi.org/10.1186/s11689-021-09358-1, doi:10.1186/s11689-021-09358-1. This article has 78 citations and is from a peer-reviewed journal.
(NCT03718923 chunk 1): Alexander Kolevzon. FOXP1 Syndrome: The Seaver Autism Center for Research and Treatment is Characterizing FOXP1-related Neurodevelopmental Disorders Using Genetic, Medical, and Neuropsychological Measures.. Icahn School of Medicine at Mount Sinai. 2016. ClinicalTrials.gov Identifier: NCT03718923
(NCT03718923 chunk 2): Alexander Kolevzon. FOXP1 Syndrome: The Seaver Autism Center for Research and Treatment is Characterizing FOXP1-related Neurodevelopmental Disorders Using Genetic, Medical, and Neuropsychological Measures.. Icahn School of Medicine at Mount Sinai. 2016. ClinicalTrials.gov Identifier: NCT03718923
(NCT06211673 chunk 2): Psychiatric Phenotype Characterization of Individuals With FOXP1 Syndrome. Assistance Publique - Hôpitaux de Paris. 2024. ClinicalTrials.gov Identifier: NCT06211673
(OpenTargets Search: FOXP1 syndrome-FOXP1): Open Targets Query (FOXP1 syndrome-FOXP1, 5 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.
(co2020foxptranscriptionfactors pages 13-15): Marissa Co, Ashley G. Anderson, and Genevieve Konopka. Foxp transcription factors in vertebrate brain development, function, and disorders. Wiley Interdisciplinary Reviews: Developmental Biology, Jan 2020. URL: https://doi.org/10.1002/wdev.375, doi:10.1002/wdev.375. This article has 107 citations.
(khandelwal2024foxp1regulatesthe pages 15-16): Nitin Khandelwal, Ashwinikumar Kulkarni, Newaz I. Ahmed, Matthew Harper, Genevieve Konopka, and Jay R. Gibson. Foxp1 regulates the development of excitatory synaptic inputs onto striatal neurons and induces phenotypic reversal with reinstatement. Science Advances, May 2024. URL: https://doi.org/10.1126/sciadv.adm7039, doi:10.1126/sciadv.adm7039. This article has 15 citations and is from a highest quality peer-reviewed journal.

Artifacts

Edison artifact artifact-00

Ask OpenScientist

OpenScientist Report

Definitions

Inheritance

Discussions and Knowledge Gaps

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

Variants

Medical Actions

Diagnosis

Progression

Prevalence

Clinical Burden

Differential Diagnoses

Clinical Trials

Animal Models

Source YAML

References & Deep Research

References

Deep Research

FOXP1 Syndrome: Disease-Characteristics Research Report

Executive summary

1. Disease information

Definition and classification

2. Etiology, risk, and protective factors

Causal factors

Genetic risk

Environmental, lifestyle, infectious, and protective factors

3. Phenotypes

Core neurodevelopmental and behavioral phenotype

Neurologic and musculoskeletal findings

Feeding, growth, congenital anomalies, and dysmorphism

Functional and quality-of-life impact

4. Genetic and molecular information

Gene and protein

Pathogenic variants and interpretation

5. Environmental information

6. Mechanism and pathophysiology

Causal chain

Striatal single-cell and synaptic mechanisms

Cortical and sensory mechanisms

Other biological systems and omics gaps

7. Anatomical structures affected

8. Temporal development

9. Inheritance and population

10. Diagnostics

Recommended molecular pathway

Clinical assessment after diagnosis

Differential diagnosis

Screening

11. Outcome and prognosis

12. Treatment and current implementation

Standard care

Advanced/experimental therapies

Clinical studies

13. Prevention

14. Other species and natural disease

15. Model organisms

Mouse models

Cellular and omics models

Key recent developments and expert interpretation

Selected sources and publication dates

Artifacts